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2. Abstract 
Lacrimo-auriculo-dento-digital (LADD) syndrome, also known as Levy-Hollister 
syndrome, is a rare autosomal dominant developmental disorder, mainly 
characterized by abnormalities of the lacrimal system and salivary glands, ears and 
hearing, teeth and distal limb development. Besides these cardinal features, facial 
dysmorphism and malformations of the kidney and the respiratory system have been 
reported. In this study, the LADD1 locus was mapped to chromosome 10q26 by 
genome wide linkage analysis using the Affymetrix GeneChip 10K array in three 
large LADD families. In all three LADD families and in one sporadic case, 
heterozygous missense mutations were found in exon 16 of the gene encoding the 
fibroblast-growth-factor-receptor 2 (FGFR2). After exclusion of the FGFR2 locus by 
haplotype analysis in two additional LADD families, one missense mutation was 
identified in FGFR3 and one mutation was found in the  fibroblast-growth-factor 10 
(FGF10), a known ligand of FGFR2 [Rohmann et al., 2006]. The functional properties 
of FGF10 LADD and FGFR2 LADD mutants were analyzed and compared to the 
activities of their normal counterparts. Protein expression in BL21 cells and binding 
studies showed that each of the three analyzed FGF10 mutations demonstrated 
severely impaired activity by different mechanisms. Transient and stable expression 
studies exhibited that the FGFR2 mutations possess a reduced autophosphorylation 
and a weaker tyrosine kinase activity. Mutations also lead to diminished 
phosphorylation activity in FGFR2-mediated substrates (e. g. FRS2 and Shc) and to 
a decreased downstream signaling pathway, as shown by MAPK activity. While 
tested FGF10 LADD mutations caused haploinsufficiency, the FGFR2 LADD mutants 
could exert a dominant-negative effect on normal FGFR2 protein [Shams and 
Rohmann et al., 2007]. An in vitro kinase assay and crystallization of both, FGFR2 
WT and the p.A628T missense mutation in the catalytic part of the tyrosine kinase 
domain, demonstrated that the A628T LADD mutation disrupts the catalytic activity 
due to conformational changes, leading to LADD syndrome. In addition, the newly 
described crystal structure of FGFR2 in comparison to FGFR1 revealed that the 
FGFR2 utilizes a less stringent mode of autoinhibition [Lew, Bae and Rohmann et al., 
2007]. 
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2. Zusammenfassung 
Das Lakrimo-aurikulo-dento-digitale (LADD) Syndrom, auch als Levy-Hollister 
Syndrom bekannt, ist eine seltene autosomal-dominante angeborene Erkrankung, 
die hauptsächlich durch Fehlbildungen und Störungen der Tränen- sowie der 
Speicheldrüsen, der Ohren und des Hörvermögens, der Zähne und der Entwicklung 
distaler Extremitäten gekennzeichnet ist. Außerdem sind Gesichtsdysmorphien, 
Fehlbildungen der Nieren und des respiratorischen Systems beschrieben. Der 
LADD1-Locus wurde durch eine genomweite Kopplungsanalyse mit dem Affymetrix 
GeneChip 10K Array in drei großen LADD-Familien auf Chromosom 10q26  kartiert. 
In allen drei LADD-Familien und in einem sporadischen Fall wurden heterozygote 
Mutationen in Exon 16 des Gens, welches den Fibroblasten Wachstumsfaktor-
Rezeptor 2 (FGFR2) kodiert, identifiziert. Nachdem in zwei zusätzlichen Familien der 
LADD1-Locus durch Haplotypanalyse ausgeschlossen wurde, konnte eine kausale 
Mutation in FGFR3 und eine weitere Mutation in FGF10, einem bekannten FGFR2-
Liganden, identifiziert werden [Rohmann et al., 2006]. Die funktionellen 
Eigenschaften der FGF10-LADD- und der FGFR2-LADD-Mutanten wurden analysiert 
und mit den Aktivitäten des normalen Wildtyp(WT)-Repezptors verglichen. Durch 
Proteinexpression in BL21 Zellen und Bindungsstudien konnte gezeigt werden, dass 
die drei analysierten FGF10-Mutationen eine stark beeinträchtigende Aktivität 
aufweisen, die durch verschiedene Mechanismen verursacht wird. Transiente und 
stabile Expressionsstudien zeigten, dass die FGFR2-LADD-Mutanten eine reduzierte 
Autophosphorylierung und eine verringerte Tyrosinkinaseaktivität des Rezeptors 
besitzen. Des Weiteren konnte eine stark abgeschwächte Phosphorylierung von 
FGFR2-vermittelten Substraten, wie FRS2 und Shc, als auch eine herabgesetzte 
nachgeschaltete Signalweiterleitung (was durch die reduzierte MAPK-Aktivität 
gezeigt wurde) beobachtet werden. Während die getesteten FGF10-LADD-
Mutationen Haploinsuffizienz bedingen, zeigen die FGFR2-LADD-Mutationen 
wahrscheinlich einen dominant-negativen Effekt auf das normale FGFR2-Protein 
[Shams und Rohmann et al., 2007]. Zur weiteren Charakterisierung wurde eine in 
vitro Kinaseuntersuchung und eine Kristallisation des FGFR2-WTs und der A628T-
LADD-Mutation, die in dem katalytischen Teil der Tyrosinkinasedomäne von FGFR2 
lokalisiert ist, durchgeführt. Die Ergebnisse zeigten, dass die p.A628T-LADD-
Mutation die katalytische Aktivität auf Grund von Konformationsänderungen zerstört 
und hierdurch die Rezeptoraktivität herabsetzt. Außerdem hat die neu beschriebene 
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Kristallstruktur von FGFR2-WT im Vergleich zu FGFR1 hervorgebracht, dass FGFR2 
einen weniger stringenten Mechanismus der Autoinhibition benutzt [Lew, Bae and 
Rohmann et al., 2007].  
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3. Introduction 
3.1 Fibroblast growth factors 
Fibroblast growth factors (FGFs) belong to a large family of highly conserved 
polypeptide growth factors that are found in organisms from nematodes to humans. 
FGFs mediate a variety of cellular responses during embryonic development and in 
the adult organism. During embryonic development, FGFs regulate the 
communication between mesenchym and epithelium and are essential for the 
development of tissues and organs. FGFs play a critical role in embryonic 
morphogenesis by regulating cell proliferation, differentiation and migration. In the 
adult organism, FGFs play a crucial role in the control of the nervous system, tissue 
repair, wound healing, tumor angiogenesis, cholesterol metabolism and serum 
phosphate regulation (Eswarakumar et al., 2005, Yamashita, 2005, Yu et al., 2000).  
In humans, 22 FGF genes have been identified with known chromosomal location. 
They are found scattered throughout the genome and can be subdivided into seven 
families, each consisting of 2-4 members. The members of a subfamily share 
increased sequence similarity and biochemical and developmental properties. Most 
of the FGF genes consist of three coding exons. FGFs have a conserved ~120-
amino acid residue core, with 30-60% amino acid identity (Itoh and Ornitz, 2004). 
Some of these highly conserved regions are responsible for the interaction with their 
receptors (fibroblast growth factor receptors (FGFRs); see 3.2).  
 
Most FGFs (FGF 3-8, 10, 15, 17-19, and 21-23) have amino-terminal signal peptides 
and are readily secreted from cells. Subsets of FGFs lack an obvious amino-terminal 
peptide. FGF 9, 16 and 20 are secreted due to an N-terminal hydrophobic sequence 
(Miyamoto et al., 1993, Miyake et al., 1998, Ohmachi et al., 2000). FGF1 and FGF2 
are not secreted, but can be released from damaged cells or independently through 
the endoplasmic-reticulum-golgi pathway (Miyakawa et al., 1999). FGF 11-14 are 
thought to remain intracellular and act in a receptor independent manner. Therefore, 
they are also called FHFs (fibroblast growth factor homologous factors), which have a 
high similarity in sequence and structure to the FGFs, but show different biochemical 
and functional properties (Schoorlemmer and Goldfarb, 2001, Goldfarb, 2005). 
Initial structural studies on FGF1 and FGF2 identified 12 antiparallel β strands in the 
conserved core region of the protein. The regions between the β strands 1 and as 
well as between the β strands 10 and 12 form a coherent surface, which contains 
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several basic amino-acid residues that mediate binding to negatively charged heparin 
or heparan sulfate proteoglycan (HSPG). These interactions stabilize FGFs towards 
thermal denaturation and proteolysis and may severely limit their diffusion and 
release into the interstitial space (Flaumenhaft et al., 1990). Due to the binding to 
heparan sulfates, FGFs are located on the cell surface and are therefore available for 
their targets. Furthermore, heparin or HSPG are required by FGFs, which act as 
ligands, to effectively activate specific FGFRs (Yayon et al., 1991). Thereby, heparin 
and HSPG cause specific conformation changes within the ligand that increase 
affinity to bind the receptor, thus lead to efficient activation and further signal 
transduction. The FGF-FGFR signaling system is highly conserved throughout the 
metazoan evolution (see 3.3).  
 
3.2 Fibroblast growth factor receptors 
The fibroblast growth factor receptors (FGFRs) belong to the family of the receptor 
tyrosine kinases (RTKs) and trigger the transduction of FGF mediated signals into the 
cells. RTKs are transmembrane glycoproteins and activate numerous signaling 
pathways within cells leading to cell proliferation, differentiation, migration, or 
metabolic changes (Schlessinger and Ullrich, 1992).  
RTKs consist of an extracellular portion that binds polypeptide ligands, a 
transmembrane helix, and a cytoplasmic portion that possesses tyrosine kinase 
catalytic activity. Tyrosine kinases (TKs) catalyze the transmission of the terminal 
phosphate from ATP (adenosintriphosphate) to the hydroxyl group of a tyrosine side 
chain in a protein. The vast majority of RTKs exist as single polypeptide chain and 
are monomeric in the absence of a ligand. Dimerization upon ligand binding causes 
the transfer of the extracellular signal to the cytoplasm by phosphorylating tyrosine 
residues in the activation loop within the kinase domain on the receptors 
(autophosphorylation) and subsequently on downstream signaling proteins (Hubbard 
and Till, 2000). The autophosphorylation increases the catalytic activity within the 
kinase domain and leads to a positive feedback. Hence, the phosphorylated 
tyrosines mediate the possible binding of substrates to the cytoplasmic domain. 
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Four functional FGFR genes (FGFR1-4) have been identified in humans (Itoh and 
Ornitz, 2004). The FGFRs consist of a single polypeptide chain and have a molecular 
weight of 100-150 kDa. The extracellular domain of FGFRs comprises an N-terminal 
signal peptide and a region containing three immunoglobulin (Ig)-like domains (D1-
D3).  Each of the Ig-like domains is stabilized by disulfide bonds formed by cysteines. 
FGFRs possess a contiguous stretch of acidic residues in the linker region between 
D1 and D2 which is termed ´acid box`. D2 contains a conserved positively charged 
region to bind heparin (Schlessinger et. al., 2000). D2 and D3 are responsible for 
ligand binding, whereas D1 and the ´acid box` account for the autoinhibition. 
Moreover, the FGFRs comprise a single transmembrane helix and a cytoplasmic 
region. The cytoplasmic domain is subdivided into a juxtamembrane domain and a 
tyrosine kinase domain. The catalytic TK domain of a receptor consists of an ATP-
binding site, a catalytic and an activation loop. Specific tyrosines of the activation 
loop produce cis- and trans-autophosphorylations to ensure further signal 
transduction (see 3.3).  
An important hallmark of the FGFR1-3 is that a variety of FGFR isoforms are 
generated by alternative splicing (Eswarakumar et al., 2005). The N-terminal half of 
the third Ig-like domain (D3) is always encoded by the same exon and the C-terminal 
half of D3 is encoded by alternatively spliced exons. For example, it has been shown 
that exon 7 of the FGFR2 gene encodes for the N-terminal half of D3 (designated 
´a`), while exon 8 and 9 alternatively encode for the C-terminal half of D3 and are 
thus designated as ´b` and ´c` isoforms of FGFR, respectively. The generated 
isoforms show different ligand-binding specificities and affinities. While FGFR2b can 
bind FGF7 and FGF10, but not FGF2, the FGFR2c isoform binds FGF2 and FGF18, 
but not FGF7 and FGF10 (Eswarakumar et. al., 2005). Furthermore, these alternative 
splicing events occur in a tissue specific fashion, resulting in mesenchymal ´c` and 
epithelial ´b` isoforms (Mohammadi et al., 2005). Importantly, the tissue expression 
patterns of the FGFs are opposite to their receptors and result in the creation of a 
paracrine signaling loop between mesemchym and epithelium that is fundamental for 
human development. 
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3.3 FGF/FGFR signal transduction 
The interaction of FGF, FGFR and heparan sulfate proteoglycan (HSPG) is 
responsible for the activation of intracellular signal transduction. 
Two fundamentally different crystallographic models have been proposed to explain, 
at the molecular level, how HSPG/heparin enables FGF and FGFR to assemble into 
a functional dimer on the cell surface (Mohammadi et al., 2005).  In the symmetric 
two-end model, heparin promotes dimerization of two FGF-FGFR complexes by 
stabilizing bivalent interactions of the ligand and receptor through primary and 
secondary sites and by stabilizing direct receptor-receptor contacts. In the 
asymmetric model, there are no protein-protein contacts between the two FGF-FGFR 
complexes, which are bridged solely by heparin (Ibrahimi et al., 2005).  In general the 
symmetric model is more widely accepted. 
Upon ligand binding, receptor dimers are formed and their intrinsic tyrosine kinase is 
activated leading to trans-phosphorylation of multiple tyrosine residues on the 
receptor. These residues then serve as docking sites for the recruitment of SH2 (src 
homology-2) or PTB (phosphotyrosine binding) domains of adaptors, docking 
proteins or signaling enzymes (Dailey et al., 2005). Signaling complexes are 
assembled and recruited to the activated receptors resulting in a cascade of 
phosphorylation events (Schlessinger, 2000). The best understood signal 
transduction pathways concomitantly activated by FGFs are the RAS-MAP kinase 
pathway, which includes ERK1/2, p38 and JNK kinases; the P-I-3 kinase-AKT 
pathway, and the PLCγ pathway (see Figure 1). The activation of the RAS-MAP 
kinase pathway has been observed in all cell types, while the activities of other signal 
transduction pathways vary depending on the cell type. Key components of the FGF 
signaling are the docking protein FRS2 (FGF-receptor substrate 2) and the signaling 
enzyme PLCγ (phospholipase Cγ). Most of these phosphorylation transduction 
pathways target transcription factors within the nucleus, thereby affecting gene 
expression, cell proliferation and differentiation (see Figure 1).  
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Figure 1: a) Scheme of the FGFR2/3 structure. b) FGF signaling transduction pathways. Activated 
FGFRs (red rectangles) stimulate PLCγ pathway (blue highlight), the P-I-3 kinase-AKT/PKB pathway 
(yellow highlight), and the FRS2-Ras-MAP kinase pathway (grey highlight). The activated MAP 
kinases (ERKs, p38, or JNKs) are translocated to the nucleus where they phosphorylate (P) 
transcription factors, thereby regulating target genes (Dailey et al., 2005).  
 
3.4 Biological roles of FGF and FGFR isoforms 
The biological roles of more than half of the 22 known mammalian FGFs and all 
known FGFRs have been investigated by targeting their genes by homologues 
recombination. These studies showed that certain members of the FGF family have 
very specialized biological roles resulting in a highly specific phenotype (i.e. Angora 
mutant of FGF5 -/- mice), while the loss of other FGFs can be compensated by 
related members of the FGF family resulting in no obvious phenotypes (no obvious 
defect in FGF1 -/- mice) (Eswarakumar et al., 2005). A mean part of the mutant FGF 
mice models were lethal at different developmental stages, for instance caused by 
inner cell mass proliferation (FGF4 -/- mice) or delayed ossification and increased 
chondrocyte proliferation (FGF18 -/- mice). A major part of the mutant FGF mice 
models were viable but showed alterations in, e. g. muscle regeneration (FGF6 -/- 
mice), neuronal, skeletal and skin phenotype (FGF2 -/- mice) or midline cerebral 
development (FGF17 -/- mice). 
Targeted disruption of each FGFR and the corresponding isoforms (´b` and ´c`) 
generated different phenotypes. The FGFR1 -/- mice were lethal as a result of 
defects in cell migration through the primitive streak, which was also observed in 
FGFR1c -/- mice. However, the FGFR1b -/- mice showed no obvious phenotype. The 
FGFR2 -/- and FGFR2b -/- mice were both lethal. While the FGFR2 -/- mice died due 
D1 
 
D2 
 
D3 
heparin  
   binding site 
IIb/IIc isoforms 
 
FGFR2/3 
FGF 
b a 
tyrosine 
kinase 
domain 
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of defects in the placenta at E10.5, the FGFR2b -/- mice died immediately after birth 
because of severe impairment in the development of the lung, limbs, and other 
tissues. In contrast, the FGFR2c -/- mice were viable and resulted in impairment of 
skull and bone development. Targeted disruption of the FGFR3 gene resulted in 
bone overgrowth and no obvious phenotype was observed in FGFR4 -/- mice 
(Eswarakumar et al., 2005).  
The interaction of Fgf10 with Fgfr2b is essential for bud formation during 
development. Fgf10 is expressed in the mesoderm during organogenesis and 
diffuses to its receptor Fgfr2b, which is located in adjacent cells originated from the 
endoderm and ectoderm. Activation of the receptor initiates the bud formation (Orr-
Urtreger et al., 1993). Numerous mice models showed that a disruption of Fgf10-
Fgfr2b signaling causes severe malformations and dysfunction in many organs and 
was, therefore, embryonically lethal. Fgfr2b-/- zygotes died shortly after implantation 
due to defects of the trophoblast (Arman et al., 1998). Further experiments showed 
that Fgfr2b is fundamentally required for limb outgrowth and branching lung 
morphogenesis and that a disturbed function of Fgfr2b leads to agenesis of multiple 
organs.  FGF10-/- mice showed a similar phenotype. The mice died during birth 
because of the absence of the lung and showed no initiation of the bud formation. 
Besides, several other mice models of Fgf10 and Fgfr2b identified the lack of 
different other organs and also a formation of cleft palate. Additional affected organs 
are the pituitary gland, thyroid gland, salivary gland, lacrimal gland, inner ear, teeth, 
pancreas, kidney, thymus, skin and hair follicle.  
 
3.5 Human malformation syndromes due to defective FGF signaling 
3.5.1 Craniosynostosis and skeletal dysplasia syndromes   
Mutations in FGFR1-3 were identified in a variety of craniosynostosis syndromes. 
Craniosynostosis, the premature fusion of one or more cranial sutures, occurs with a 
prevalence of 1 in 2500 births and is the hallmark of over 100 distinct syndromes, 
including Apert syndrome (AS) (Wilkie et al., 1995, Anderson et al., 1998), Pfeiffer 
syndrome (PS) (Jabs et al., 1994, Muenke et al., 1994, Rutland et al., 1995), 
Crouzon syndrome (CS) (Reardon et al., 1994, Steinberger et al., 1998) and 
Jackson-Weiss syndrome (Jabs et al., 1994, Sabatino et al., 2004). Hallmarks of 
craniosynostosis include abnormally shaped skull, often associated with increased 
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intracranial pressure, mental retardation, developmental delay, seizures, and 
blindness caused by constrictions of the growing brain (Eswarakumar et al., 2006).  
AS is characterized by a markedly fore-shortened skull base and severe midfacial 
retrusion with hypertelorism. It is mostly associated with coronal sutural synostosis 
and a widely unossified median sagittal diastema in place of metopic and sagittal 
sutures. In contrast, the related CS, PS and Jackson-Weiss syndromes display more 
variable and overlapping craniofacial anomalies. AS is often accompanied by severe 
syndactyly of hands and feet, whereas traditionally, limb pathology in PS is moderate 
and not evident in CS. PS patients show broad fingers and feet. Jackson-Weiss 
syndrome is characterized by brachy- and acrocephaly.  
 
The inheritance of the mentioned syndromes is autosomal dominant and caused 
mainly by gain-of-function mutations in FGFR1-3. The majority of the known 
mutations have been found in the extracellular domain of the receptor and resulted in 
constitutive receptor activation. In FGFR2, mutations occur mostly in the regions 
between D2 and D3, within D3 or between D3 and the transmembrane domain and 
can therefore manifest in both mesenchymal `c´ and epithelial `b´ splice isoforms of 
FGFR2. A ligand independent receptor dimerization and signal transduction occurs 
due to the mutations. If one of two highly conserved cysteines in D3 or adjacent 
amino acids are changed, the residual cysteine forms a disulfide bridge with a 
cysteine of the second receptor molecule. The same is true for mutations found in the 
transmembrane domain. Amino acid changes lead to the formation of hydrogen 
bonds between two receptor molecules and therefore cause activation of the receptor 
independent of ligand binding. Exceptions were found for AS mutations. Here, the 
mutations activate the receptor only in the presence of a ligand due to changed 
binding specificity of the receptor. Just a few mutations responsible for syndromic 
craniosynostosis were found in the tyrosine kinase domain of FGFR1-3, which also 
led to constitutive activation of the receptor. In addition, mutations in FGFR3 cause 
different forms of dwarfism, like achondroplasia, hypochondroplasia and 
thanatophoric dysplasia type I and II. Mutations responsible for hypochondroplasia 
and thanatophoric dysplasia type II are located within the catalytic tyrosine kinase 
domain. These mutations are also gain-of-function mutations leading to ligand 
independent receptor activation (Eswarakumar et al., 2005). The mutations generate 
conformational changes in the TK domain of the monomeric receptor leading to 
 12
autophosphorylation of tyrosines. Hence, receptor dimerization for activation or signal 
transduction is not necessary. Because activated FGFR3 is needed for inhibition of 
chondrocyte proliferation, dysfunction herein leads to dwarfism. In 2006, a novel tall 
stature syndrome (CATSHL, camptodactyly, tall stature, hearing loss) was 
described, caused by a putative loss-of-function mutation in FGFR3 (Toydemir et al., 
2006).   
 
3.5.2 Levy-Hollister/lacrimo-auriculo-dento-digital (LADD) syndrome 
The Levy-Hollister syndrome, also known as LADD syndrome, was first described in 
1967 by W.J. Levy and in 1973 by D.W. Hollister (Levy, 1967; Hollister, 1973). LADD 
syndrome is a rare autosomal dominant disorder, which is characterized by 
distinctive malformations of several organ systems. LADD syndrome mainly affects 
the lacriamal glands and ducts, external and inner ears, salivary glands and ducts, 
teeth and digital development. The lacrimal system is affected by hypoplasia, atresia 
and aplasia of the nasolacrimal ducts and puncta leading to frequent conjunctivitis. 
Auricular symptoms include ear malformations such as cup-shaped, small and low-
set ears, as well as sensorineural, conductive or mixed-type hearing loss. Hypoplasia 
or aplasia of the parotid and submandibular glands leads to xerostomia and early-
onset caries. Teeth malformations are characterized by microdontia and hypodontia. 
The digital system most often involves the thumbs, ranging from total aplasia to 
hypoplastic, digitalized, triphalangeal, and duplicated thumbs. Mild syndactylies of 
fingers and lower limb anomalies are less frequent. Additional features of LADD 
syndrome include renal abnormalities (Bamforth and Kaurah, 1992), lung hypoplasia, 
cleft lip/palate (Ramirez and Lammer, 2004), facial dysmorphisms, and long QT 
syndrome (Fierek, 2003).  
At the time this PhD study was initiated, the etiology of the LADD syndrome was 
unknown.   
 
 
 
 
 
 
 
 13
4. Aims and major findings of this PhD thesis 
4.1 Aims 
The aim of the study performed in this PhD thesis was to identify the genes 
underlying autosomal dominantly inherited LADD syndrome and to understand the 
pathophysiological mechanisms leading to the developmental anomalies present in 
LADD syndrome.  
Genome wide linkage analysis in large LADD families were performed to identify 
linked genomic regions and positional as well as candidate gene approaches were 
intended to identify disease causing genes. In order to understand the molecular 
mechanisms of LADD syndrome mutations, a combination of biochemical assays of 
purified mutant proteins, functional analysis in transiently and stably transfected cells 
and structural analysis of a mutant crystal was utilized.  
 
4.2 Major findings 
(1) Mapping of the first LADD locus to 10q26 
(2) Identification of three causative LADD genes and mutations in FGFR2/3 and in 
FGF10 responsible for LADD syndrome 
(3) Screening of additional LADD patients and families showing the mutational 
spectrum of LADD mutations. Establishment of quantitative gene copy analysis and 
identification of large deletions and a duplication of FGF10. Determination of 
breakpoints using high density tiling arrays covering the FGF10 region 
(4) First case of autosomal recessively inherited LADD syndrome and functional 
analysis of the identified homozygous mutation in stably transfected L6 myoblasts 
(5) Molecular analyses identified TWIST1 and TP73L mutations as causative in 
LADD-like phenotypes  
(6) Detection of reduced tyrosine kinase activity of FGFR2 underlying the 
pathogenesis of LADD syndrome in 4 patients with FGFR2 mutations 
(7) Combination of biochemical studies and structural analysis of p.A628T-FGFR2 
mutant crystal showed alteration of the catalytic pocket of the tyrosine kinase domain 
leading to impaired substrate coordination 
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5. Present investigations 
5.1 Mutations in different components of FGF signaling in LADD syndrome 
(Rohmann et al., Nat Genet. (2006): Apr. 38 (4): 414-7) 
 
The autosomal dominant lacrimo-auriculo-dento-digital (LADD) syndrome is a 
multiple congenital anomaly mainly characterized by lacrimal duct aplasia, malformed 
ears and deafness, small teeth, and digital anomalies. To identify the genetic cause 
of the LADD syndrome, we initially genotyped three large LADD families using the 
Affymetrix GeneChip 10K array and mapped the LADD1 locus to chromosome 10q26 
to a 6.2 Mb critical region between markers D10S1693 and D10S1723. The gene 
encoding the fibroblast-growth-factor-receptor 2 (FGFR2) was regarded to be an 
excellent positional and functional candidate gene because: (i) a mouse model 
carrying a dominant interfering Fgfr2b mutant presents with limb and digit 
malformations; (ii) submandibular gland morphogenesis is regulated by Fgfr2b; and 
(iii) haploinsufficiency of the known FGFR2b ligand, FGF10, causes lacrimal and 
salivary gland abnormalities in humans and mice.  
 
We sequenced the entire coding and non-coding exons of FGFR2 and identified 
heterozygous missense mutations in exon 16 in all three LADD families and in one 
sporadic case. Two families carried the c.1942G>T transition predicting the 
substitution of the highly conserved alanine at position 648 by threonine (p.A648T). 
The third family showed a 3-bp deletion, c.1947-1949delAGA, leading to a 
substitution of the highly conserved arginine to serine at position 649 and to the 
deletion of the neighboring aspartic acid (p.R649Sdel650D). In the sporadic case a 
de novo mutation, c.1882G>A (p.A628T), was identified. In two additional LADD 
families the FGFR2 locus was excluded by haplotype analysis. To identify further 
causative genes, FGFR1, FGFR3, and FGFR4, as well as two known FGFR2 
ligands, FGF8 and FGF10, were tested as functional candidate genes. In one family 
the causative missense mutation c.317G>T in exon 1 of FGF10 was detected, which 
is predicted to change the conserved amino acid cysteine at position 106 to 
phenylalanine (p.C106F). In the other family a missense mutation in FGFR3 was 
found. The c.1537G>A transition results in the amino acid substitution p.D513N 
within the conserved tyrosine kinase domain. We confirmed further that the 
mutations, which cosegregated with the disease, were present neither in unaffected 
family members nor in 200 ethnically matched control individuals. 
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Notably, all LADD mutations identified in FGFR2/3 are located within the tyrosine 
kinase domains of the receptors within loops that have an important regulatory 
function in the control of receptor activity. 3D-modeling of the identified mutations 
suggested that – in contrast to described FGFR2/3 gain-of-function mutations in 
syndromic craniosynostosis and skeletal dysplasia syndromes - LADD syndrome 
might be caused by diminished FGF-signaling due to tyrosine kinase impairment. 
Therefore, reduced functional activity of FGFR2/3 seemed to be a plausible 
mechanism underlying the molecular basis of LADD syndrome. 
 
Own contributions: 
At first I evaluated and interpreted the Affymetrix GeneChip 10K Array data and 
carried out haplotype analysis in the pedigrees. Subsequently, I identified FGFR2 as 
the causative gene in the linked region. Furthermore, I established test assays for 
additional candidate genes, such as FGFR3 and FGF10, analyzed patients and 
families and identified causative mutations. Finally, I analyzed and construed the 
results and set up the segregation of the mutations within each family and performed 
the control studies either by enzyme restriction assays or direct sequencing.  
 
 
5.2 LADD syndrome is caused by reduced activity of the FGF10-FGF receptor 2 
signaling pathway (Shams et al., Mol Cell Biol. (2007); 27: 6903-6912) 
 
The next aim was to determine the molecular mechanisms of the previously identified 
LADD mutations. In this paper, we described the functional effects of FGF10 (I156R, 
C106F and K137X) and FGFR2 LADD mutants (A628T, A648T and R649S) in 
comparison to the properties of their normal counterparts. In addition, we generated a 
kinase-defective (KD) mutant (K508A) and a Pfeiffer syndrome gain-of-function 
FGFR2b (K641R) mutant as controls for the functional analysis. 
 
Protein expression of the FGF10 LADD mutations and binding studies in L6 cells 
stably expressing FGFR2b showed that the mutants were unable to stimulate 
tyrosine autophosphorylation of the receptor or tyrosine phosphorylation of the 
downstream signaling molecules FRS2 and Shc. Furthermore, no MAPK stimulation 
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was detected. Additionally, ligand displacement assays with radiolabeled FGF10, 
limited proteolysis analyses and intrinsic fluorescence measurements demonstrated 
that each of the three FGF10 mutants affected the FGF10 activity by a different 
mechanism. The initially identified p.C106F mutant showed reduced protein stability 
responsible for its disturbed biological function, which was indicated by the formation 
of low-molecular-weight degradation products and also by increased changes of the 
fluorescence spectrum. Moreover, stimulation of L6 cells stably expressing FGFR2b 
with or without heparin and with the p.C106F mutant showed a protective effect for 
the MAPK stimulation when treated with heparin. The subsequently described 
p.I156R mutation presented a drastically reduced receptor binding capacity indicated 
by a higher 50% inhibitory concentration of 125I-labeled FGF10 bound to FGFR2b in 
L6 cells. Modeling based on the X-ray crystal structure of FGF10 depicted that Ile156 
is located in a region forming contact with FGFR2b and that the amino acid change to 
arginine leads to the disruption of critical electrostatic interactions essential for 
binding between FGF10 and FGFR2b. In contrast, p.Cys106 is located on the 
surface of FGF10 and the amino acid change to the larger phenylalanine is 
suggested to form a bulky region causing instability of the mutant protein. Finally, the 
p.K137X mutant exhibited no expression in different experimental conditions 
assuming a rapid degradation.  
 
FGFR2 mutants were characterized using transient expression in HEK293 cells and 
stable expression in L6 cells. Western-blot analysis demonstrated that the FGFR2 
LADD mutants possess different degrees of tyrosine autophosphorylation. The 
p.R649Sdel650D mutant had the highest residual TK activity, whereas p.A628T had 
the lowest. Further, we demonstrated that the three mutants failed to stimulate 
tyrosine phosphorylation of two well-characterized FGFR substrates, FRS2 and Shc, 
and also of the MAPK pathway. Combining the findings of the co-expression studies 
of FGFR2 WT and LADD mutants and with known mouse data suggested that LADD 
mutants might exert a dominant-negative effect on normal FGFR2 protein.  
 
We concluded that FGF10 LADD mutants cause haploinsufficiency of FGF10. 
Moreover, we concluded that FGFR2 LADD mutants cause a strongly attenuated 
intrinsic tyrosine kinase activity leading to impaired tyrosine phosphorylation of critical 
substrates and cell signaling. Since all LADD mutations are clustered in the catalytic 
 17
domain of FGFR2, these mutations are not isoform specific. Furthermore, we 
described the importance of exact doses of receptor signaling in mediating biological 
responses.  
 
Own contributions: 
Initially, I generated different mutant constructs of FGF10 and FGFR2 by site directed 
mutagenesis and expressed human FGF10 WT and FGF10 LADD mutants in E. coli 
using the bacterial expression vector pET11c. In addition, I generated the cloning 
strategy for the human FGFR2b WT construct using the retroviral pBABE/neo 
expression vector for stable L6 cell line transfection. For the transient transfection of 
FGFR2b WT in HEK293 cells, I used the pcDNA-3 expression vector. Furthermore, I 
transformed FGF10 WT and FGF10 LADD mutants in BL21(DE3)pLysS E. coli 
strains and purified the recombinant proteins by fast-perfomance liquid 
chromatography. Consequently, I determined the protein purity by SDS-PAGE 
analysis and performed the binding studies between the purified FGF10 WT/LADD 
mutants and the FGFR2b in L6 cells. Additionally, I conducted the transfection 
experiments of FGFR2b WT and FGFR2b LADD mutants in L6 cells and assembled 
the immunoprecipitation (IP) assays and applied the IP products of all performed 
experiments on SDS-PAGE followed by Western Blot analysis.  
 
 
5.3 Structural basis for reduced FGFR2 activity in LADD syndrome: 
Implications for FGFR autoinhibition and activation (Lew et al., Proc Natl Acad 
Sci U S A. (2007) Dec. 104 (50): 19802-19807) 
 
After demonstrating that FGFR2 mutations responsible for LADD syndrome cause a 
decreased tyrosine kinase phosphorylation and a reduced ligand-induced recruitment 
of downstream signaling molecules (Shams and Rohmann et al., 2007), we wanted 
to investigate how these point mutations located in highly conserved regions of the 
kinase domain lead to partial inactivation or loss of function phenotype. For this 
purpose, we biochemically analyzed the kinetics of tyrosine phosphorylation and in 
addition generated crystals of FGFR2 WT and the identified de novo missense 
mutation p.A628T, which is located in the catalytic part of the tyrosine kinase domain 
of FGFR2.  
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Purification of the intact kinase domains of FGFR2 WT and p.A628T-FGFR2 mutant 
exhibited that both proteins are monomers with similar elution profiles. Therefore, we 
suggested that the p.A628T-FGFR2 mutant remains intact and possesses a surface 
charge in concordance with that of the FGFR2 WT. Applying an in vitro kinase assay, 
we observed a fully phosphorylated (5P, 5 phosphorylations sites) FGFR2 WT kinase 
after 45 min at 4 ˚C and after 10 min at RT. In contrast, the mutant failed to undergo 
autophosphorylation at 4 ˚C and showed incomplete tyrosine phosphorylation at RT. 
These results proved that the p.A628T-FGFR2 mutant directly compromises the 
intrinsic catalytic activity of FGFR2 kinase, which is in agreement with the decreased 
tyrosine phosphorylation of ectopically expressed p.A628T-FGFR2 mutant in 
transfected L6 cells (Shams and Rohmann et al., 2007). In addition, we performed 
the in vitro kinase assay for FGFR1 WT in comparison to FGFR2 WT. We detected 
that FGFR2 WT was modestly more catalytically active than FGFR1 WT, indicated by 
a faster emergence of the full phosphorylated (5P) FGFR2 WT, concluding that the 
kinase of FGFR2 WT is less autoinhibited than the one of FGFR1. 
 
The crystal structures of several receptor tyrosine kinases (RTKs), like FGFR1 and 
IRK (Insulin receptor kinase), are known. We compared those with the generated 
FGFR2 WT and p.A628T-FGFR2 mutant crystal. The crystals illustrated a very 
similar structure between the inactive crystals of FGFR2 WT and p.A628T-FGFR2 
mutant. Both crystal structures in the inactive state appeared accessible at the 
nucleotide-binding site as well as at the substrate-binding pocket. These 
observations were quite in contrast to the crystal structure of FGFR1, although 
FGFR1 and FGFR2 share >90% sequence identity. Viewed closely, the conformation 
of the C-terminal lobe was nearly identical, whereas the N-terminal lobe of FGFR2 
relative to FGFR1 revealed a rotation, which is reminiscent of an active state. 
Instead, the crystal structure of FGFR2 in the inactive state had a stronger similarity 
to the structure of active IRK (IRK-3P) leading to the conformation that FGFR2 kinase 
is less autoinhibited than FGFR1. Further fluorescence titration experiments of the 
p.A628T-FGFR2 crystal with an ATP analog demonstrated that the mutant does not 
affect ATP binding and confirmed that the p.A628T-FGFR2 mutant is responsible for 
disruption of the catalytic pocket. 
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In conclusion, the structure definitely depicted that the p.A628T-FGFR2 LADD 
mutation alters the conformation of key residues in the catalytic pocket, which impairs 
the ability of the tyrosine kinase to coordinate its substrate and, finally, causes partial 
inactivation, as seen in LADD syndrome mutations. Furthermore, we demonstrated 
that FGFR2 utilizes a less stringent mode of autoinhibition than FGFR1 and that the 
mechanism of autoinhibition is dependent on alteration of the conformational 
dynamics. 
 
Own contributions: 
Initially, I performed bacterial expression of a construct containing residues 461-768 
of the human FGFR2. For the protein crystallization, I integrated a TEV enzymatic 
cleavage site by PCR and produced the single point mutation, p.A628T, by site 
directed mutagenesis. Moreover, I set up the bacterial expression of p.A628T-FGFR2 
LADD mutant and purified the protein using French Press and a Ni-NTA-His resin. 
Subsequently, I analyzed the phosphorylation states of the purified proteins of 
FGFR2 WT and p.A628T-FGFR2 via an in vitro kinase assay and visualized the 
results by native gel electrophoresis.  
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6. Progress and concluding remarks 
 
During my PhD thesis further genetic analysis was done in familial and sporadic 
LADD patients and several novel mutations were identified: FGF10: p.E145X, 
IVS1+3delA; FGFR2: p.R488G, p.E710-L712dupELF. Autosomal recessive 
inheritance was found for the first time in one family, which was caused by the 
homozygous p.R579W in the TK domain of FGFR2. Both parents were carriers and 
clinically not affected. Using newly established quantitative assays, such as multiplex 
ligation-dependent probe amplification (MLPA) and quantitative Taqman analysis, 
one large deletion and two duplications of FGF10 were identified. These large 
structural anomalies were further investigated by fine-tiling array comparative 
genomic hybridization (CGH) and the exact breakpoints of a 12.15 kb deletion 
affecting exons 2 and 3 of FGF10 in a large LADD family were defined. A junction 
fragment could be amplified confirming the deletion. In two other patients, 
duplications of different sizes were found, one of them determined as a 2.2 Mb 
duplication including the complete FGF10 gene.  
 
Additional candidate genes were tested in patients negative for LADD mutations to 
identify novel LADD genes. In one sporadic patient who presented overlapping 
features with LADD syndrome, a de novo deletion of the complete TWIST1 gene on 
chromosome 7p21.2 was found by MLPA. Screening of the TP73L gene (p63 
protein) in our cohort with possible diagnosis of LADD identified the heterozygous 
p.R298Q, which is a hot-spot mutation for the acro-dermato-ungual-lacrimal-tooth 
(ADULT) syndrome and was described in 3 out of 4 ADULT syndrome patients. The 
p.R279H mutation in TP73L (previously described in patients with ectrodactyly, 
ectodermal dysplasia and cleft lip/palate (EEC) syndrome) was found in a patient 
diagnosed with LADD but presenting an EEC-syndrome-like phenotype upon re-
examination.  
 
Within the present PhD thesis, I identified the molecular basis of the congenital LADD 
syndrome and determined the pathophysiological mechanisms underlying different 
LADD genes and mutations. The identified mutations in FGF10 caused 
haploinsufficiency of FGF10 leading to a loss-of-function phenotype in LADD 
syndrome. The mutations identified in FGFR2 caused a strongly attenuated intrinsic 
tyrosine kinase activity due to conformational changes and resulted in an impaired 
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signal transduction in the cascade of the FGF-FGFR signaling pathway, finally 
resulting in LADD syndrome. LADD patients with mutations in FGF10 or FGFR2 
present no specific phenotypic differences. Furthermore, LADD syndrome exists with 
a wide range of phenotypic variability of symptoms, even within one family carrying 
the identical mutation. This impedes genotype-phenotype correlations. The 
heterogeneity of the LADD syndrome and the absence of known LADD mutations in 
some of our patients, led us to the suggestion of further genes to be involved in the 
pathogenesis of LADD syndrome.Therefore, I performed further genetic analysis and 
could identify mutations in genes already described for syndromes with overlapping 
clinical features in LADD-like syndromes. These results display nicely the overlap of 
clinical phenotypes between p63-associated disorders and LADD syndrome. Future 
functional analysis of the FGFR3-LADD mutation might provide additional insights 
into impaired FGF signaling causing LADD syndrome. 
 
6.1 Awards/Talks 
 
Participant and young scientist representative of the University of Cologne at the 
Meeting of Nobel Laureates in Medicine/ Physiology in Lindau, 2007 
 
Medical faculty prize 2006 for the best individual publication of the University of 
Cologne will be given for the Nature Genetics publication. 
 
Rohmann E., Lax I., Lew E.D., Eswarakumar V.P., Brunner H.G., Li Y., Kayserili H., 
Schlessinger J., Wollnik B. Oral Presentation: LADD syndrome is caused by 
mutations that reduce the tyrosine kinase activity of FGFR2. 18th Annual Meeting of 
the German Society of Human Genetics March 7 –10, 2007, Bonn. 
 
Rohmann E., Lax I., Lew E.D., Eswarakumar V.P., Brunner H.G., Li Y., Kayserili H., 
Schlessinger J., Wollnik B. Oral Presentation: LADD syndrome is caused by 
mutations that reduce the tyrosine kinase activity of FGFR2. 56th Annual Meeting of 
The American Society of Human Genetics, October 9 –13, 2006, New Orleans. 
 
Wollnik B., Brunner H.G., Kayserili H., Uyguner O., Nürnberg G., Lew E.D., Dobbie 
A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G., Li Y., Becker C., 
Lehnerdt K., Cremers C.W., Yuksel-Apak M., Nürnberg P.,  Kubisch C., 
Schlessinger J., van Bokhoven H., Rohmann E. Oral Presentation: Mutations in 
different components of FGF-signaling in LADD syndrome. 17th Annual Meeting of 
the German Society of Human Genetics, March 8 –11, 2006, Heidelberg.  
 
Wollnik B., Brunner H.G., Kayserili H., Uyguner O., Nürnberg G., Lew E.D., Dobbie 
A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G., Li Y., Becker C., 
Lehnerdt K., Cremers C.W., Yuksel-Apak M., Nürnberg P.,  Kubisch C., Schlessinger 
J., van Bokhoven H., Rohmann E. Oral Presentation: Mutations in different 
components of FGF-signalling in LADD syndrome. 38th European Human Genetics 
Conference, May 9 –12, 2006, Amsterdam. 
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7. Additional publications and activities during the PhD thesis 
 
7.1 Kaplan Y, Vargel I, Kansu T, Akin B, Rohmann E, Kamaci S, Uz E, Ozcelik T, 
Wollnik B, Akarsu NA: Skewed X-inactivation in an X-linked Nystagmus Family 
Resulted From a Novel, p.R229G, Missense Mutation in the FRMD7 Gene. Br J 
Ophthalmol. (2007): Oct 25; [Epub ahead of print] 
 
Congenital motor nystagmus (NYS) is a genetically heterogeneous disorder and is 
characterized by ocular oscillatory movement caused by a motor instability that can 
manifest with or without afferent visual system dysfunction. Autosomal dominant, 
recessive and X linked inheritance are described, whereby the X linked inheritance is 
the most common form of NYS (NYS1). To date, two loci on the Xq26-q27 and on 
Xp11.4 have been reported for X-linked dominant NYS. Recently, for the former loci 
mutations in the FRMD7 (FERM domain-containing 7) gene have been reported as a 
molecular cause in Xq26-linked families. This gene shows restricted expression 
pattern in the human embryonic brain and developing neural retina, but minor 
knowledge exists about the function of FRMD7.  
 
We investigated a large NYS1 pedigree, including 162 individuals from six 
generations of South-Eastern Turkish decent. The two most prominent findings in this 
family were nystagmus, obesity, and/or type 2 diabetes. The penetrance of the NYS1 
phenotype in females was estimated to be approximately 36% for this family. We 
mapped the disease locus to chromosome Xq26-q27 by genetic linkage analysis. 
Subsequently, we identified a novel missense mutation in the gene FRMD7 by direct 
sequencing. The c.686C>G mutation in exon 8 leads to the substitution of a 
conserved arginine by a gylcine (p.R229G) in the functionally important FERM-C 
domain of the protein. We performed X-chromosome inactivation analysis by 
enzymatic predigestion of DNA with a methylation-sensitive enzyme, followed by 
PCR of the polymorphic CAG repeat of the androgen receptor gene. We 
demonstrated that skewed X-inactivation was significantly increased in affected 
females compared to unaffected females in this family. Besides, we observed the first 
homozygote female case of the NYS phenotype, but no obvious phenotypic 
differences to heterozygote females was detected. 
 
In conclusion, we identified a novel missense mutation in the FRMD7 gene 
responsible for NYS1 and we demonstrated skewed X inactivation, which influences 
the manifestations of the disease in X linked females.  
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Own contributions: 
I designed the primers of the FRMD7 gene by using genome databases and 
established the test conditions for PCR amplification and sequencing. Furthermore, I 
evaluated the sequencing results by using database analysis and performed the 
control studies of 120 control individuals by establishing a restriction enzyme 
digestion assay. 
 
 
7.2 Pabst S, Wollnik B, Rohmann E, Hintz Y, Grohé C: A novel stop mutation 
truncating critical regions of the cardiac transcription factor NKX2.5 in a large 
family with autosomal-dominant inherited congenital heart disease. Clin Res 
Cardiol. (2007): Sep 25; [Epub ahead of print] 
 
Congenital cardiovascular diseases (CCVD) are the most common developmental 
anomalies, and are diagnosed in 1% of newborns. Atrial septal defect (ASD) is the 
most often inherited CCVD and is characterized by an abnormality of the upper 
chambers of the heart (atria) where the wall between the right and left atria does not 
close completely. In sporadic patients and families presenting association of ASD 
with atrioventricular AV conduction block and other CCVDs heterozygous mutations 
in the cardiac transcription factor NKX2-5 were identified. Also, mice models carrying 
homozygote deletion of NKX2-5 are lethal due to impaired cardiac looping. 
Heterozygosity results in hypoplasia of the atrioventricular conduction system in 
mice.   
 
We described a family affected by an autosomal dominantly inherited AV conduction 
block associated with ASD and CCVD. For the reasons described above, we 
screened the NKX2-5 gene by direct sequencing. We identified a novel heterozygous 
nonsense mutation c.325G>T (p.E109X) in exon 1 of the cardiac transcription factor 
in this family. The mutation is predicted to truncate the protein after 109 amino acids, 
which results either in an truncated protein lacking all known domains that are 
necessary for its functionality or in rapid degradation of the mutated mRNA due to 
nonsense-mediated mRNA decay (NMD).  
 
We concluded that the described AV associated with ASD and CCVD in this family is 
caused by the novel nonsense mutation in the NKX2-5 gene and that the 
pathophysiological mechanism is triggered by loss of function leading to 
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haploinsufficiency of NKX2-5. In general, the phenotype of patients with defects in 
NKX2-5 mutations shows high variability, even within the same family. Therefore, no 
genotype-phenotype correlation could be established yet. Molecular screening of 
candidate genes, as done in the present study, is helpful for the identification of high 
risk family members and important for accurate and early therapy. 
 
Own contributions: 
First of all, I considered NKX2-5 as a highly relevant candidate gene for the disorder 
in the family and designed the primers of the NKX2-5 gene for PCR amplification and 
established the test assays for the PCR conditions as well as for the sequencing 
reactions. In addition, I performed the control studies of 50 control individuals also by 
direct sequencing and analyzed all sequencing results by using database analysis. 
 
 
7.3 Kalay E, Li Y, Uzumcu A, Uyguner O, Collin R, Caylan R, Ulubil-Emeroglu M, 
Kersten F, Hafiz G, van Wijk E, Kayserili H, Rohmann E, Wagenstaller J, 
Hoefsloot L, Strom T, Nürnberg G, Baserer N, Hollander A, Cremers F, Cremers 
C, Becker C, Brunner H, Nürnberg P, Karaguzel A, Basaran S, Kubisch C, 
Kremer H, Wollnik B ; Mutations in the lipoma HMGIC fusion partner-like 5 
(LHFPL5) Gene Cause Autosomal Recessive Nonsyndromic Hearing Loss ; 
Human Mutat. (2006): 27(7), 633-639 
 
Autosomal recessive nonsyndromic hearing loss (ARNSHL) is the most common 
hereditary form of deafness and accounts for >70% of cases. Until now, more than 
70 loci for ARNSHL (DFNB) and 23 of the corresponding genes have been identified.  
 
We investigated two large Turkish consanguineous families (DF44 and TR77) 
diagnosed with isolated hearing loss. After exclusion of common genes known to be 
responsible for hearing loss by sequencing and haplotype analysis, we performed 
genome wide linkage analysis and homozygosity mapping using the Affymetrix 
GeneChip Human Mapping 10K Array. We mapped the disease causing locus to 
chromosome 6p21.3-21.1 in both families. Further fine-mapping with microsatellite 
markers and inclusion of additional family members minimized the critical region to 
an 8.4-Mb interval between the markers D6S1629 and D6S400 in the family DF44 
and to a 7.5-Mb interval between the markers D6S1583 and D6S1575 in the family 
TR77. In both families the critical region partially overlaps with the recently described 
DFNB66 locus and excluded at the same time the locus DFNB53, in which the gene 
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COL11A2 is known to cause autosomal recessive deafness. Further analysis of the 
critical region led to the investigation of the lipoma HMGIC fusion partner-like 5 
(LHFPL5) gene. Due to the fact that the recently described mouse model carrying 
homozygous mutation in Lhfpl5 showed deafness and vestibular dysfunction (hscy, 
“hurry-scurry” mouse), LHFPL5 seemed to be a highly relevant positional candidate 
gene. In family DF44, we found a homozygous one-base pair deletion 
(p.Glu216ArgfsX26) and in family TR77 we identified a homozygous transition 
(p.Thr165Met) in LHFPL5 by direct sequencing. We screened further index patients 
from 96 Turkish ARNSHL families and 90 Dutch ARNSHL patients and identified the 
one-base pair deletion (p.Glu216ArgfsX26) in one additional Turkish family. In 
addition, we found a heterozygous putative mutation (p.Arg176Leu) in a Dutch 
patient, but could not find a second mutation in LHFPL5. We continued the molecular 
analysis and sequenced the LHFPL5 homologs LHFPL3 and LHFPL4 for 78 index 
patients from Turkish ARNSHL families, but we identified no disease-associated 
mutation. 
 
In conclusion, we found a novel deafness gene, LHFPL5, responsible for ARNSHL in 
humans without vestibular dysfunction, which is in contrast to the “hurry-scurry” 
mouse with vestibular dysfunction. We suggested that loss-of-function of LHFPL5 
causes the phenotype in the investigated families. Moreover, we showed evidence 
from haplotpye analysis that the identified one-base pair deletion was originated by a 
shared founder in the two investigated Turkish families.  
 
Own contributions:  
For this project, I established the test conditions for the sequencing reactions to 
perform the control studies for the identified mutations in control DNAs from 170 
unrelated individuals of Turkish origin and over 90 Caucasian individuals from The 
Netherlands. 
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7.4 Li Y, Wollnik B, Pabst S, Lennarz M, Rohmann E, Gillissen A, Vetter H, 
Grohe C ; BTNL2 gene variant and sarcoidosis ; Thorax. (2006): 61, 273-274 
 
Sarcoidiosis is an immune system disorder characterized by non-caseating 
granulomas (small inflammatory nodules), which primarily affects the lungs and 
lymph node. The clinical course is presented by the acute and chronic type, whereby 
the latter can lead to lung fibrosis. The pathogenesis of the disease is still unknown, 
but a genetic predisposition to develop the disease is assumed due to investigations 
of familial clustering and relatives with increased risk of sacroidosis.  
 
We confirmed a recently described significant association between sarcoidosis and a 
frequent single nucleotide polymorphism (SNP) in the BTNL2 gene, rs2076530, by 
using a case-control association study including 210 patients with sarcoidosis and 
202 controls. By applying the quantitative Taqman technique, we observed that A 
allele carriers of rs2076530 have a more than twofold increased risk of developing 
sarcoidosis compared with GG homozygotes. In addition, we showed that 
susceptibility is preferential towards the chronic form of sarcoidosis. 
 
Own contributions: 
I supported the design of the oligonucleotides and the probe for testing the SNP 
rs2076530. Furthermore, I supported the establishment of the Taqman technique to 
perform the SNP analysis. 
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Mutations in different
components of FGF signaling
in LADD syndrome
Edyta Rohmann1,2, Han G Brunner3, Hu¨lya Kayserili4,
Oya Uyguner4, Gudrun Nu¨rnberg5,6, Erin D Lew7,
Angus Dobbie8, Veraragavan P Eswarakumar7,
Abdullah Uzumcu4, Melike Ulubil-Emeroglu9,
Jules G Leroy10, Yun Li1,2, Christian Becker5,6,
Kai Lehnerdt11, Cor W R J Cremers12,
Memnune Yu¨ksel-Apak4, Peter Nu¨rnberg5,13,
Chriu¨tian Kubisch2,13, Joseph Schlessinger7,
Hans van Bokhoven3 & Bernd Wollnik1,2,4
Lacrimo-auriculo-dento-digital (LADD) syndrome is
characterized by lacrimal duct aplasia, malformed ears and
deafness, small teeth and digital anomalies. We identified
heterozygous mutations in the tyrosine kinase domains of the
genes encoding fibroblast growth factor receptors 2 and 3
(FGFR2, FGFR3) in LADD families, and in one further LADD
family, we detected a mutation in the gene encoding fibroblast
growth factor 10 (FGF10), a known FGFR ligand. These
findings increase the spectrum of anomalies associated
with abnormal FGF signaling.
Autosomal dominant lacrimo-auriculo-dento-digital (LADD) syn-
drome (OMIM 149730), also known as Levy-Hollister syndrome, is
a multiple congenital anomaly mainly affecting lacrimal glands and
ducts, salivary glands and ducts, ears, teeth and distal limb seg-
ments1,2. In addition to these cardinal features, facial dysmorphism,
malformations of the kidney and respiratory system and abnormal
genitalia have been reported3.
We have clinically examined five large LADD families and one
sporadic case presenting a wide range of typical clinical symptoms
with variable expression, even within a family (Table 1 and Fig. 1a–i).
Hypoplasia, atresia and aplasia of the nasolacrimal ducts and puncta
led to frequent conjunctivitis in patients, and salivary gland abnorm-
alities such as hypoplasia or aplasia of the parotid and submandibular
glands caused xerostomia and early-onset caries. Frequently we
observed hypo- and microdontia (Fig. 1d). External ear anomalies
included cup-shaped, small and low-set ears (Fig. 1a–c,e,f), and in over
50% of the cases, we found sensorineural, conductive or mixed-type
hearing loss. Limb defects most often involved the thumbs, ranging
from total aplasia to hypoplastic, digitalized, triphalangeal and dupli-
cated thumbs (Fig. 1g–i). Mild syndactylies of fingers or toes and
lower-limb anomalies were less common. We did not find short stature
or craniosynostosis in any of the affected individuals (Fig. 1a–d).
Initially, we genotyped available DNA samples from 12 affected and
ten nonaffected members in three LADD families (LADD-Ist from
Turkey, LADD-Nij from The Netherlands and LADD-Le from
England) using the Affymetrix GeneChip Human Mapping 10K
Array. We obtained a combined maximum parametric LOD score of
3.61 for a region located between SNPs rs36322 and rs718949 on
chromosome 10q26 (Supplementary Methods and Supplementary
Fig. 1 online), defining a critical interval of about 8.7 Mb. By
performing fine-mapping with microsatellite markers and including
additional family members, we reduced the critical region to a 6.2-Mb
interval between markers D10S1693 and D10S1723 with a maximum
multipoint LOD score of 4.52 (Supplementary Fig. 1 and Supple-
mentary Table 1 online). We considered the FGFR2 gene a highly
relevant positional candidate gene for the following reasons: (i)
conditional knockout of Fgfr2 or expression of a dominant interfering
Fgfr2b mutant in mice results in limb and digit malformations4,5; (ii)
Fgfr2b regulates submandibular gland morphogenesis6 and (iii) hap-
loinsufficiency of FGF10, a known ligand of FGFR2b, in mice and
humans causes lacrimal and salivary gland abnormalities (OMIM
180920)7. We sequenced all 24 coding and noncoding exons of FGFR2
(Supplementary Table 2 online) in affected family members and
identified a heterozygous mutation in each one of them (Fig. 1j–m).
The mutations that cosegregated with the disease were present neither
in unaffected family members nor in 200 ethnically matched control
individuals. We found the 1942G-A transition in exon 16 in all five
affected individuals of the Dutch LADD-Nij family (Fig. 1j and
Supplementary Fig. 2 online), predicting the substitution of the
highly conserved Ala648 by threonine (Supplementary Fig. 3 online).
The same heterozygous A648T missense mutation was identified in all
affected family members of the English LADD-Le family (Fig. 1k and
Supplementary Fig. 2). We subsequently demonstrated by haplotype
analysis that the A648T mutation most likely originated independently
in both families, as it is not located on a common founder haplotype
(Supplementary Fig. 1). All affected individuals in the LADD-Ist
family carried a heterozygous 3-bp deletion, D1947-AGA-1949, in
exon 16 of FGFR2 (Fig. 1m and Supplementary Fig. 2), leading at
position 649 to a substitution of the highly conserved arginine to
Received 19 December 2005; accepted 27 January 2006; published online 26 February 2006; doi:10.1038/ng1757
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serine and to the deletion of the neighboring aspartic acid (R649S
DAsp650). We found further evidence for the involvement of FGFR2
mutations in the pathogenesis of LADD syndrome by identifying a de
novo FGFR2 mutation, 1882G-A (A628T), in a sporadic LADD case
from Belgium (Fig. 1l and Supplementary Fig. 2). Neither of the two
healthy parents (paternity confirmed) carried this mutation. Domi-
nant missense mutations in FGFR2 have been implicated in various
syndromic forms of craniosynostosis, including Pfeiffer (OMIM
101600), Crouzon (OMIM 123500), Apert (OMIM 101200),
Jackson-Weiss (OMIM 123150), Antley-Bixler (OMIM 207410)
and Beare-Stevenson (OMIM 123790) syndromes8. The vast majority
of FGFR2 mutations in these patients are located in the immunoglo-
bulin-like IIIa and IIIc loops in the extracellular ligand-binding
domain of FGFR2. Many of them recurred as de novo mutations
exclusively on the paternal allele8–10. Individuals with Crouzon and
Pfeiffer syndromes very rarely carried a mutation in the intracellular
tyrosine kinase domains (TK1 or TK2)11. It is well established that
FGFR2 mutations found in craniosynostosis are gain-of-function
mutations leading to an increased activation of FGFR2 (refs. 12,13).
We describe for the first time FGFR2 mutations associated with a
different clinical entity that is associated neither with craniosynostosis
nor with severe syndactyly. Notably, inspection of the three-dimen-
sional structure of the tyrosine kinase domain shows that LADD
mutations A648T and R649S DAsp650 are confined to the activation
loop, and the A628T mutation is located in the catalytic loop of the
kinase domain of FGFR2, respectively
(Fig. 1p and Supplementary Fig. 3). This
clustering suggests that these mutations
might affect the tyrosine kinase activity of
FGFR2 and generate developmental distur-
bances leading to LADD syndrome. The
pathophysiological mechanism should differ
significantly from that underlying the cranio-
synostosis syndromes caused by FGFR2
mutations, which are believed to be most
commonly mediated by constitutive tyrosine
kinase activation leading to enhanced para-
crine signaling in the embryonic mesoderm
induced by either FGF10 or related FGFs12.
We continued the molecular analysis in two
newly ascertained LADD families, LADD-Bo
from Germany (of Turkish origin) and
LADD-Ala from Turkey, and excluded
FGFR2 in both families by haplotype analysis.
Subsequently, we used a candidate gene
approach for gene identification in these
families and searched for mutations in other
members of the FGFR gene family including
FGFR1, FGFR3, FGFR4 and two of the known
ligands of FGFR2, FGF10 and FGF8 (Supple-
mentary Table 2). We detected a 317G-T
mutation in exon 1 of FGF10 in the affected
father and three affected children of the
LADD-Bo family (Fig. 1n and Supplementary
Fig. 2) that we did not observe in 200 matched
control individuals. Recently, heterozygous
loss-of-function mutations in FGF10 caused
by a nonsense mutation and gene deletion
have been shown to cause lacrimal system and
salivary gland aplasia in humans and in het-
erozygous Fgf10+/– knockout mice7. In con-
trast, the FGF10 mutation we identified in LADD syndrome is a
missense mutation affecting a conserved amino acid at position 106
(C106F). Supplementary Figure 3 depicts the location of the mutation
within the structure of FGF10. It is plausible that the effect of this
missense mutation is different from the loss-of-function mutations
described in isolated anomalies of the lacrimal system and salivary
glands and that a dominant-negative effect of C106F might explain why
this mutation affects additional organs in LADD syndrome.
Furthermore, we detected a mutation in FGFR3 in the father and
two children in the LADD-Ala family. The 1537G-A transition in
exon 11 of FGFR3 leads to the predicted amino acid substitution
D513N in the conserved TK1 domain of FGFR3 (Fig. 1o and
Supplementary Fig. 2). This mutation was not present in 200 control
individuals. The finding that 1537G-A occurred de novo in the
affected father and was subsequently transmitted to his affected
offspring provides further evidence for the disease-causing nature of
this mutation. Inspection of the structure of the tyrosine kinase
domain has shown that the D513N mutation is located in a loop
that connects the b3 sheet to the aC helix of the tyrosine kinase core
(Supplementary Fig. 3). It is well established that activating FGFR3
missense mutations cause short-limbed bone dysplasias and cranio-
synostosis syndromes, including achondroplasia (OMIM 100800),
severe achondroplasia with developmental delay and acanthosis nigri-
cans (SADDAN; OMIM 134934), hypochondroplasia (OMIM
146000), thanatophoric dysplasia I and II (OMIM 187600), Muenke
Table 1 Phenotypic characteristics of index cases in five LADD families and one sporadic
LADD case
LADD-Ist LADD-Nij LADD-Le LADD-Be LADD-Bo LADD-Ala
III-4 III-4 I-2 Sporadic II-4 III-4
FGFR2 FGFR2 FGFR2 FGFR2 FGF10 FGFR3
Lacrimal
Alacrima + – + + + +
Aplastic or hypoplastic ducts, puncta + – + + + +
Aplastic or hypoplastic gland + – – U – –
Conjunctivitis + – – – – +
Aural
Cup-shaped + + + + + +
Small sized + – + + – +
Hearing loss + + + + U +
Dental
Peg-shaped – – – + – +
Microdontia + + – + U +
Hypodontia – – + + U +
Root anomalies – – – + – +
Dental caries + – – + + +
Digital
Bifid thumb – – + – + –
Triphalangeal thumb + – – – – –
Digitalized thumb – – – – – –
Hypoplastic thumb + + – + – –
Missing thumb – – – – – –
Short radius and ulna – – – – – –
First toe abnormalities – – – – – +
Syndactyly in fingers/toes – – + – – –
Additional findings
Salivary gland anomalies – – + + U –
Facial dysmorphisma + – – – – +
+, present. –, absent. U, unknown.
aIncluding, for example, high forehead, telecanthus, hypotelorism, downslanting palpebral fissures and prognathia.
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syndrome (OMIM 602849) and Crouzon syndrome with acanthosis
nigricans (OMIM 134934)13. Similar to the spectrum of mutations in
FGFR2, the FGFR3 mutations are mainly confined to the extracellular
immunoglobulin-like IIIa and IIIc domains, and few mutations have
been identified in the tyrosine kinase domains8,12,14. In our LADD-Ala
family, there is neither short-limbed bone dysplasia, nor is there
craniosynostosis or severe syndactyly. As with the mutations in
FGFR2, it is likely that the effect of this FGFR3 mutation on the
physiological role of FGF signaling during development substantially
differs from the activating nature of mutations identified in
short-limbed bone dysplasias and syndromic craniosynostosis. An
FGFR3 R621H mutation was identified previously (R. Toydemir
et al., Am. J. Hum. Genet. 73 (Suppl.), 171, 2003) in a family with
an autosomal dominant inherited syndrome characterized by sensor-
ineural hearing loss, camptodactyly, tall stature, microcephaly and
developmental delay. Because of the phenotypic overlap with
Fgfr3-deficient mice, a putative dominant-negative effect of R621H
was hypothesized, although no experimental support was provided.
We find a clear phenotypic difference between the family reported in
that study and our LADD-Ala family, with only bilateral hearing loss
as an overlapping feature, suggesting different functional effects of the
two mutations.
We conclude that LADD syndrome is a genetically heterogeneous
disorder caused by heterozygous missense mutations in FGFR2,
FGFR3 or FGF10. Notably, all FGFR mutations so far identified in
LADD are located in the tyrosine kinase domains of FGFR2 or FGFR3,
in loops that have a regulatory function in the control of tyrosine
kinase activity. Although experimental support is needed, a reduced
functional activity of FGFR2 and FGFR3 seems to be an attractive,
plausible mechanism underlying the molecular basis for LADD.
Note: Supplementary information is available on the Nature Genetics website.
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Figure 1 Clinical findings, pedigrees and mutations in FGFR2, FGFR3 and FGF10 in LADD syndrome. (a–i) Phenotypic characteristics of LADD patients
from different families: (a,d) LADD-Ala, III-2; (b) LADD-Ala, III-1; (c) LADD-Ist, II-5 and III-4; (e) LADD-Be, II-1; (f) LADD-Nij, III-4; (g,h) LADD-Nij, II-3;
(i) LADD-Bo, II-4. (a–f) Photographs show facial appearance and typical ear anomalies in LADD patients. Digital anomalies included hypoplastic (g), absent
(h) and bifid (i) thumbs. (j–o) Pedigrees of LADD families. Family name, gene involved and identified mutation are given in the gray box on top of each
pedigree. Symbols: +, mutation present; –, mutation absent. Filled black symbols indicate affected individuals; filled gray symbols in the LADD-Bo family
represent individuals who were probably affected but for whom a detailed clinical description is lacking. (p) Schematic model of FGFR2 and FGFR3. The
locations of different mutations are marked by red dots on the receptor or ligand (FGF10). The intracellular tyrosine kinase domains of FGFR2 and FGFR3
are shown in orange.
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Lacrimo-auriculo-dento-digital (LADD) syndrome is characterized by abnormalities in lacrimal and salivary
glands, in teeth, and in the distal limbs. Genetic studies have implicated heterozygous mutations in fibroblast
growth factor 10 (FGF10) and in FGF receptor 2 (FGFR2) in LADD syndrome. However, it is not clear whether
LADD syndrome mutations (LADD mutations) are gain- or loss-of-function mutations. In order to reveal the
molecular mechanism underlying LADD syndrome, we have compared the biological properties of FGF10
LADD and FGFR2 LADD mutants to the activities of their normal counterparts. These experiments show that
the biological activities of three different FGF10 LADDmutants are severely impaired by different mechanisms.
Moreover, haploinsufficiency caused by defective FGF10 mutants leads to LADD syndrome. We also demon-
strate that the tyrosine kinase activities of FGFR2 LADD mutants expressed in transfected cells are strongly
compromised. Since tyrosine kinase activity is stimulated by ligand-induced receptor dimerization, FGFR2
LADD mutants may also exert a dominant inhibitory effect on signaling via wild-type FGFR2 expressed in the
same cell. These experiments underscore the importance of signal strength in mediating biological responses
and that relatively small changes in receptor signaling may influence the outcome of developmental processes
in cells or organs that do not possess redundant signaling pathway.
Fibroblast growth factors (FGFs) mediate their biological
responses by binding to four receptor tyrosine kinases (RTKs)
designated FGF receptor 1 (FGFR1) to FGF4 (25). The bind-
ing of FGF to FGFR in the presence of heparin sulfate gly-
cosaminoglycan induces receptor dimerization and the activa-
tion of the protein tyrosine kinase domain (30). Tyrosine
autophosphorylation and the recruitment of a complement of
downstream signaling molecules result in the stimulation of
various signaling cascades that play critical roles in mediating
the pleiotropic responses of FGFs during development and in
the adult organism (10).
Like all RTKs, FGFRs are composed of an extracellular ligand
binding domain, a transmembrane region, and a cytoplasmic re-
gion containing a catalytic protein tyrosine kinase core and addi-
tional regulatory sequences. The extracellular domain is com-
posed of three immunoglobulin-like domains (designated D1, D2,
and D3), a stretch of negatively charged amino acids in the linker
connecting D1 and D2 termed the acidic box, and a conserved
positively charged region in D2 that serves as the binding site for
heparin sulfate or heparin (13, 17, 30, 31). FGFR1, -2, and -3
transcripts are subject to alternative RNA splicing in which exon
7 of the FGFR gene codes for a common N-terminal half of D3
(referred to as a) and exons 8 and 9 code for the C-terminal
half of D3 to generate the b and c isoforms, respectively (21,
39). The b isoforms are expressed exclusively in epithelial cells,
while the c isoforms are expressed only in mesenchymal cells
(1, 9, 26, 38). Moreover, the IIIb and IIIc isoforms of FGFR1, -2,
and -3 bind to different complements of FGFs that are expressed
exclusively in mesenchymal or epithelial cells, respectively. For
example, the FGFR2-b isoform (also designated FGFR2b)
binds FGF7, FGF10, and FGF22, while FGFR2-c (also desig-
nated FGFR2c) binds FGF2, FGF8, FGF17, and FGF18 (14).
FGF1, on the other hand, functions as a universal FGFR ligand,
as it binds to all “b” and “c” FGFR isoforms. Strict lineage-
specific expression of the two alternatively spliced isoforms of
FGFR2 is essential for normal embryonic development.
Targeted disruption of the FGFR1 gene has shown that the
FGFR1c isoform plays an essential role during early embryo-
genesis. The biological roles of FGFR2b, FGFR2c, and their
specific ligands have also been explored by targeted disruption
of isoform-specific genes fragments in the mouse by use of
homologous recombination. Targeted disruption of the
FGFR2b results in lethality at birth due to lung agenesis (7).
Interestingly, the phenotype of the FGF10 null mice is similar
to the phenotype of FGFR2b null mice (32). Characterizations
of the phenotypes of mice deficient in FGF10 or FGFR2b have
shown that FGF10 and FGFR2b play an essential role in the
control of branching morphogenesis during the development
of lung, pancreas, mammary gland, thyroid, lacrimal gland, and
salivary gland. Moreover, aplasia of the lacrimal gland and
hypoplasia of the salivary gland were observed for adult het-
erozygous FGF10 mice, indicating that the normal develop-
ment of both glands depends on a precisely balanced dose of
signaling stimulated by FGF10 (5, 17). Finally, human genetic
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studies and selective targeting of the FGFR3b and FGFR3c
isoforms in mice have implicated the FGFR3c isoform in a
variety of skeletal disorders (6, 8).
Recent studies have shown that patients with aplasia (or
hypoplasia) of the lacrimal and salivary glands (ALSG) bear
heterozygous mutations in the FGF10 gene (4, 5). Mutations in
FGF10 were also detected for patients with lacrimo-auriculo-
dento-digital (LADD) syndrome, which shows overlapping
features with ALSG but in addition is characterized by facial
dysmorphisms, outer and inner ear anomalies and hearing loss,
teeth anomalies, distal limb malformations, and, more infre-
quently, impairment of kidney and lung development (2, 4, 12,
20, 22, 28). Genetic analysis has also revealed heterozygous
mutations in FGFR2 and FGFR3 in LADD syndrome patients
(28), implicating aberrant signaling by FGF10, FGFR2, or
FGFR3 in this heterogeneous disorder.
In this report, we describe the biological properties of
FGF10 and FGFR2b mutants implicated in LADD syndrome.
We show that LADD syndrome mutations (LADD mutations)
cause inactivation of FGF10 and that the tyrosine kinase ac-
tivity of FGFR2b LADD mutants expressed in cultured cells is
severely compromised. While the FGF10 mutation causes
haploinsufficiency, the FGFR2b mutants may exert a dominant
interfering effect on signaling via normal FGFR2b, causing
LADD syndrome.
MATERIALS AND METHODS
Growth factors, antibodies, plasmids, and recombinant proteins. FGF1 and
FGF2 were prepared and used as a stock solution at a concentration of 100 g/ml
with 5 mg/ml heparin for stimulation of cultured cells (33). Heparin agarose
beads and Lipofectamine 2000 were purchased from Sigma and Invitrogen,
respectively. Anti-FGFR2, anti-Grb2, anti-FRS2, and anti-Shc antibodies were
previously described (6, 19). Antiphosphotyrosine (anti-p-Tyr) antibodies were
purchased from Upstate Biotechnology. Anti-phospho-mitogen-activated pro-
tein kinase (anti-pMAPK) and anti-MAPK were purchased from Cell Signaling
Technology. Horseradish peroxidase-conjugated protein A and horseradish per-
oxidase-conjugated goat anti-mouse antibodies were purchased from Kirkegaard
& Perry Laboratories and Santa Cruz Biotechnology, respectively. Geneticin was
purchased from GIBCO. Human FGF10 and FGF10 LADD mutants were
expressed in Escherichia coli by use of the bacterial expression vector pET11c
(Novagen) (3). Both Mirb and retroviral pBABE/neo expression vectors were
used for human FGFR2 expression as previously described (11, 24). Point mu-
tations in FGF10 and FGFR2 were generated using a QuikChange site-directed
mutagenesis kit from Stratagene. pcDNA-3 expression vector (Invitrogen) was
used for FGFR2b transient expression in 293 cells.
Purification of FGF10 and FGF10 LADD mutants. BL21(DE3) pLysS E. coli
cells were transformed with expression vector for FGF10 or FGF10 LADD
mutants and grown overnight in LB medium at 25°C. The bacterial cell pellet was
resuspended in lysis buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 5% glycerol,
1 mM phenylmethylsulfonyl fluoride, and 2 mM EDTA), lysed by use of a French
pressure cell (Thermo Electron Corp.), and centrifuged for 1 h at 32,000  g.
The cell supernatant was incubated with heparin-agarose beads for 1.5 h at 4°C,
and FGF-bound beads were washed three times with lysis buffer. Washed beads
were applied to a column and FGF10 or FGF10 LADD mutants were eluted
using 20 mM HEPES buffer, pH 7.4, containing 1 M NaCl. Eluted proteins were
further purified by fast-performance liquid chromatography (Amersham Bio-
sciences) using a Mono S column (GE Healthcare). Protein purity was deter-
mined using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) analysis.
Cell lines. L6 cells devoid of endogenous FGFRs were cultured in Dulbecco’s
modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS), 2
mM L-glutamine with 100 g/ml penicillin and 100 g/ml streptomycin. L6 cells
were transfected with expression vectors for wild-type (WT) FGFR2b and
FGFR2b mutants that were cloned into the Mirb or pBABE/neo expression
vectors. Cells were transfected with Lipofectamine 2000 and selected in growth
medium containing 1 mg/ml geneticin. Individual clones as well as cell pools were
screened for FGFR2 expression using anti-FGFR2 antibodies. Prior to growth
factor stimulation, cells were starved overnight in medium containing 0.1% FBS.
293 cells were transfected with Lipofectamine 2000 and incubated in transfection
medium for 6 h; this was followed by changing the medium to DMEM containing
10% FBS. Cells were harvested and lysed 18 h later.
Radiolabeling of FGF10 and ligand displacement assay. Human FGF10 (10
g) was labeled with 0.5 mCi of 125I by use of Iodo-Gen iodination tubes (Pierce)
following the manufacturer’s instructions. For the displacement binding assay,
L6 cells expressing FGFR2b were grown in 24-well plates in DMEM containing
10% FBS. Confluent cells were washed with DMEM containing 0.5% bovine
serum albumin (BSA) and then incubated for 1 h at room temperature with 2 ng
of 125I-labeled FGF10 in the presence of increasing concentrations of FGF1,
FGF10, or the FGF10 LADD mutants. Cells were then washed three times with
cold DMEM-BSA and lysed in 0.5 ml of 0.5 M NaOH for 30 min at room
temperature, and 100 l of the cell lysate was applied to 10 ml of Opti-Fluor
scintillation cocktail (Perkin Elmer) in order to measure cell-associated radio-
activity (using an LS6500 scintillation counter from Beckman Coulter).
Limited proteolysis. Limited proteolysis analysis of FGF10 or FGF10 LADD
mutants was carried out using factor Xa (12 105 U/l), endoproteinase Glu-C
(V8 protease) (0.04 g/l), and endoproteinase Lys-C (12  104 U/l). All
enzymes were purchased from Roche and used in a series of 10-fold dilutions.
FGF10 or FGF10 LADD mutants were incubated with the enzymes for 2 h at
25°C, and the proteolytic products were visualized by SDS-PAGE followed by
Coomassie brilliant blue staining.
Intrinsic fluorescence spectrum measurements. FGF10 or the FGF10 LADD
mutants (30 g/ml in 20 mM HEPES, pH 7.4, 400 mM NaCl) were incubated at
37°C for various periods and then cooled to room temperature. To measure
fluorescence emission, samples were excited at a wavelength of 285 nm, and
emission was scanned at  of between 300 and 380 nm by use of a fluorometer
(Photon Technology International).
RESULTS
Several mutations in FGF10 were identified in LADD pa-
tients, including a missense mutation in which cysteine 106 is
substituted by a phenylalanine (p.C106F), a missense mutation
in which isoleucine 156 is substituted by an arginine (p.I156R),
and a nonsense mutation (p.K137X) causing a deletion of 71
carboxy-terminal residues of FGF10 (22, 28). To study the
biological activities of the FGF10 LADD mutants, WT or
mutant FGF10 proteins were expressed in E. coli. While the
expression of WT FGF10 and the I156R mutant was detected
in cells that were induced by isopropyl--D-thiogalactopyrano-
side (IPTG) at 37°C, expression of the C106F mutant was
detected only in cells induced at 25°C, suggesting temperature
sensitivity of the C106F LADD mutant (data not shown). Ex-
pression of the K137X mutant could not be detected for any
experimental condition that was tried. We surmised that be-
cause of the large truncation, the K137X FGF10 mutant was
probably misfolded, resulting in rapid degradation. For large-
scale production of WT FGF10 and the two FGF10 LADD
mutants, cells were induced at 25°C overnight. WT or mutant
FGF10 was purified on a heparin affinity matrix followed by
cation-exchange chromatography using a Mono S column. WT
FGF10 and the LADD mutants were eluted from either hep-
arin or the Mono S columns (Fig. 1) at similar salt concentra-
tions, indicating that the surface charge of the FGF10 LADD
mutants was not substantially altered.
Impaired activity of the I156R mutant is caused by defi-
ciency in receptor binding. We first compared the capacities of
WT FGF10 and the I156R LADD mutant to stimulate L6 cells
expressing FGFR2b. Lysates of unstimulated or ligand-stimu-
lated cells were subjected to immunoprecipitation with anti-
FGFR2 antibodies followed by SDS-PAGE and immunoblot-
ting with anti-p-Tyr antibodies. The experiment presented in
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Fig. 2A shows that unlike WT FGF10, which stimulated L6
cells, the I156R mutant was unable to stimulate the tyrosine
autophosphorylation of FGFR2b or the tyrosine phosphoryla-
tion of the downstream signaling molecules FRS2 and Shc.
Furthermore, MAPK stimulation was not detected in L6 cells
stimulated with the I156R LADD mutant. To understand why
the I156R FGF10 mutant was unable to induce receptor au-
tophosphorylation, we next examined its binding affinity to-
wards FGFR2b by using a displacement assay in which cell-
bound 125I-labeled WT FGF10 was displaced by increasing
concentrations of native FGF10 (as a control) or the I156R
FGF10 LADD mutant. The experiment presented in Fig. 2C
shows that the 50% inhibitory concentration of 125I-labeled
FGF10 bound to FGFR2b of the I156R LADD mutant is
approximately ninefold higher than the 50% inhibitory con-
centration of FGF10 towards FGFR2b expressed on the cell
surfaces of L6 cells. This experiment demonstrates that the
impaired biological activity of the I156R mutant is caused by
compromised binding affinity towards FGFR2b.
Reduced stability of the C106F LADD mutant is responsible
for its impaired biological activity. During the course of the
expression and purification of FGF10 and the FGF10 LADD
mutants, the production of the C106F LADD mutant after the
E. coli cells were induced at 37°C was very low compared to the
production of WT FGF10 and of the I156R LADD mutant
under the same conditions. The displacement assay presented
in Fig. 2C showed that the receptor binding profile of the
purified C106F LADD mutant is similar to the binding char-
acteristics of FGF10 towards FGFR2b expressed on the cell
surfaces of L6 cells. Moreover, both WT FGF10 and the
C106F LADD mutant showed similar levels of stimulation of
tyrosine autophosphorylation of FGFR2b and similar MAPK
responses upon cell stimulation when a broad range of FGF10
or C106F LADD mutant concentrations were applied (Fig. 2A
and B). We next examined whether the C106F mutation affected
FGF10 stability. Protein stability was first tested by comparing the
susceptibilities of FGF10 and the C106F LADD mutant towards
limited proteolysis by the enzymes V8 protease, factor Xa, and
Lys-C. The experiment presented in Fig. 3A shows that unlike
WT FGF10, the C106F LADD mutant undergoes rapid degra-
dation, resulting in the formation of low-molecular-weight degra-
dation products when treated with these enzymes.
The stabilities of WT FGF10 and the C106F and I156R
LADD mutants at 37°C were further tested by comparing the
intrinsic fluorescence spectra of FGF10 and the FGF10 LADD
mutant as a function of time at 37°C. The experiments pre-
sented in Fig. 3B show that the fluorescence spectra of FGF10
and the I156R LADD mutant were stable over a period of 3 h
of incubation at 37°C. By contrast, the fluorescence spectrum
of the C106F LADD mutant changed within 2 min of incuba-
tion at 37°C. Moreover, a strong increase in the fluorescence
intensity emitted from the C106F LADD mutant was observed
after 20 min of incubation at 37°C. It is well established that
fluorescence spectra of tryptophan and tyrosine residues of
proteins can be used as a diagnostic tool to reveal local struc-
tural alterations that take place in host proteins (34). Since
FGF10 and the FGF10 LADD mutants were excited at a wave-
length of 285 nm, changes in fluorescence spectra will reflect local
structural changes that take place in the vicinity of tryptophan
residues of the proteins. The changes in the fluorescence spec-
trum of the C106F LADD mutant at 37°C may reflect the re-
duced stability of FGF10 mutant at a physiological temperature.
Since our results show that incubation of the C106F LADD
mutant at 37°C affected the structural integrity of the mutant
protein, we next examined the impact of these changes on
cellular responses induced by the C106F LADD mutant at
37°C. Both FGF10 and the C106F LADD mutant were prein-
cubated for various periods at 37°C in the absence or presence
of heparin, and each sample was then used to stimulate, for an
additional 5 minutes, L6 cells stably expressing FGFR2b. The
experiment presented in Fig. 3C shows that the capacity of
C106F LADD mutant to induce the tyrosine autophosphory-
lation of the FGFR2b and MAPK response was strongly com-
promised and that within 30 min of incubation at 37°C the
activity of the C106F LADD mutant nearly vanished (Fig. 3C).
Interestingly, in the presence of exogenous heparin the stabil-
ity of C106F was protected. It is possible, however, that the
majority of C106F LADD mutant molecules were not secreted
from the cells after biosynthesis, as most of the unstable mu-
tant molecules were degraded shortly after production.
Potential mechanism for impairment FGF10 LADD mutant
activity. In order to gain insights into the mechanism underly-
ing the diminished receptor binding activity of the I156R mu-
tant, we examined the potential impact of the substitution of
isoleucine 156 by an arginine residue on the receptor binding
region of FGF10 in the X-ray crystal structure of FGF10 (40).
Figure 4 shows that isoleucine 156 is located in the 8 strand
of FGF10, in a region that forms contacts with the F-G loop
of FGFR2b (23, 40). It is expected that the substitution of
isoleucine 156 with the larger arginine residue will cause a
FIG. 1. Profiles of purification of WT FGF10 and LADD FGF10
mutants. (A) Mono S column elution profiles of FGF10 (WT) and the
two FGF10 C106F and I156R LADD mutants. (B) Coomassie brilliant
blue staining of FGF10 and the LADD mutants after SDS-PAGE
analysis of two fractions of purified proteins.
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steric clash with critical amino acids in the ligand binding
pocket of FGFR2b (Fig. 4B). Moreover, the I156R LADD
mutation may also destroy the highly conserved hydrogen
bonds between Gly160 and Asn162 of FGF10 with Arg251 in
the D2-D3 linker region of FGFR2, due to repulsion between
Arg156 of the FGF10 LADD mutant and Arg251 of FGFR2b.
The I156R mutation may also destroy the electrostatic inter-
action between Arg78 of FGFR10 with Arg251 and Asp283 of
D3 of FGFR2b. Moreover, the Arg156 mutation in FGF10
may cause a steric clash and/or an electrostatic repulsion with
Arg251 of FGFR2b that will disrupt three critical electrostatic
interactions essential for FGF10 binding to FGFR2b.
We have also examined the potential impact of the substi-
tution of cysteine 106 with a phenylalanine residue on the
structure of FGF10 and its interactions with FGFR2b. Cys-
teine 106 is located in the 3-4 loop of FGF10, a region that
does not play a role in FGFR2b recognition (40). Indeed, the
FGFR2b binding activity of the C106F LADD mutant re-
mained unchanged. However, the replacement of cysteine 106
with a large hydrophobic residue such as phenylalanine may
create a bulky region, which will become exposed, resulting in
reduced stability and susceptibility to proteolytic digestion.
Human mature FGF10 (amino acids 38 to 208) contains an
additional cysteine residue at position 150. Inspection of the
FGF10 structure (40) shows that Cys106 is located on the
surface of FGF10, while Cys150 is buried in FGF10, and that
the distance between Cys106 and Cys150 is 22 Å. The two
cysteines are unlikely to form an intramolecular disulfide bond.
Reduced tyrosine kinase activity of FGFR2b LADD mu-
tants. The mutations in FGFR2 that were identified for a
variety of skeletal dysplasias have been mapped to the extra-
cellular ligand binding domain in the vast majority of cases and
less frequently in the tyrosine kinase domain, including the
catalytic core and its regulatory activation loop. Biochemical
characterization of mutant receptors has shown that FGFR2
mutations that are responsible for craniosynostosis and other
FIG. 2. Functional activities of LADD FGF10 mutants. (A) FGFR activation, substrate phosphorylation, and MAPK response following
stimulation with FGF1, FGF10, or C106F and I156R LADD mutants. L6 cells stably expressing FGFR2b were stimulated with buffer alone or with
FGF1, FGF10, or the C106F and I156R LADD mutants for 5 minutes at 37°C at different ligand concentrations as indicated. Lysates from
unstimulated or ligand-stimulated cells were subjected to immunoprecipitation (IP) with anti-FGFR2 antibodies (top) or anti-Grb2 antibodies
(middle). The bottom shows total cell lysates (TCL). The samples were subsequently subjected to immunoblotting (IB) with anti-FGFR2 or
anti-p-Tyr antibodies (top), anti-Grb2 or anti-p-Tyr antibodies (middle), or anti-MAPK or anti-activated pMAPK antibodies (bottom). (B) Stim-
ulation of FGFR2 activation and MAPK response by FGF1, FGF10, and the C106F mutant as a function of ligand concentration. L6 cells
expressing FGFR2b were stimulated with buffer alone or with FGF1, FGF10, or the C106F LADD mutant at different ligand concentrations as
indicated for 5 min at 37°C. Lysates from unstimulated or ligand-stimulated cells were subjected to immunoprecipitation with anti-FGFR2
antibodies (top) or presented as total cell lysates (bottom) followed by immunoblotting with anti-FGFR2 or anti-p-Tyr antibodies (top) and
immunoblotting with anti-MAPK or anti-activated pMAPK antibodies (bottom). (C) Displacement assay of cell-bound 125I-labeled FGF10 with
FGF1, FGF10, or the FGF10 C106F and I156R LADD mutants. L6 cells expressing FGFR2b were incubated with 125I-labeled FGF10 in the
presence of increasing concentrations of FGF1, FGF10, or the two FGF10 C106F and I156R LADD mutants for 1 hour at room temperature. The
cells were washed three times with DMEM containing 0.1% BSA, pH 7.5, and lysed in 0.1 M NaOH for 30 min at room temperature. Samples
were collected and their radioactive contents were determined using a scintillation counter. Samples of displacement curves were done in duplicate
for FGF1 (f), FGF10 (✚), C106F (), and I156R ().
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severe bone disorders are gain-of-function mutations that en-
hance the tyrosine kinase activity of the receptor molecules.
The mutations in FGFR2 that have been implicated in LADD
syndrome were mapped to the activation loop or the catalytic
loop of FGFR2. However, it is not clear whether the LADD
mutations in FGFR2 are gain- or loss-of-function mutations.
In order to reveal the molecular mechanism of the FGFR2
LADD mutations, expression vectors that direct the synthesis
of FGFR2b carrying the LADD mutations were prepared and
tested for their biological activity following transient expres-
sion in 293 cells or by stable expression in L6 cells. The tyrosine
kinase activities of FGFR2b carrying LADD mutations in the
activation loop (A648T and R649S) or in the catalytic loop
(A628T) were compared to the tyrosine kinase activities of
WT FGFR2b, of a kinase-defective (KD) FGFR2b mutant
(K508A), and of a Pfeiffer syndrome gain-of-function FGFR2b
FIG. 3. Decreased stability of C106F FGF10 LADD mutants. (A) Enhanced susceptibility to proteolytic degradation of the C106F LADD
mutant. Purified FGF10 or the two FGF10 LADD mutants, the C106F and I156R mutants (marked by arrows), were incubated with different
amounts of V8 protease, factor Xa, or Lys-C for 2 hours at 25°C. The proteolytically digested samples were analyzed by SDS-PAGE and stained
with Coomassie brilliant blue. (B) Fluorescence spectra of the C106F LADD mutant reveals structural changes after incubations at 37°C. Intrinsic
fluorescence spectra of purified FGF10 or the two FGF10 LADD mutants incubated for increasing periods of time at 37°C. Shown are fluorescence
spectra excited at a wavelength of 285 nm of buffer alone () or of WT FGF10 and the I156R and C106F mutants after 0 (f)-, 20 (Œ)-, 40 ()-,
60 ()-, 120 (F)-, or 180 ()-min incubations at 37°C. The bottom right shows additional fluorescence spectra of the C106F mutant taken after
0 (f)-, 2 (F)-, 5 (E)-, 10 ()-, 15 ()-, and 20 (Œ)-min incubations at 37°C. (C) Reduced activity of the C106F LADD mutant after incubations
at physiological temperature. L6 cells expressing FGFR2b were stimulated for 5 min at 37°C with purified FGF10 or C106F mutant in the absence
(left) or presence (right) of heparin that was preincubated for increasing periods at 37°C. Lysates from unstimulated and ligand-stimulated cells
were subjected to immunoprecipitation (IP) with anti-FGFR2 antibodies (top). Shown at the bottom are total cell lysates (TCL). After
SDS-PAGE, the samples were subjected to immunoblotting (IB) with anti-FGFR2 or anti-p-Tyr antibodies (top) or anti-MAPK or anti-activated
pMAPK antibodies (bottom).
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(K641R) mutant (18, 29) as controls. Cells expressing WT
FGFR2b or the various mutants were stimulated with FGF10,
and lysates from unstimulated or FGF10-stimulated cells were
subjected to immunoprecipitation with anti-FGFR2 antibodies
followed by SDS-PAGE and immunoblotting with anti-p-Tyr
antibodies. The results presented in Fig. 5 show FGF10 stim-
ulation of the tyrosine autophosphorylation of WT FGFR2b
and the K641R Pfeiffer syndrome FGFR2b mutant. By con-
trast, FGF10 stimulation of the three FGFR2b LADD mutants
led to very weak tyrosine autophosphorylation of mutant
FGFR2b. Different degrees of tyrosine autophosphorylation
were detected for the three LADD mutants, with the R649S
mutant having the highest tyrosine kinase activity and the
A628T mutant having the weakest tyrosine kinase activity. In
addition, the three LADD mutants failed to stimulate tyrosine
phosphorylation of two well-characterized FGFR substrates,
FRS2 and Shc, as revealed by immunoprecipitation with anti-
Grb2, anti-FRS2, or anti-Shc antibodies followed by SDS-
PAGE and immunoblotting with anti-p-Tyr antibodies (Fig.
5B). We have also shown that MAPK stimulation in response
FIG. 4. Models of FGF10 LADD mutation based on the X-ray crystal structure of FGF10. (A) Ribbon diagram of part of the interface between
FGF10 and the extracellular ligand binding domain of FGFR2b in the region that is mutated in the FGF10 I156R LADD mutant. Asn162 and
Gly160 of FGF10 form hydrogen bonds with Arg251 of FGFR2b. Arg251 is also involved in mediating intramolecular interactions with Arg251
and Asp285 that contribute towards the formation of the D3 cleft of FGFR2b. FGF10 is colored in green and FGFR2b is colored in cyan. (B) The
same view as in panel A; in this view, isoleucine 156 is replaced by an arginine residue in the FGF10 LADD mutant. It is expected that an arginine
residue (shown in red mesh) in place of an isoleucine residue will interrupt FGF10 binding by steric clash and by introducing electrostatic repulsion
between Arg251 of FGFR2b with Arg156 of the FGF10 LADD mutant. FGF10 is colored in green and FGFR2b is colored in cyan. (C) A ribbon
diagram of FGF10 in the region that is mutated in the C106F LADD mutant. The LADD mutation is located in a region of FGF10 that does not
participate in FGFR2b binding. FGF10 is colored in green and FGFR2b is colored in cyan. (D) The same view as in panel C; in this view, cysteine
106 in the 3-4 loop is replaced by a phenylalanine residue in the FGF10 LADD mutant. Substitution of a cysteine residue by a hydrophobic bulky
phenylalanine residue will perturb the structure of this region. This may result in decreased stability of the C106F LADD mutant. FGF10 is colored
in green and FGFR2b is colored in cyan.
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to FGF10 stimulation could barely be detected in L6 cells
expressing the FGFR2b LADD mutants. By contrast, robust
FGF10-dependent or FGF10-independent MAPK responses
were detected in L6 cells expressing WT FGFR2b or the
K641R Pfeiffer syndrome FGFR2b mutant, respectively (Fig.
5C). Furthermore, coexpression of WT FGFR2b with the
R649S LADD mutant in transfected cells reveals a dominant
interfering effect on the autophosphorylation of WT FGFR2
expressed in the same cells (Fig. 5D).
On the basis of these experiments, we conclude that the
intrinsic tyrosine kinase activity of FGFR2 LADD mutants is
strongly attenuated, resulting in impaired tyrosine phosphory-
lation of critical substrates and cell signaling. It is noteworthy,
however, that weak tyrosine kinase activities could be detected
for the LADD mutants that are above the background tyrosine
kinase activity detected for the KD K508A mutant. Since all
LADD mutations are clustered in the catalytic domain of
FGFR2, a region common to both the b and c isoforms, these
mutations will affect the tyrosine kinase activities of both the
FGFR2b and FGFR2c isoforms.
DISCUSSION
Signaling pathways activated by FGFs and FGFRs have
been identified in multicellular organisms from Caenorhabditis
elegans to vertebrates. It is now well established that the FGFR
family of RTKs and their numerous ligands play crucial roles in
many developmental and physiological processes and that a
variety of diseases are caused by aberrant signaling induced by
FGFs or FGFRs (25, 30). The biological roles of individual
FGFs and FGFRs have been analyzed by targeted disruption
in mice of individual or combinations of FGF or FGFR genes
or via analysis of disease-causing mutations in humans. In
humans, both loss- and gain-of-function heterozygous muta-
tions have been described. Several human skeletal dysplasias
are caused by gain-of-function mutations in FGFR1, FGFR2,
FIG. 5. Reduced tyrosine kinase activity, substrate phosphorylation, and MAPK response by FGFR2b LADD mutants. (A) Tyrosine kinase
activity of FGFR2b LADD mutants. L6 cells expressing WT FGFR2b, a kinase-negative FGFR2b mutant (KD), a Pfeiffer syndrome FGFR2b
mutant (K641R), or FGFR2b A628T, A648T, and R649S LADD mutants were stimulated with FGF10 for 5 minutes at 37°C as indicated. Lysates
of unstimulated or FGF10-stimulated cells were subjected to immunoprecipitation (IP) with anti-FGFR2 antibodies followed by SDS-PAGE and
immunoblotting (IB) with anti-FGFR2 or anti-p-Tyr antibodies. (B) Impaired substrate phosphorylation by FGFR2b LADD mutants. L6 cells
expressing WT FGFR2b, a kinase-negative FGFR2b mutant (KD), a Pfeiffer syndrome FGFR2b mutant (K641R), or FGFR2b A628T, A648T,
and R649S LADD mutants were stimulated with FGF10 for 5 minutes at 37°C. Lysates of unstimulated or FGF10-stimulated cells were subjected
to immunoprecipitation with anti-FRS2 antibodies (top), anti-Shc antibodies (middle), or anti-Grb2 antibodies (bottom). After SDS-PAGE, the
samples were subjected to immunoblotting with anti-FRS2 or anti-p-Tyr antibodies (top), anti-Shc or anti-p-Tyr antibodies (middle), or anti-Grb2
or anti-p-Tyr antibodies (bottom). (C) Impaired MAPK response in cells expressing FGFR2b LADD mutants. L6 cells expressing WT FGFR2b,
a kinase-negative FGFR2b mutant (KD), a Pfeiffer syndrome FGFR2b mutant (K641R), or the FGFR2b A628T, A648T, and R649S LADD
mutants were stimulated with FGF10 for 5 minutes at 37°C. Lysates of unstimulated or FGF10-stimulated cells were subjected to immunopre-
cipitation with anti-FGFR2 antibodies followed by SDS-PAGE and by immunoblotting with anti-FGFR2 or anti-p-Tyr antibodies (top). The
bottom shows total cell lysates (TCL) subjected to SDS-PAGE and immunoblotting with anti-MAPK or anti-activated pMAPK antibodies.
(D) Dominant interfering effect of the FGFR2b R649S LADD mutant on tyrosine kinase activity of WT FGFR2b. HEK 293 cells coexpressing
WT FGFR2b (0.2 g DNA/10-mm plate) together with increasing amounts (0.2, 0.4, and 1 g DNA) of WT FGFR2b, a kinase-negative FGFR2b
mutant (KD), and the FGFR2b R649S LADD mutant were analyzed. Cell lysates were subjected to immunoprecipitation with anti-FGFR2
antibodies followed by SDS-PAGE and immunoblotting with either anti-FGFR2 or anti-p-Tyr antibodies.
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and FGFR3. Activating mutations mapped in the extracellular
ligand binding domain were found in FGFR1 and FGFR2
associated with Pfeiffer, Crouzon, Jackson-Weiss, and Apert
syndromes and in the FGFR2 kinase domain associated with
Pfeiffer and Crouzon syndromes. Likewise, activating muta-
tions in FGFR3 were mapped to the transmembrane and the
tyrosine kinase domains found for achondroplasia, thanato-
phoric dysplasia type I (TDI), and TDII (reviewed in refer-
ences 6, 27, 35, and 36). Interestingly, the nature and severity
of the disease might depend on the mutated amino acid; re-
placement of the same residue by different amino acids may
strongly influence the severity of disease. For example, re-
placement of lysine 650 in the tyrosine kinase domain of
FGFR3 by a methionine results in short limbs and develop-
mental delay (dwarfism, severe achondroplasia with develop-
mental delay and acanthosis nigricans), while replacement of
the same lysine by a glutamic acid results in lethality (TDII)
(15, 16, 35). These observations emphasize the complexity of
molecular change that takes place as the consequence of mu-
tations in FGFRs that may influence receptor activity, receptor
stability, and receptor localization, among other changes. It is
striking that all syndromes described above are caused by gain-
of-function mutations in the c isoform of FGFRs, although in
some cases mutations were also found in a region common to
both b and c FGFR isoforms.
Genetic studies of families and patients with sporadic
LADD syndrome revealed mutations in the tyrosine kinase
domains of FGFR2 and FGFR3 (28). The three missense
mutations identified in FGFR2 are located in catalytic
(A628T) and activation (A648T, R649S) loops, and a single
mutation was found in the tyrosine kinase domain of FGFR3
(D513N). Several mutations in LADD syndrome patients were
identified in FGF10 (C106F, I156R), including a nonsense
mutation leading to a premature stop of translation (K137X)
(22, 28). A nonredundant role of the FGF10-FGFR2b signal-
ing pathway in lacrimal and salivary gland development was
proposed based on the phenotypes of mice deficient in these
genes. Aplasia in the lacrimal gland and hypoplasia in the
salivary gland were observed for FGF10/ mice as well as for
mice heterozygous for FGF10 and FGFR2b (FGF10/
FGFR2b/ mice) (5). Despite the observation that mutations
in either FGF10 or FGFR2 cause LADD syndrome, the un-
derlying mechanism is not clear. Moreover, in the absence of
biochemical data, modeling of the mutations in the structures
of FGF10 and FGFR2 kinase domain did not provide conclu-
sive insights concerning molecular mechanisms.
To reveal the mechanism underlying the molecular basis of
LADD syndrome, we have compared the biochemical and
biological properties of FGF10 or FGFR2b LADD mutants to
the properties of their normal counterparts. Our results show
that each of the three LADD mutations affects FGF10 activity
by a different mechanism. While the I156R mutant is deficient
in binding to FGFR2b, the C106F mutant is unstable at phys-
iological temperatures and is most likely degraded shortly after
synthesis before being delivered to its target cell. The K137X
mutant, lacking a large C-terminal part of the molecule, was
not produced; if it is produced, this mutant will not have any
biological activity because its FGF core will have been severely
disrupted.
The biological characterization of the FGF10 LADD mu-
tants shows that the activity of the three LADD mutants is
strongly compromised. Haploinsufficiency caused by the se-
verely impaired FGF10 mutant leads to LADD syndrome, as
the signal induced by FGF10 coded by the normal allele of
LADD syndrome patients is not sufficient for mediating the
normal development of the salivary and lacrimal glands. This
conclusion is supported by genetic studies with mice demon-
strating that two copies of FGF10 are required for the normal
development of the salivary and lacrimal glands (5). Moreover,
the description of two additional FGF10 mutants (R80S and
G138E) for patients with ALSG further emphasizes the critical
and nonredundant role of FGF10 in salivary and lacrimal gland
development (4). The reason why FGF10 haploinsufficiency
causes ALSG and the more severe LADD syndrome remains
to be elucidated.
Analysis of the biological properties of ectopically expressed
FGFR2 LADD mutants in the activation loops (A648T and
R649S) or in the catalytic loop (A628T) shows that the
FGFR2b LADD mutants are deficient in tyrosine kinase ac-
tivity. The A628T mutant has the weakest activity, the A648T
mutant exhibits an intermediate activity, and the R649S mu-
tant has the highest activity, albeit lower than the tyrosine
kinase activity of WT FGFR2 following ligand stimulation.
Unlike the LADD mutation in the ligand molecule that is
caused by the haploinsufficiency of FGF10, the FGFR2 LADD
mutation will have a dominant negative effect on signaling
mediated via WT FGFR2 expressed in the same cell (Fig. 5D).
Three types of FGFR2 dimers will be formed in cells express-
ing equal amounts of normal FGFR2 and the FGFR2 LADD
FIG. 6. A model for the dominant negative effect of the FGFR2
LADD mutant (mut) on activity and signaling by WT FGFR2. FGF10
stimulation of cells coexpressing WT FGFR2b together with the FGFR2b
LADD mutant leads to the formation of three populations of receptor
homodimers and heterodimers: 25% of the receptor molecules are ho-
modimers of WT receptors with normal tyrosine kinase activity (wt-wt),
25% of the receptor molecules are homodimers of the FGFR2b LADD
mutant with severely impaired tyrosine kinase activity (mut-mut), and
50% of the receptor molecules are heterodimers of WT and LADD
mutant receptors (wt-mut). The tyrosine kinase activity of the het-
erodimers is strongly attenuated because of the dominant interfering
effect exerted by the LADD mutant on the activity of WT FGFR2b.
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mutant in response to FGF10 stimulation (Fig. 6): one-fourth
of the molecules are homodimers of WT FGFR2 with normal
tyrosine kinase activity, one-fourth are homodimers of the
FGFR2 LADD mutant with a very weak tyrosine kinase activ-
ity, and one-half of the molecules are heterodimers composed
of WT and LADD FGFR2 with attenuated tyrosine kinase
activities. Since the activation of FGFRs is mediated by ligand-
induced receptor dimerization and transphosphorylation, mu-
tant receptors are unable to efficiently phosphorylate WT re-
ceptors on autophosphorylation sites in the activation loop of
the tyrosine kinase core, a step essential for enhanced and
sustained tyrosine kinase activity. Consequently, the defective
LADD mutant will exert a dominant inhibitory affect on nor-
mal FGFR2, resulting in a strongly attenuated signal.
It has been reported that FGFR2/ mice are normal, in-
dicating that a single FGFR2 allele (providing 50% of the
signal that take place in normal mice) is sufficient to support
normal mouse development, including development at the lac-
rimal and salivary glands. The attenuated signal transmitted in
cells coexpressing an FGFR2 LADD mutant together with WT
FGFR2 in response to ligand stimulation (assuming that the
WT and the FGFR2 LADD mutant are equally expressed) is
expected to be larger than 25% and lower than 50% (25% 
signal  50%) of the signal transmitted by FGFR2 in normal
mice. This conclusion underscores the importance of exact
doses of receptor signaling in mediating biological responses; a
small change in signal strength may have a strong impact on
development and homeostasis in cells and tissues that do not
possess a redundant signaling pathway.
On the basis of the previous genetic studies with and bio-
chemical characterization of LADD mutations, it is possible to
conclude that signaling pathways that are stimulated by FGF10
and mediated by FGFR2b play a critical role in the develop-
ment and morphogenesis of branching organs such as salivary
and lacrimal glands, kidneys, and lungs, which among other
organs are affected by LADD syndrome. It has been shown
that FGF10 expressed by mesenchymal cells will stimulate
FGFR2b expressed in epithelial cells. Activation of FGFR2b
in epithelial cells leads to the production of FGF8, which in
turn stimulates the activity of FGFR2c and FGFR1c expressed
in mesenchymal cells (37). Attenuation in signaling via FGF10
or FGFR2b will lead to the disruption of an important cell
signaling circuit that takes place between epithelial and mes-
enchymal cells during development. Disruption of the epithe-
lial-mesenchymal cell signaling circuit may lead to the dental
and skeletal abnormalities seen for LADD syndrome patients.
We also conclude that normal development of lacrimal
glands, salivary glands, ears, skeleton, and other organs relies
on a correct dose of FGF10 signaling through FGFR2b and
that both copies of the FGF10 gene are required for the nor-
mal development of these organs; these requirements are not
met in the case of the ear, skeletal, and dental abnormalities
associated with LADD syndrome. Unlike FGF10 mutations
causing ligand haploinsufficiency without affecting the action of
the product of the WT FGF10 allele, mutations in FGFR2 lead
to more-severe diseases by exerting a dominant negative effect
on WT FGFR2 and potentially also on other FGFRs that are
expressed in the same cell.
No specific phenotypic differences were observed for pa-
tients with mutations in FGF10 and FGFR2 or by comparing
phenotypes caused by different FGFR2 mutations. In general,
a wide range of phenotypic variability of symptoms exists in
LADD syndrome patients, even those within the same family
and carrying the identical mutation. This fact makes genotype-
phenotype correlations difficult. We propose that the pheno-
typic outcome of impaired FGF signaling caused by mutations
in LADD genes is further modified by genetic, environmental,
and stochastic factors which remain to be elucidated.
Finally, although both FGFR2b and FGFR2c carry the
LADD mutations, LADD mutation is primarily mediated by
the FGFR2b isoform, implying that the compromised signaling
via the FGFR2c mutant seen for LADD syndrome is compen-
sated for by other members of the FGFR family expressed in
mesenchymal cells.
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Mutations in fibroblast growth factor receptor 2 (FGFR2) and its
ligand, FGF10, are known to cause lacrimo-auriculo-dento-digital
(LADD) syndrome. Multiple gain-of-function mutations in FGF
receptors have been implicated in a variety of severe skeletal
disorders and in many cancers. We aimed to elucidate the mech-
anism by which a missense mutation in the tyrosine kinase domain
of FGFR2, described in the sporadic case of LADD syndrome, leads
to reduced tyrosine kinase activity. In this report, we describe the
crystal structure of a FGFR2 A628T LADD mutant in complex with
a nucleotide analog. We demonstrate that the A628T LADD mu-
tation alters the configuration of key residues in the catalytic
pocket that are essential for substrate coordination, resulting in
reduced tyrosine kinase activity. Further comparison of the struc-
tures of WT FGFR2 and WT FGFR1 kinases revealed that FGFR2 uses
a less stringent mode of autoinhibition than FGFR1, which was also
manifested in faster in vitro autophosphorylation kinetics. More-
over, the nearly identical conformation of WT FGFR2 kinase and the
A628T LADD mutant to either the phosphorylated FGFR2 or FGFR2
harboring pathological activating mutations in the kinase hinge
region suggests that FGFR autoinhibition and activation are better
explained by changes in the conformational dynamics of the kinase
rather than by static crystallographic snapshots of minor structural
variations.
cell signaling  genetic disease  growth factor receptors 
protein kinases  structural biology
Lacrimo-auriculo-dento-digital (LADD) syndrome is charac-terized by multiple congenital anomalies including aplasia of
the lacrimal and salivary glands, cup-shaped, small, and low-set
ears, hypo- and microdentia, hearing loss, and malformation of
the digits, most commonly the thumb (1). Patients with LADD
syndrome exhibit overlapping phenotypic features with aplasia
(or hypoplasia) of lacrimal and salivary gland (ALSG) syndrome.
Recent genetic studies have implicated mutations in fibroblast
growth factor 10 (FGF10) and the ‘‘IIIb’’ isoform of FGFR2
(also designated FGFR2b) in LADD syndrome (2–4).
FGFR2 is a member of the FGFR family of receptor tyrosine
kinases (RTK) that includes three additional receptors. FGF-
receptors play an important role in the control of diverse cellular
processes including cell proliferation, differentiation, migration,
and maintenance of cellular homeostasis (5). The four members
of the FGFR family (FGFR 1–4) each consist of an extracellular
ligand-binding region composed of three Ig-like domains desig-
nated D1, D2, and D3, a single transmembrane-spanning do-
main, and an intracellular tyrosine kinase domain with addi-
tional regulatory sequences. FGFRs 1–4 exhibit different
temporal and spatial expression patterns, and FGFRs 1–3 are
additionally subject to alternative splicing in the C-terminal half
of D3 to generate either the “IIIb” or the ‘‘IIIc’’ spliced isoforms.
It was shown that the IIIb isoforms are expressed in epithelial
cells, and the IIIc isoforms are expressed in the mesenchymal
cells. Moreover, FGFs that activate the IIIb FGFR isoforms are
expressed in mesenchyme, whereas FGFs that activate the IIIc
FGFR isoforms are produced in epithelial cells (6).
After ligand binding, FGFRs undergo receptor-mediated
dimerization and subsequent transautophosphorylation on nu-
merous tyrosine residues in the tyrosine kinase core and in other
parts of the cytoplasmic region (7). The tyrosine kinase domain
catalyzes the transfer of the -phosphate of ATP to the hydroxyl
group of tyrosine residues, which serves to both increase the
intrinsic catalytic activity of the kinase and recruit a number of
downstream signaling molecules via their conserved Src homol-
ogy-2 (SH2) or phosphotyrosine-binding (PTB) domains (8).
The x-ray crystal structure of the tyrosine kinase domain of
FGFR1 revealed that in the inactive state, FGFR1 exists in an
autoinhibited conformation in which the nucleotide-binding
loop is open, but the catalytic loop is occluded by residues from
the C terminus of the activation loop (9). Crystal structures of
tyrosine kinase domains of other RTKs have shown a variety of
autoinhibitory conformations (10), highlighting the requirement
for precise regulation of the tyrosine kinase activity, a principle
exemplified by the discovery of numerous gain-of-function and
loss-of-function mutations in the kinase domain of FGFRs
responsible for a variety of clinical entities including Crouzon
syndrome, Pfeiffer syndrome, Kallmann syndrome, various can-
cers, and LADD syndrome, among others (11).
More recent biochemical evidence suggests that FGFR2 mu-
tations responsible for LADD syndrome exhibit decreased ty-
rosine phosphorylation as well as decreased ligand-induced
recruitment of downstream signaling molecules (12). However,
the precise mechanism governing how these point mutations in
highly conserved regions of the FGFR kinase domain lead to
partial inactivation or a loss-of-function phenotype is poorly
understood.
In this article, we describe the crystal structure at 1.8Å resolution
of the tyrosine kinase domain of FGFR2 harboring a single
missense mutation, A628T, described in a sporadic case of LADD
syndrome, in complex with a nucleotide analog. The structure
precisely revealed that the A628T LADD mutation altered the
catalytic pocket, whichwould compromise the ability of the tyrosine
kinase to coordinate its substrate and thus, lead to the partial
FGFR2 inactivation found in LADD syndrome. Moreover, the
structure provides more detailed insight into RTK-mediated phos-
photransfer and provides a molecular mechanism at atomic reso-
lution for how this single point mutation directly affects FGFR2
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enzymatic activity. We also show that FGFR2 adopts a less auto-
inhibited conformation relative to FGFR1, suggesting that FGFR2
uses a somewhat different mode of autoregulation to maintain its
tyrosine kinase domain in an inactive state. Finally, the nearly
identical conformation of WT FGFR2 kinase to those of A628T
LADD mutant and various forms of activated FGFR2 kinase
underscores the significance of conformational dynamics in the
control of FGFR autoinhibition and activation.
Results and Discussion
In a sporadic LADD case, a de novo missense mutation was
found in the catalytic loop in the tyrosine kinase domain of
FGFR2 resulting in the substitution of a highly conserved
alanine to a threonine (A628T) residue (13). Although recent
biochemical evidence has shown that this mutation leads to
decreased tyrosine phosphorylation of FGFR2 and recruitment
of downstream signaling molecules (12), we sought to precisely
determine how this mutation affects the intrinsic properties of
the FGFR2 kinase domain. We first purified the intact kinase
domains of both wild-type FGFR2 (WT) and FGFR2 harboring
a single A628T point mutation (A628T) [supporting information
(SI) Fig. 5]. Both WT FGFR2 and A628T-FGFR2 migrated as
a monomer of 36 kDa on an SDS/PAGE gel and had very
similar elution profiles from an anion exchange column, sug-
gesting that the A628T mutant remained intact and that the
surface charge was comparable to the WT FGFR2 tyrosine
kinase.
Reduced Kinase Activity of LADDMutant Is Not Caused by Impairment
of ATP Binding. We next asked whether the A628T mutation had
a direct effect on the intrinsic catalytic activity of FGFR2 kinase.
The mutation resides in center of the catalytic loop, which is a
highly conserved region within the FGFR family and among
other RTKs (14). An in vitro kinase assay was performed by
incubating 69.4 M WT FGFR2 or A628T-FGFR2 with ATP
and MgCl2 to a final concentration of 10 mM and 25 mM at 4°C,
respectively (Fig. 1A). The reaction was stopped at various time
points upon addition of EDTA to a final concentration of 100
mM, and the formation of phosphorylated species was followed
by native gel electrophoresis. For WT kinase, formation of a
monophosphorylated species (1P) was detected as early as 3 min,
and formation of a fully phosphorylated species (5P) was visible
by 45 min. In contrast, the A628T mutant failed to undergo
autophosphorylation even after a 5-h incubation with ATP/
MgCl2, suggesting that the A628T mutation greatly impaired
FGFR2 catalytic activity. The kinase assay was also performed
at room temperature (5 mM ATP and 10 mM MgCl2, final
concentration) to determine whether the mutation renders the
kinase inactive (Fig. 1B). Although tyrosine phosphorylation of
the A628T-FGFR2 mutant was observed, the kinetics of auto-
phosphorylation were significantly slower than those observed
for WT FGFR2 and were similar to the phosphorylation kinetics
of WT FGFR2 observed at 4°C. These results show that the
A628T mutation directly compromises the intrinsic catalytic
activity of FGFR2 kinase, which would account for the de-
creased tyrosine phosphorylation of ectopically expressed
A628T-FGFR2 mutant in transfected L6 cells (12).
To examine the structural basis for the decreased catalytic
activity of the A628T mutant, we crystallized the kinase domain
of the A628T LADD mutant in complex with a nucleotide
analog, AMP-PCP, in the inactive state. The 1.8 Å resolution
structure revealed that the kinase domain adopts the classical
RTK bilobate architecture, and clear density was observed for
the activation loop, the catalytic loop including the A628T
mutation, and the ATP analog (Fig. 2A and SI Fig. 6 A and C).
AMP-PCP resides in the nucleotide-binding pocket between the
N- and C-terminal lobes, and the adenine ring is hydrogen
-bonded to the backbone of Glu-565 and Ala-567, analogous to
the interactions observed between inactive FGFR1 and AMP-
PCP and in other RTKs (Fig. 2B) (9, 15). The nucleotide analog
does not appear to be in a productive binding mode because the
-phosphates in both molecules in the asymmetric unit were
disordered, and Mg2 ions were not observed in coordination
with AMP-PCP. The -, and -phosphate groups extend in a
configuration parallel to the nucleotide-binding loop, in contrast
to what was seen in the structure of inactive FGFR1 (9), but they
do not make direct contacts with the protein backbone.
The rate of catalysis can also be affected by a change in the
affinity of the tyrosine kinase for ATP. To determine whether
the A628T LADD mutation affected ATP binding, we per-
formed fluorescence titration experiments whereWT FGFR2 or
A628T-FGFR2 were incubated with increasing concentrations
of AMP-PNP in the presence of excess MgCl2. The kinase was
excited at 285 nm, and the change in intrinsic protein fluores-
cence due to binding of the ATP analog was monitored between
300 and 420 nm (Fig. 2C). Decrease in fluorescence intensity was
observed with increasing concentrations of AMP-PNP, and the
data were fit to a quadratic equation. The dissociation constants
obtained for WT and A628T were KD  4.56  1.27 M and
KD  6.21  2.10 M, respectively, indicating that the LADD
mutation did not affect ATP binding and that the diminished
FGFR2 catalytic activity in the A628T mutant was not caused by
decreased ATP binding.
FGFR2 Kinase Is Less Autoinhibited Than FGFR1 Kinase.Recent crystal
structures have shown that, in the inactive state, RTKs adopt a
number of autoinhibitory configurations often involving inhibi-
tion of the substrate-binding pocket or blockage of the nucle-
otide-binding pocket (10). The structure of the A628T-FGFR2
mutant revealed that in the inactive state, both the nucleotide
binding site and the substrate-binding pocket appeared accessi-
Fig. 1. Reduced tyrosine kinase activity of the A628T LADD FGFR2 mutant.
(A) FGFR2 WT or FGFR2-A628T (69.4 M final concentration) were incubated
with ATP and MgCl2 at 4°C to a final concentration of 10 mM and 25 mM,
respectively. Reactions were quenched at each time point upon addition of
EDTA (100 mM final concentration), and the phosphorylation states were
visualized by native gel electrophoresis. (B) Autophosphorylation reaction
was similarly performed at room temperature upon addition of ATP and
MgCl2 to a final concentration of 5 mM and 10 mM, respectively. Reactions
were quenched with EDTA (100 mM final concentration), and results were
visualized by native gel electrophoresis. The positions of unphosphorylated
(0P) and FGFR2 phosphorylated on 1 to 5 tyrosine residues are marked (1P–5P).
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ble, and the kinase adopted a configuration much different from
that observed in the structure of inactive FGFR1 (Figs. 2A and
3A) (9). To determine whether this altered configuration was
due to the A628T point mutation or whether it is an intrinsic
property of FGFR2 kinase, the tyrosine kinase domain of WT
FGFR2 (PDB ID code, 1GJO) and the A628T-FGFR2 mutant
were compared (Fig. 3C). The two FGFR2 structures were
nearly identical, with an overall r.m.s.d. value of 0.7 Å. The
tyrosine kinase domains of FGFR1 and FGFR2 share 90%
sequence identity; however, the divergence of their three-
dimensional structures warranted a detailed comparison of the
two structures (Fig. 3A). Overall, the conformation of the
C-terminal lobe was nearly identical, whereas the N-terminal
lobe of FGFR2 relative to FGFR1 (PDB ID code, 1FGK)
appeared rotated toward the C-lobe with movement of C 20o
downward in a configuration reminiscent of an active state. In
addition, the activation loop of FGFR2 is flipped outward and
adopts a conformation more favorable to C downward move-
ment as well as more conducive to substrate binding. This
conformation was observed for both WT FGFR2 and the
A628T-FGFR2, which were crystallized in two different space
groups and had different crystal-packing arrangements, suggest-
ing that the conformation is intrinsic to FGFR2 kinase. Com-
parison of FGFR2 to activated insulin receptor kinase (IRK-3P)
(PDB ID code, 1IR3) (Fig. 3B) (15) showed that the positions
of C and the activation loop, especially near the P  1 loop,
were very similar, further suggesting that FGFR2 kinase is less
autoinhibited than FGFR1 kinase. Furthermore, in FGFR1
kinase, substrate binding is occluded by Pro-663 and Arg-661,
which appear to directly interfere with the binding of a substrate
Tyr (P-site). In contrast, in FGFR2, the corresponding residues,
Pro-666 and Arg-664, are away from the catalytic pocket (Fig. 4
A and I). Pro-666 is in a conformation very similar to that found
for the equivalent residue in IRK-3P and appears poised to form
favorable van der Waals interactions with a substrate Tyr(P)
residue. Arg-664 forms an ion pair with Asp-530 in C, prevent-
ing it from adopting the autoinhibitory conformation found in
the structure of FGFR1 and furthermore, stabilizing the active
configuration of the C helix (Fig. 4I). To determine whether the
less autoinhibited conformation may affect the intrinsic catalytic
activity of FGFR2 relative to FGFR1, we next incubated either
69.4 M purified FGFR2WT kinase or FGFR1WT kinase with
ATP and MgCl2 to a final concentration of 10 mM and 25 mM,
respectively, at 4°C and quenched the reaction mixture with 100
mM EDTA at different time points. The experiment presented
in Fig. 3D shows that formation of mono-phosphorylated and
Fig. 2. Overview of the structure of FGFR2 A628T LADD mutant and effect of LADD mutations on ATP binding. (A) Ribbon diagram of A628T FGFR2 structure
in complex with nucleotide analog, AMP-PCP. The mutation in the catalytic loop is indicated. The nucleotide-binding loop is shown in blue, the hinge region
in green, the catalytic loop in purple, and the activation loop in cyan. AMP-PCP is shown in stick representation with nitrogen atoms blue, carbon atoms white,
oxygen atoms red, and phosphate atoms orange. (B) Close view of nucleotide-binding pocket. Hydrogen bonds are indicated by solid black lines. Coloring is as
in A (C) Fluorescence titration experiments measuring FGFR WT or FGFR2 A628T intrinsic protein fluorescence at 340 nm in the presence of increasing
concentrations of AMP-PNP from 0 to 50 M. Data were fit to a quadratic equation by nonlinear regression (Kaleidograph). AMP-PNP-binding values for FGFR2
WT and FGFR2 A628T were KD  4.56  1.27 M and KD  6.21  2.10 M, respectively.
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bis-phosphorylated FGFR2 was observed by 1 min, with forma-
tion of the fully phosphorylated species visible by 15 min. In
contrast, by 1 min, only monophosphorylated FGFR1 was
visible, with formation of the fully phosphorylated species visible
by 30 min, suggesting that FGFR2 is modestly more catalytically
active than FGFR1, most prominently in the initial stages of
phosphorylation. Despite its less autoinhibited conformation,
unphosphorylated FGFR2 kinase does not fully adopt an active
conformation. The N-lobe of FGFR2 was not fully closed for
proper coordination of the Mg2 ions or full interaction with
the nucleotide analog, AMP-PCP, as evidenced from the lack
of clear electron density for both the Mg2 ions and the
-phosphate of AMP-PCP and also from lack of engagement of
the - and -phosphate groups of AMP-PCP with the protein
backbone (Figs. 2B and 3B). In addition, C is oriented such that
the highly conserved Lys-517 and Glu-534 (Lys-514 and Glu-531
in FGFR1), found 4 Å apart after activation of IRK, are
hydrogen-bonded, which prevents proper orientation of the
five-stranded -sheets of the N-lobe relative to C and may also
be inhibitory for Mg2 binding. In addition, structures of acti-
vated kinases in complex with peptide analogs have shown that,
in addition to accommodating the substrate Tyr(P) moiety,
residues C-terminal to Tyr(P) comprise a -strand that forms an
antiparallel sheet with 11 at the C terminus of the activation
loop (Fig. 4B) (15, 16). In FGFR2, residues in the C terminus of
the activation loop fail to adopt this configuration but, rather, are
internally stabilized by a hydrogen-bonding network consisting
of Arg-649, Thr-660, Asn-662, and Arg-625 (Fig. 4I). Transition
from the inactive to the active state most likely involves rear-
rangement of these hydrogen-bond interactions upon autophos-
phorylation, including the hydrogen bond between Arg-664 with
Asp-530 on C, and rearrangement of the activation loop to
form interactions more similar to those seen in the crystal
structure of IRK-3P and other phosphorylated RTKs.
A628T LADD Mutation Alters the Conformation of Key Residues
Essential for Substrate Coordination. Despite the structural differ-
ences observed within the FGFR family and the conformational
changes associated with the transition from the inactive to active
state, the catalytic loop is a highly conserved region in the kinase,
and superimposition of the catalytic loops revealed a high degree
of structural similarity among both active and inactive RTKs (Figs.
3B and 4H) (17). In the structures of the activated IRK (15) and
IGFR1 (18) in complex with peptide substrate, both the catalytic
base (D1132 in IRK) and the conserved arginine residue within the
catalytic loop (R1136 in IRK) are hydrogen-bonded to the hydroxyl
group of the substrate Tyr(P), presumably in position for proton
abstraction and charge neutralization, respectively (Fig. 4B). The
A628T LADD mutation resides in the center of the catalytic loop
and results in substitution of a small hydrophobic residue with a
more bulky, polar residue (Fig. 4E). The A628T-FGFR2 structure
revealed that the threonine substitution resulted in movement of
the conserved Arg-630 160o away from the catalytic base, Asp-
626, in a position stabilized by interaction with Asp-521 from the
neighboring molecule in the asymmetric unit. Structures of both
inactive and active RTKs in the presence and absence of substrate
Fig. 3. Comparison of the structure of the tyrosine kinase domains of FGFR1, FGFR2, and insulin receptor. (A) Overlay of inactive FGFR2 kinase (PDB ID code,
1GJO) and inactive FGFR1 kinase (PDB ID code, 1FGK). FGFR2 WT is shown in green, its activation loop in red, and its catalytic loop in yellow. FGFR1 WT is illustrated
in gray, its activation loop in cyan, and its catalytic loop in purple. (B) Overlay of inactive FGFR2 WT kinase (PDB ID code, 1GJO) and activated IRK (PDB ID code,
1IR3). Colors for FGFR2 WT are as in A. Activated IRK is shown in gray, its activation loop in cyan, and its catalytic loop in purple. (C) Overlay of inactive FGFR2
WT (PDB ID code, 1GJO) and FGFR2 A628T LADD mutant. Colors for FGFR2 WT are as in A. FGFR2 A628T is illustrated in gray, its activation loop in cyan, and its
catalytic loop in purple. (D) FGFR2 WT or FGFR1 WT (69.4 M final concentration) were incubated with ATP and MgCl2 at 4°C to a final concentration of 10 mM
and 25 mM, respectively. Reactions were quenched at each time point upon addition of EDTA (100 mM final concentration), and the phosphorylation states were
visualized by native gel electrophoresis.
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have shown that the hydrogen bond between Arg-630 and Asp-626
in the catalytic pocket is highly conserved (Fig. 4H), and in the
A628T-FGFR2mutant, movement of Arg-630 is most likely due to
steric hindrance between Arg-630 and Thr-628, because superim-
position of the catalytic loops of WT FGFR2 and the A628T-
FGFR2mutant showed that the Arg-630 cannot be accommodated
in the catalytic pocket upon substitution of Ala-628 with threonine
(Fig. 4 D–F). The position of Asp-626 remains roughly unchanged
(Fig. 4F) and seemingly, would still be in position to interact with
the substrate Tyr(P). The position of Arg-630, however, is too far
from the catalytic pocket to contact the substrate Tyr(P), and this
conformation would hinder phosphotransfer by failing to stabilize
the substrate interaction and, thus, result in severely compromised
catalytic activity as seen in LADD syndrome. The crystal structure
of the A628T-FGFR2 mutant presented in this study is also in
agreement with the crystal structure ofWTFGFR2 kinase that was
recently described, most notably in the P  1 loop (SI Fig. 7) (19).
Furthermore, despite similar crystal-packing arrangements, the two
structures differ in the orientation of the Arg-630 side chain in the
catalytic loop (Fig. 4C,E, andG), further supporting the notion that
the A628T LADD mutation is responsible for disruption of the
catalytic pocket.
Inactive LADD Mutant Adopts a Virtually Identical Conformation to
both Phosphorylated FGFR2 and Activated Pathological FGFR2 Mu-
tants. Comparison of the structure of the kinase domain of the
inactive A628T-FGFR2 LADD mutant to the crystal structures of
either phosphorylated or activated FGFR2 mutants (19) that have
been implicated in severe bone disorders or other pathological
conditions revealed nearly identical structures (SI Fig. 7). The
virtually identical conformations of the kinase domain of the
inactive A628T LADD mutant, unphosphorylated WT FGFR2,
phosphorylated FGFR2, and several pathological activating
FGFR2 mutants (SI Fig. 7) support the argument that autoinhibi-
tion is likely not caused by a static and crystallographically defined
‘‘molecular brake’’ in the hinge region of FGFRs and other RTKs
(19), but, instead, it seems likely that the activating mutations in the
hinge region exert their effects by altering the conformational
dynamics. Interestingly, despite the compromised catalytic activity
observed with the A628T LADDmutant, the triad of residues that
comprise the molecular brake in the LADD mutant are partially
disengaged in this structure and participate in a different network
of hydrogen bonding interactions, suggesting that minor variations
in the hinge and other flexible regions may be influenced by
crystallization conditions and crystal lattices. The surprising simi-
larity of activated and inactive forms of FGFR2 when viewed as
static crystal structures suggest that both autoinhibition and acti-
vation of FGFRs and otherRTKsmay be dictated, to a large extent,
by conformational dynamics rather than by well defined minor
changes observed in FGFR2 kinase (19).
Materials and Methods
Expression, Purification, and Crystallization of A628T FGFR2 Tyrosine
Kinase Domain. A bacterial expression vector was engineered to
encode residues 461–768 of the human fibroblast growth factor
Fig. 4. A628T LADD FGFR2 mutation compromises substrate binding. (A) Comparison of A-loop orientations of IRK-3P in complex with peptide substrate and A628T
FGFR2 mutant. A-loop of IRK-3P is shown in magenta and the catalytic loop in orange. The peptide substrate is shown in pink, and the tyrosine phosphorylation site
is indicatedbyastick representation.TheA-loopofA628TFGFR2 is colored incyan,andthecatalytic loop is showninpurple.Thecorrespondingproline residue inFGFR2
that plays an autoregulatory role in the inactive structure of FGFR1 is indicated. (B) Catalytic pocket of IRK-3P with peptide substrate. Colors are as in A, and key
hydrogen-bonding interactions are indicated by solid black lines. (C) Catalytic pocket of phosphorylated FGFR2 WT with peptide substrate (PDB ID code, 2PVF). The
peptide substrate is shown in white, and the tyrosine phosphorylation site is indicated by stick representation. The A-loop of activated FGFR2 WT is shown in green,
andthecatalytic loop is showninteal.Hydrogen-bonding interactionsare indicatedbysolidblack lines. (D–F)Catalytic loopofFGFR2WT(D, yellow),A628TFGFR2LADD
mutant (E, purple), and overlay (F). Key residues involved in catalysis are indicated. (G andH) Catalytic pocket of phosphorylated WT FGFR2 (G, PDB ID code, 2PVF) and
IRK-3P (H) incomplexwithpeptidesubstrate.Residues involved incatalysisare indicated. (I) InteractionswithintheA-loopofA628T-FGFR2LADDmutant.Theactivation
loop is shown in cyan, the catalytic loop is shown in purple, and key hydrogen bonds are indicated by solid black lines.
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receptor 2 (FGFR2). For crystallization studies, a tobacco etch
virus (TEV) enzymatic cleavage site was introduced after the
N-terminal His6-tag by PCR, and a single point mutation,
A628T, was introduced by site-directed mutagenesis (Strat-
agene). Bacteria were grown at 37°C to an OD600 of 1.3 and
induced with 1 mM IPTG overnight at 20°C. The cells were lysed
by French press (Thermo Scientific), and the protein was puri-
fied by using a Ni-NTA-His resin (Novagen). After elution from
the column, the protein was incubated with a 1:100 molar ratio
of TEV protease to A628TFGFR2 and simultaneously dialyzed
in buffer containing 20mMTris, pH 8, and 5mMDTT overnight
at 4°C. The reaction mixture was subsequently passed over a
Superdex200 HR10/30 (GE Healthcare) and further purified by
using an anion exchange column on a Mono Q HR16/10 (GE
Healthcare). Purified A628T FGFR2 was concentrated to 20
mg/ml in 20 mM Tris, pH 8, 200 mM NaCl, and 5 mM DTT.
Crystals were grown at 4°C by vapor diffusion in hanging drops
containing 1 l of protein solution (20 mg/ml A628T-FGFR2, 5
mM AMP-PCP, 10 mM MgCl2) and 1 l of reservoir solution
(0.6 M NaH2PO4, 0.6 M KH2PO4, 0.1 M Hepes, pH 8). The
crystals belonged to the orthorhombic space group P21212 and
had unit cell dimensions a  67.7 Å, b  80.3 Å, c  118.6 Å,
   90°. There were two molecules per asymmetric unit,
and the solvent content was45% (SIMaterials andMethods and
SI Tables 1 and 2).
Data Collection, Structure Determination, and Analysis. One cryo-
cooled crystal was used for data collection. The crystal was
transferred stepwise into a cryosolution containing 0.6 M
NaH2PO4, 0.6 M KH2PO4, 0.1 M Hepes, pH 8, with increasing
concentrations of glycerol (5%, 15%, 20%, 25%, and 30%).
After 1 min in the final cryosolution, the crystal was flash-
cooled in liquid nitrogen and transferred to the goniostat, which
was bathed in a dry nitrogen stream at 180°C. Data were
collected at beamline X29 at Brookhaven National Laboratory.
All data were processed by using DENZO and SCALEPACK
(20). A molecular replacement solution was found by using the
program PHASER (21) with the FGFR2 tyrosine kinase domain
(PDB ID code, 1GJO) as the search molecule. The A628T
structure was subject to rigid body refinement from 50 to 3 Å by
using REFMAC (22), resulting in a Rcryst value of 33.9%. Model
building and refinement were carried out from 50 to 1.8 Å by
using COOT (23) and CNS (24), respectively, to an Rcryst and
Rfree value of 20.1% and 23.1%, respectively. For calculation of
Rfree, 7% of the data were omitted. Figures were generated by
using PyMOL (25). The stereochemistry of the model was
analyzed with PROCHECK (26).
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ABSTRACT
Aims: This study aimed to identify the underlying genetic
defect of a large Turkish X linked nystagmus (NYS) family.
Methods: Both Xp11 and Xq26 loci were tested by
linkage analysis. The 12 exons and intron–exon junctions
of the FRMD7 gene were screened by direct sequencing.
X chromosome inactivation analysis was performed by
enzymatic predigestion of DNA with a methylation-
sensitive enzyme, followed by PCR of the polymorphic
CAG repeat of the androgen receptor gene.
Results: The family contained 162 individuals, among
whom 28 had NYS. Linkage analysis confirmed the Xq26
locus. A novel missense c.686C.G mutation, which
causes the substitution of a conserved arginine at amino
acid position 229 by glycine (p.R229G) in exon 8 of the
FRMD7 gene, was observed. This change was not
documented in 120 control individuals. The clinical
findings in a female who was homozygous for the
mutation were not different from those of affected
heterozygous females. Skewed X inactivation was
remarkable in the affected females of the family.
Conclusions: A novel p.R229G mutation in the FRMD7
gene causes the NYS phenotype, and skewed X
inactivation influences the manifestation of the disease in
X linked NYS females.
Congenital nystagmus (NYS) is an ocular oscilla-
tory movement disorder caused by a motor
instability that can manifest with or without
afferent visual system dysfunction. This entity is
defined both clinically and by electronystagmogra-
phy. Certain clinical features usually differentiate
congenital NYS from other oscillations. NYS may
be irregular, but is always conjugate and horizon-
tal, though very rarely vertical. There may be a
torsional component. Some patients with this
abnormality also show head oscillations, which
tend to increase when the patient attends to an
object, an effort that also increases the NYS.
Therefore, it seems probable that both the head
tremor and the ocular oscillations are the conse-
quence of a common disordered neural mechan-
ism.1
The underlying defect in congenital NYS
remains elusive. The Eye Movement
Abnormalities and Strabismus Working Group
proposed the term, infantile nystagmus syndrome,
for the NYS that is known as congenital NYS.
Although there is some controversy concerning
classification of NYS in infancy, it has been
suggested that NYS with an onset before 6 months
of age can be divided into three categories:2 (1)
congenital idiopathic NYS in which no visual or
associated neurological impairment can be found;
(2) sensory deficit NYS in which there is a visual
abnormality, such as ocular albinism, optic nerve
hypoplasia, congenital stationary night blindness
and blue cone monochromatism; (3) neurological
NYS, which is associated with a neurological
disorder. Category 1 is also called congenital motor
NYS, which is presumed to have a primary defect
in the part of the brain responsible for ocular motor
control.3
Congenital motor NYS is a genetically hetero-
geneous disorder. Autosomal dominant (MIM
164100), recessive (MIM 257400) and X linked
(MIM 310700) patterns of inheritance are
described for this disorder. X linked inheritance is
the most common form of NYS (NYS1). An
irregular dominant pattern of X linked inheritance
has been frequently reported, although some
pedigrees support X linked recessive inheritance.4
The penetrance is full in males and approximately
50% to 29% in females.5 6 Large intrafamilial
variance in waveforms can be observed. Two
distinct loci, one on the Xq26–q273 and the other
on the Xp11.47 regions have been reported as the
likely loci for X linked dominant NYS. The locus
on the long arm (Xq26) has been confirmed by
subsequent reports of various ethnic populations.8–
10 To the best of our knowledge, there are only two
reports supporting the Xp11.4 locus.7 11 The pat-
tern of inheritance and clinical profile of Xp11-
linked families are not different from Xq26-linked
pedigrees. X linked recessive NYS has also been
mapped to the Xq26 region, which harbours the X
linked dominant NYS locus.10 Recently, mutations
in the FRMD7 (FERM domain-containing 7) gene
have been reported as a molecular cause in Xq26-
linked families.6 Little is known about the function
of the FRMD7 gene; however, the restricted
expression pattern of this gene in the human
embryonic brain and developing neural retina
suggests a role in eye movement and gaze
stability.6
Herein, we report an extensive NYS pedigree,
including 162 individuals across six generations
from southeastern Turkey. The mode of inheri-
tance is clearly X linked, demonstrating a reduced
penetrance in female obligate gene carriers. Genetic
linkage analysis confirmed the Xq26–q27 locus,
and further mutation analysis identified a novel
p.R229G missense mutation in the FRMD7 gene
that causes this disorder. We also detected a
predisposition to skewed X inactivation in affected
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females, suggesting that the X inactivation mechanism might
have a role in manifestation of the disease in females.
METHODS
Clinical evaluation
The family was identified during fieldwork to study a large
craniosynostosis pedigree in Antakya, Turkey. The complete
pedigree structure contains over 427 individuals, including a
separate branch of congenital idiopathic NYS. Only the NYS
branch is included in this study, and the pedigree structure is
shown in fig 1. Pedigree formation was completed in the field by
NA, IV and SK. Neurological evaluation of 23 individuals was
conducted by YK, a neurologist and member of the family. The
recruitment criteria were NYS noted at birth or during the first
3 months of life, and no abnormalities of the ocular or neural
visual pathway. Visual acuity of all the patients was measured
by Snellen card. Eye movements were recorded by a video
camera in 16 patients. Video recordings were further reviewed
by a neuro-ophthalmologist (TK). Peripheral blood samples
were collected from 48 individuals with informed consent for
further molecular studies. The Hacettepe University Ethics
Committee approved the study (FON 02/6-13)
Genetic linkage analysis
The family was tested for linkage to two reported loci on
chromosome regions Xp117 and Xq26.3 Map order and physical
positions (Mb) of the polymorphic markers were obtained from
the University of California Santa Cruz (USCS), Genome
Bioinformatics Center (http://genome.ucsc.edu). Oligonucleotide
samples were purchased from MWG-Biotechnology (Ebersberg,
Germany). Site-specific PCR, 7% polyacrylamide gel electrophor-
esis and silver staining technique were used in genotyping the
individuals. Gels were manually pictured. The Cyrillic program
was used to generate haplotype and input files for linkage analysis.
Two-point linkage was performed with the MLINK component of
the LINKAGE package, assuming X linked dominant inheritance
with 0.36 penetrance in females. Mutant allele frequencies were
kept as 0.0001. Equal marker allele frequency of DNA markers was
assumed.
Mutation analysis
We designed primers to amplify all 12 protein-coding exons and
adjacent intronic sequences of the FMRD7 gene by PCR using
standard conditions (supplementary table). Due to its size, exon
12 was amplified in three overlapping fragments. Subsequent to
amplification, PCR fragments were purified, with QIAquick
spin columns (Qiagen), and directly sequenced using the
corresponding forward primers with the ABI PRISMH
BigDyeTM Terminator v2.0 cycle sequencing ready reaction kit
and an ABI PRISMH 3100 genetic analyser (Applied Biosystems).
We re-sequenced all identified mutations in independent
experiments, tested for co-segregation within the families, and
screened 120 Turkish control individuals for the c.686C.G
mutation by PCR and subsequent restriction digestion using
BccI (MBI Fermentas, Germany).
Evaluation of X chromosome inactivation (XCI)
Genotyping of a highly polymorphic CAG repeat in the
androgen-receptor (AR) gene was performed to assess the XCI
patterns.12 DNA was divided into two identical aliquots, one of
Figure 1 Complete pedigree structure of X linked idiopathic congenital NYS. Full shaded symbols indicate the NYS phenotype. Quarter shaded
symbols demonstrate individuals with craniosynostosis. The craniosynostosis branch (relatives of individuals 150, 151 and 51) was not included in this
study.
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which was incubated overnight at 37uC with the methylation-
sensitive restriction enzyme HpaII (MBI Fermentas, Vilnius,
Lithuania), for the digestion of unmethylated (or active) alleles.
A second restriction enzyme, RsaI (MBI Fermentas, Vilnius,
Lithuania), which recognises a four-base-pair sequence not
present in the amplified region of the AR locus, was also
included in the reaction to facilitate the HpaII digestion process.
Male DNA with a cytogenetically verified 46,XY karyotype was
used as the control for complete digestion. The other half of the
DNA was treated similarly, but without HpaII. After restric-
tion-enzyme digestion, residual DNA was amplified using the
primers 59-GTC CAA GAC CTA CCG AGG AG-39 and 59-CCA
GGA CCA GGT AGC CTG TG-39. PCR products were
separated on 10% denaturing 29:1 acrylamide-bisacrylamide
gel for 5 h at 20 W. Gels were stained with ethidium bromide
and visualised under UV light. Densitometric analysis of the
alleles was performed at least twice for each sample using the
appropriate software (MultiAnalyst v1.1; Bio-Rad, Hercules,
CA). A corrected ratio (CrR) was calculated by dividing the ratio
of the predigested sample (upper/lower allele) by the ratio of the
non-predigested sample for normalisation of the ratios that
were obtained from the densitometric analyses. The use of a CrR
compensates for preferential amplification of the shorter allele
when the number of PCR cycles increases.13 A skewed population
is defined as a cell population with.80% expression of one of the
AR alleles. This corresponds to CrR values of ,0.25 or .4.0.
Table 1 Examination findings of the family members
PID Gender DOB Nystagmus Head oscillations DM type II Obesity Other findings
23 F 1939 Pendular + – – –
24 M 1929 Pendular + + + Asthma, corneal opacity on the left, hypertension
32 M 1961 Pendular + jerk + + + Diabetic neuropathy, cataract, hypertension
38 M 1950 Pendular – + + Diabetic neuropathy, amyloid lichenosis
40 M 1945 Pendular + + + –
42 M 1943 Pendular + + + Diabetic neuropathy, psoriasis, hypertension
46 M 1939 Pendular + + + Diabetic neuropathy, ptosis on the left
48 M 1930 Pendular + + + Diabetic neuropathy, hypertension, ptosis on the right
65 F 1981 Pendular + jerk + – – –
66 F 1982 Pendular + jerk – – – Strabismus
93 F 1980 Pendular – – – –
105 M 1986 Pendular + jerk + – + Febrile convulsion
108 M 1985 Pendular + – – –
112 M 1998 Pendular – – – –
121 F 1971 Pendular + – + –
131 F 1965 Pendular + – – –
133 F 1969 Pendular – – – –
136 M 1968 Pendular + – + –
138 M 1993 Pendular – – – –
139 M 1993 Pendular – – – –
36 M 1957 – – + + –
39 F 1951 – – – + –
43 F 1951 – – – + –
53 F 1959 – – + + Psoriasis, hypertension
54 F 1960 – – – + –
69 M 1978 – – – + –
79 M 1971 – – – + –
80 M 1974 – – – + –
81 M 1976 – – – + –
82 M 1989 – – – + –
87 F 1970 – – – + –
91 M 1969 – – – + –
94 M 1989 – – – + Allergic conjuctivitis
95 M 1976 – – – + –
107 F 1983 – – – + –
115 M 1975 – – – + –
116 M 1979 – – – + –
117 M 1980 – – – + Asthma bronchiale
118 F 1970 – – – + –
119 F 1978 – – – + Asthma bronchiale
120 F 1984 – – – + –
122 F 1986 – – – + –
123 M 1967 – – – + –
124 M 1968 – – – + –
125 M 1969 – – – + –
126 M 1960 – – – + –
134 M 1968 – – – + –
DM, diabetes mellitus; DOB, date of birth; PID, Personal Identification Number presented in fig 1.
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RESULTS
Clinical presentation and formal genetics of the family
The most striking findings of this pedigree were, 1, NYS and, 2,
obesity and type 2 diabetes in some family members (table 1).
Other findings included craniosynostosis and allergic com-
plaints, such as bronchial asthma. In all, 20 patients had
rhythmic pendular type NYS, with varying frequencies and
amplitudes. Video recordings of 16 individuals supported the
clinical observations. On lateral gaze, four individuals had
horizontal jerk NYS, whereas six patients had spontaneous head
oscillations, and 13 had oscillations during fixation (table 1).
Visual acuity among the patients varied from 20/20 to 20/100.
Direct ophthalmoscopic findings were unremarkable. In all,
seven NYS patients had diabetes, and 10 were obese. Among the
non-NYS family members, 27 were obese (two of them with
diabetes) (table 1) suggesting independent segregation of the
two disorders (NYS and obesity and/or type 2 diabetes) in the
same family. Regarding the NYS phenotype, male-to-male
transmission was not observed. This finding supported X linked
inheritance. There were 33 obligate gene carrier females in this
family, and only 12 of them developed NYS (fig 1); therefore,
the penetrance of the NYS phenotype in females was estimated
to be approximately 36% for this family.
Linkage studies
The family was tested for a linkage to both Xp11.4-p11.37 and
Xq26–q273 loci. The NYS phenotype was previously mapped
between the DNA markers DXS8015 and DXS1003 on the
Xp11.4 locus. The DNA markers DXS6810, GATA144D04 and
DXS7132 were used in this study, and the physical positions of
these markers are: DXS8015 (39.44 Mb)-DXS6810, (42.57 Mb)-
GATA144D04 and (44.67 Mb)-DXS1003 (46.19 Mb)-DXS7132
(64.33 Mb). Four NYS patients were recombinant for the entire
region (data not shown). Negative LOD scores were also
obtained. The excluded region was 6–7 cM for each DNA
marker (table 2).
Significant LOD scores were obtained for the entire region,
with a maximum of 4.04 at h= 0 cM for the DNA marker
DXS8094 (table 2) in the Xq26–q27 region (fig 2). A single
cross-over event in an NYS patient (person 40) positioned the
disease gene telomeric to the DNA marker DXS8068. We also
observed the first homozygote female case of the NYS
phenotype (fig 1, person 133). No phenotypic differences were
observed among the females, in terms of homozygote and
heterozygote states (table 1).
Mutation results
We sequenced all 12 coding exons of the recently described X
linked NYS gene FRMD7, which was located in the critical
region in two affected male individuals of the family, and
identified the c.686C.G mutation in exon 8 of the gene (fig 3A).
The mutation co-segregated with the disease in the family
(fig 3B) and was not observed in 120 healthy individuals of the
same ethnic background. The novel c.686C.G mutation
predicted a substitution of a conserved arginine at amino acid
position 229 in the functionally important FERM-C domain of
the protein by glycine (p.R229G). Interestingly, three other
missense mutations in the FERM-C domain of FRMD7 have
been described in the original gene identification paper6 (fig 3C),
suggesting an important role for this domain in the pathogen-
esis of congenital NYS.
X chromosome inactivation results
Since at least seven females in the pedigree had NYS, we
analysed the XCI patterns to verify if skewed XCI could be
responsible for the clinical manifestation of the disease. Skewed
patterns with ratios of 81:19 per cent in individual 65, 85:15 per
cent in 121, and 80:20 per cent in 131 and 133 was apparent,
while individual 23 was not informative, and only individuals
93 and 66 displayed random XCI with ratios of 57:43 per cent
and 62:38 percent, respectively. Among the non-NYS females,
XCI status was analysed in 18 individuals. With the exception
of individual 35, who had a skewed XCI (93:7) pattern, and four
more non-informative females (individuals 41, 43, 54 and 86), all
women displayed random XCI profiles (table 3). Skewed X
inactivation was significantly increased in the NYS females
when compared with the non-NYS females in the family (odds
ratio was 26:1; 95% CI = 1.83 to 367.7).
Table 2 Two point LOD scores with the DNA markers selected from Xp11 and Xq26 regions
Recombination fraction (h) cM
Marker 0.00 0.01 0.05 0.10 0.20 Exclusion (cM)
Xp11
DXS6810 2‘ 25.35 22.64 21.54 20.58 7
GATA144D03 2‘ 25.19 22.50 21.43 20.52 6
DXS7132 2‘ 25.32 22.62 21.53 20.57 7
Xq26
GATA172D05 2‘ 21.78 20.53 20.11 0.12 2
GATA165B12 2‘ 0.54 1.07 1.16 1.00 2
DXS1047 2‘ 1.08 1.58 1.62 1.37 2
DXS8068 2‘ 0.38 0.93 1.03 0.91 2
DXS8072 3.74 3.68 3.44 3.12 2.45 2
DXS8071 0.82 0.80 0.72 0.62 0.43 2
DXS1187 3.37 3.32 3.10 2.81 2.21 2
DXS8033 3.68 3.62 3.38 3.07 2.41 2
DXS8094 4.04 3.98 3.72 3.38 2.65 2
DXS1062 2.55 2.51 2.33 2.09 1.59 2
DXS1192 0.48 0.47 0.43 0.38 0.29 2
DXS984 3.74 3.68 3.44 3.12 2.45 2
GATA31E08 3.37 3.32 3.10 2.81 2.21 2
Exclusion area = recombination fraction (cM) at which the LOD score was (22. Significant LOD scores were obtained with the DNA markers from the Xq26 region.
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DISCUSSION
In this study, we described a large family with X linked
congenital NYS. The disorder was completely penetrant in
males; however, reduced penetrance was observed in females.
Various penetrance rates, ranging from 54% to 29%, are
suggested to be due to family size.3 5 6 Our study also supported
36% penetrance in females. This extremely low penetrance rate
in females might challenge the mode of inheritance estimations.
For genetic counselling purposes, it might be difficult to
distinguish X linked recessive and dominant patterns in small
family trees. Genetic linkage analysis provided strong evidence
of linkage to the previously established locus on Xq26–27,
which is the major locus for X linked NYS (NYS1). A
recombination event in a single affected male positioned the
disease gene telomeric to the DNA marker DXS8068 (fig 2).
Combining these data with previous studies, the 8 Mb region
residing between DNA markers DXS8068 and DXS1211
containing the recently reported FRMD7 gene6 was critical for
this family.
We identified the novel p.R229G missense mutation in the
FRMD7 gene in the study family. The following points support
the disease-causing nature of this mutation: (i) p.R229G co-
segregated with the disease in this family; (ii) our control
studies excluded p.R229G as a non-synonymous polymorphism
Figure 2 Haplotype structure between the NYS phenotype and the DNA markers selected from Xq26. The order and the physical locations (Mb) of the
DNA markers are shown to the upper left. A single recombination event in affected individual 40 positioned the disease gene telomeric to DXS8068
containing the FRMD7 gene (130.93 Mb).
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Figure 3 Identification of a novel missense mutation in the FRMD7 gene. (A) Representative sequence chromatograms of the identified c.686C.G
(p.R229G) mutation in an affected male (mutant), a carrier female (carrier) and an unaffected male (wild-type). (B) Co-segregation of the mutation in the
family. Results of BccI restriction fragment analysis presenting an undigested 234 bp PCR-fragment in affected male individuals, a fully digested PCR
fragment in unaffected males (two fragments 131 bp and 101 bp in size), and one undigested and one digested allele in carrier females (three
fragments 234 bp, 131 bp and 101 bp in size). A non-digested sample, labelled as C, was included as a control (C) schematic view of conserved
FRMD7 domains and locations of described mutations located in the FERM-C domain.
Table 3 Distribution of skewed x-inactivation between nystagmus and normal members of the family
PID DNA no. Status Skewing degree
Skewed
1 35 N42 Normal 93:7
2 121 N46 Affected 85:15
3 65 N31 Affected 81:19
4 131 N40 Affected 80:20
5 133 N21 Affected 80:20
Random
1 33 N18 Normal 72:28
2 45 N11 Normal 71:29
3 107 N28 Normal 71:29
4 72 N41 Normal 69:31
5 15 N30 Normal 67:33
6 11 N37 Normal 67:33
7 53 N27 Normal 63:37
8 66 N16 Affected 62:38
9 93 N26 Affected 57:43
10 118 N13 Normal 56:44
12 99 N10 Normal 54:46
13 122 N14 Normal 54:46
14 119 N43 Normal 53:47
15 120 N12 Normal 51:49
16 Spouse of 129 N7 normal 50:50
PID reflects personal identification numbers on fig 1. A total of five individuals (fig 1, individuals 23, 41, 43, 54 and 86) were not
informative. The disease status of non-informative individuals was normal except person 23.
Laboratory science
140 Br J Ophthalmol 2008;92:135–141. doi:10.1136/bjo.2007.128157
 on 17 April 2008 bjo.bmj.comDownloaded from 
in the Turkish population; (iii) the mutation is located in the
FERM-C domain in the surrounding of previously described
missense mutations in families with congenital NYS.6 14
The functional role of FRMD7 remains to be elucidated. The
FRMD7 transcript is abundantly expressed in most tissues, and
a localised and restricted expression was found to be involved in
embryonic development in regions affecting motor control of
eye development.6 Homologies of the B41 and FERM-C domains
of FRMD7 to other proteins, such as FARP1 and FARP2, which
are involved in neurite branching of cortical neurons, led to the
hypothesis that FRMD7 could also be involved in the develop-
ment of similar neuronal pathways.
Skewed X inactivation has consistently been suggested as a
mechanism that may influence the penetrance of X linked NYS
in females;3 7 8 9 however, except for only one study,7 an X
inactivation pattern was not previously studied in NYS families.
No correlation between X inactivation patterns and the NYS
phenotype was observed in this sole study.7 Nevertheless, NYS
in the family used in that study was linked to the Xp11 region
rather than the major NYS locus on Xq26–q27. Our Xq26-linked
NYS family implies that skewed XCI could be a factor that
influences the clinical manifestation of NYS in females. It is well
established that skewed XCI is a rare event in a diverse group of
control females.15 16 In agreement with this prior observation,
we only observed skewed X inactivation in a single healthy
spouse (individual 35). None of the obligate gene carrier females
and none of the remaining healthy spouses demonstrated
skewed X inactivation (table 3); however, increased suscept-
ibility to skewed X inactivation was apparent in the clinically
affected females. On the other hand, we observed random X
inactivation in two affected females, individuals 66 and 93, with
XCI scores of 62:38 and 57:43, respectively. This finding may be
a reflection of tissue mosaicism, which has been clearly shown
in women.16 To the best of our knowledge, inactivation status
of the FRMD7 gene has not been studied. Further investigations
of the X inactivation status of FRMD7 might help contribute to
an understanding of the irregular pattern of inheritance of
NYS1.
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ORIGINAL PAPER
n Abstract We report on a famil-
ial screen of five female members
in three generations affected by an
autosomal-dominant inherited
atrioventricular (AV) conduction
block associated with atrial septal
defects (ASD) and other congenital
cardiovascular diseases (CCVD),
such as pulmonary artery stenosis
(PAS), patent foramen ovale (PFO)
and ventricular septal defect
(VSD). We tested the cardiac
transcription factor NKX2-5 which
is known to cause CCVD with
variable phenotype and pene-
trance by direct sequencing of the
two NKX2-5 coding exons in the
index patient and identified a
novel heterozygous c.325G>T
mutation in exon 1 of the gene.
This mutation co-segregated with
the disease in the family and was
present in all five affected family
members, but not in 100 control
chromosomes. The c.325G>T
mutation is predicted to introduce
a stop codon at amino-acid posi-
tion 109 (p.E109X). The truncated
protein lacks all of the functionally
important domains of the cardiac
transcription factor. Therefore, it
is very likely that this novel mu-
tation causes a complete loss of
NKX2-5 function and haploinsuf-
ficiency is the pathophysiological
mechanism underlying the disease
in the family.
n Key words
congenital heart disease –
mutation – NKX2-5 –
AV conduction block
Introduction
Congenital cardiovascular diseases (CCVDs) are the
most common developmental anomalies, and are di-
agnosed in 1% of newborns. Failure of atrial or ven-
tricular septation accounts for nearly 50% of CCVDs.
The secundum atrial septal defect (ASD) accounts
for ~10% of congenital cardiac malformations, af-
fecting 1 in 1000 live births [1].
ASD, as the most often inherited CCVD, can oc-
cur in monogenic familial conditions, sometimes in
association with other cardiac malformations, or as
one feature of syndromes. Large ASDs can lead to
heart failure in childhood, pulmonary hypertension
and right heart dilatation due to smaller untreated
defects can develop in later life. In adults, percuta-
neous closure techniques via catheterization are
mostly used to occlude the ASD.
An association of ASD with AV conduction block
and other CCVDs was previously described in spo-
radic patients and families with heterozygous muta-
tions in the cardiac transcription factor NKX2-5
gene [2–6].
The human NKX2-5 gene is located on chromo-
some 5q31.1 and the two protein-coding exons en-
code a 324 amino-acid protein with several impor-
tant functional domains for transcriptional activa-
tion and gene regulation. Mutations in NKX2-5 were
described in patients with variable clinical presenta-
tion of CCVD including missense, nonsense, and
frame-shifting mutations such as small deletions and
insertions [2]. Patients with NKX2-5 mutations are
known to have a higher incidence of ASD, with or
without concomitant AV conduction defects. How-
ever, many other cardiac malformations, such as tet-
ralogy of Fallot (TOF), VSD, hypoplastic left heart
syndrome and L-transposition of the great arteries,
have been reported in association with mutations of
NKX2-5. No genotype-phenotype correlation be-
tween the functional consequence of NKX2-5 muta-
tion and clinical phenotype could be established.
Deletion of both NKX2-5 alleles in mice result in
lethality due to impaired cardiac looping [7]. Inter-
estingly, heterozygosity resulted in hypoplasia of the
atrioventricular conduction system in mice [8].
We report a family with five female members in
three generations affected by an autosomal-dominant
inherited atrioventricular (AV) conduction block as-
sociated with atrial septal defects (ASD) and other
congenital cardiovascular diseases (CCVD), such as
pulmonary artery stenosis (PAS), patent foramen
ovale (PFO) and ventricular septal defect (VSD).
The aim of the study was to identify the molecular
basis of this autosomal-dominant disorder causing
CCVD in the family. The primary candidate gene to
examine was NKX2-5 for the reasons described above.
Patients and methods
The female index patient (Fig. 1a, II.5) was 63 years
old. She presented with bradyarrhythmia absoluta
(pacemaker since 1984) and an ASD. She had two
daughters (III.2 and III.3). Both daughters also had a
first-degree AV-block (Fig. 1d) and an ASD. While
the elder daughter had a VSD, the younger one pre-
sented with an additional pulmonary artery stenosis
(PAS). PQ interval was progredient over the last
20 years. The elder sib had two daughters (IV.1 and
IV.2), both of them affected by a first-degree AV-
block and an ASD. Moreover, they both presented
with a patent foramen ovale (PFO). Both children
had a second-degree AV-block at night. Being with-
out clinical symptoms, they have not yet received a
pacemaker. Both parents of the index patient had
died and there was no information about CCVD. PQ
interval, QTc time and clinical presentation of af-
fected family members are shown in Table 1. We
also examined all three sibs (one sister, two broth-
ers) of the index patient (II.5), as well as the hus-
bands of patients II.5 and III.2 Blood samples were
taken from the five affected family members and the
three sibs of the index patient.
DNA was isolated from blood samples taken by
venous puncture. Informed consent of all individuals
or parents of minors was obtained before examina-
tion. The study was approved by the Ethics Commit-
tee of the University Hospital Bonn.
Mutation analysis
The two protein-coding exons and adjacent intronic
sequences of the NKX2-5 gene were amplified by
PCR using standard conditions (exon 1, forward
primer 5-ggcaccatgcagggaagctg-3 and reverse prim-
er 5-caccaggcatcttacattctgaac-3; exon 2: forward
primer 5-ccacgaggatcccttaccatta-3 and reverse prim-
er 5-ggtctccgcaggagtgaatg-3). Subsequently, PCR
fragments were purified using QiaQuick spin col-
umns (Qiagen) and completely sequenced with an
ABI 3100 sequencer (Applied Biosystems).
Identified mutations were resequenced in inde-
pendent experiments, tested for co-segregation with-
in the family, and we screened 50 matched healthy
control individuals with the same ethnical back-
ground (non-familial, equal amount of males and fe-
males without any history for cardiac anomalies, not
matched for age) for the mutation by direct sequenc-
ing.
Molecular results
After detailed clinical characterization of the autoso-
mal-dominant inherited phenotype in the family, we
considered the NKX2-5 cardiac transcription gene as
a highly relevant functional candidate gene, because
NKX2-5 mutation had previously been described in
ASD patients associated with AV conduction block.
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Table 1 Clinical characterization of the affected family members. AF atrial fi-
brillation, ASD atrial septal defect, AV-B atrioventricular block, CCVD congenital
cardiovascular diseases, OP operation, PAS pulmonary artery stenosis, PFO pat-
ent foramen ovale, PM pacemaker, s seconds, VSD ventricular septal defect
Patient Year of
birth
CCVD (therapy) PQ interval (ms) QTC time (ms)
II.5 1942 ASD, AV-B I, AF
(PM 1984)
1984:
293
2007:
AF
1984:
320
2007:
351
III.2 1967 ASD, VSD, AV-B I 1984:
282
2007:
320
1984:
324
2007:
346
III.3 1971 ASD, PAS, AV-B I
(ASD-OP 1976)
1984:
278
2007:
344
1984:
328
2007:
364
IV.1 1983 ASD, PFO, AV-B I,
IIa
1996:
151
2005:
392
1996:
314
No
data
IV.2 1997 ASD, PFO, AV-B I,
IIb
1997:
120
2005:
212
1997:
305
No
data
Therefore, we initially sequenced the two NKX2-5 cod-
ing exons in the index patient and identified the novel
heterozygous c.325G>Tmutation in exon 1 of the gene
that was present in all five affected family members, but
neither in the three healthy sibs of the index patient
(II.5), nor in 100 control chromosomes (Figs. 1a,b).
The penetrance of the mutation in the family was
100%. The c.325G>T mutation predicts the introduc-
tion of a stop codon at amino-acid position 109
(p.E109X). The truncated protein lacks all of the func-
tionally important domains of the cardiac transcrip-
tion factor (Fig. 1 c). Therefore, it is very likely that this
novel mutation causes a complete loss of NKX2-5 func-
tion and haploinsufficiency is the pathophysiological
mechanism underlying the disease in the family.
Discussion
Our study identified a novel nonsense mutation in the
cardiac transcription factor NKX2-5 in the presented
family. Evidence for the disease-causing nature of this
mutation includes: (i) co-segregation with the disease
in the family; (ii) absence of the disease in 100 healthy
control individuals; and (iii) the predicted loss of func-
tion of the mutant allele. The mutation is predicted to
truncate the protein after 109 amino-acids and, thereby,
the mutant protein lacks all known domains that are
important for its functionality including the homeodo-
main (Fig. 1 c). This clearly shows that haploinsuffi-
ciency by loss of function is the pathophysiological
mechanism in this family. It is interesting to note that
haploinsufficiency in NKX2-5±mice caused alterations
of the AV-node, which is in accordance with the clinical
phenotype in the family we are reporting on.
In the presented family we could observe a complex
pattern of CCVD. Though ASD and AV block are the
most frequent CCVD in different NKX2-5 mutations,
they are not found in all cases and, furthermore, the
combination with other congenital heart disorders is
common, but very unpredictable [9]. The phenotype
of CCVD is also distinct in each affected family mem-
ber presented here, only ASD and AV block are found
in each patient. We emphasize the fact that the AV
block is progredient in each individual as described
before, but it also seems to be progressive in the de-
scendants compared to the respective mother
(Fig. 1d). Although there are numerous reports of tet-
ralogy of Fallot or isolated pulmonary valve stenosis,
there has been no description of patent foramen ovale
and pulmonary artery stenosis in a family before.
Atrial fibrillation though, as seen in our index patient,
seems to be common in patients with NKX2-5 muta-
tions. Taken together, the phenotype of patients with
defects in NKX2-5 mutations is highly variable, even
within families. Thus, it is difficult to outline any sig-
nificant genotype-phenotype correlation.
Genetic factors play an important role in the devel-
opment of congenital heart disease, especially ASD/
VSD, and previous studies showed that heterozygous
mutations in NKX2-5 cause a subset of familial ASD
[9–11]. ASD is the most common CCVD in over 1 in
3S. Pabst et al.
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Fig. 1 Pedigree and mutation analysis. a Pedigree of the family studied.
Affected individuals are shown by filled symbols. Results of the molecular
analysis are given for each family member tested (E109X in all affected fam-
ily members, wild type (wt) in three healthy individuals in the second gen-
eration). b Sequence chromatograms showing the identified c.325G>T muta-
tion in comparison to a control sequence. c Functional effect of the p.E109X
nonsense mutation on the protein. Comparison of wild-type and truncated
protein. d Electrocardiogram showing a first-degree AV conduction block in
individual III.2 and III.3; ECG 25 mm/s
1000 live births and its association with other AV
block types of cardiac arrhythmias increases the
symptomatic risk for patients. Therefore, a molecular
genetic analysis, as presented in this study, can identi-
fy the underlying cause as well as identify family
members at risk for the disease. Genetic and clinical
screening will appear to be most helpful in identifying
individuals who await operative reconstruction during
the progressive course of the underlying congenital
heart disease [12, 13].
Conclusion
As AV block seems to be progredient in most NKX2-
5 mutations and often requires the implantation of a
pacemaker in the course of disease, identification of
patients carrying NKX2-5 mutations is important for
accurate and early therapy.
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Communicated by Henrik Dahl
In two large Turkish consanguineous families, a locus for autosomal recessive nonsyndromic hearing loss
(ARNSHL) was mapped to chromosome 6p21.3 by genome-wide linkage analysis in an interval overlapping
with the loci DFNB53 (COL11A2), DFNB66, and DFNB67. Fine mapping excluded DFNB53 and
subsequently homozygous mutations were identified in the lipoma HMGIC fusion partner-like 5 (LHFPL5)
gene, also named tetraspan membrane protein of hair cell stereocilia (TMHS) gene, which was recently shown to
be mutated in the ‘‘hurry scurry’’ mouse and in two DFNB67-linked families from Pakistan. In one family, we
found a homozygous one-base pair deletion, c.649delG (p.Glu216ArgfsX26) and in the other family
we identified a homozygous transition c.494C4T (p.Thr165Met). Further screening of index patients from
96 Turkish ARNSHL families and 90 Dutch ARNSHL patients identified one additional Turkish family carrying
the c.649delG mutation. Haplotype analysis revealed that the c.649delG mutation was located on a common
haplotype in both families. Mutation screening of the LHFPL5 homologs LHFPL3 and LHFPL4 did not reveal
any disease causing mutation. Our findings indicate that LHFPL5 is essential for normal function of the human
cochlea. Hum Mutat 27(7), 633–639, 2006. r 2006 Wiley-Liss, Inc.
KEY WORDS: deafness; hearing loss; autosomal-recessive; gene identification; LHFPL5
INTRODUCTION
Hearing impairment is the most common inherited disorder
of a person’s senses; therefore, understanding the various pathophy-
siological processes causing hearing loss has an important impact
on advanced therapeutic strategies. The approximate prevalence
of hearing loss caused by genetic factors has been estimated to
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be at least 1 per 2,000 [Mehl and Thomson, 1998, 2002]. The
spectrum of hereditary hearing loss is broad and ranges from
nonsyndromic hearing loss without any other phenotypic abnorm-
ality to various forms of syndromic hearing loss. Overall, the most
common hereditary form is autosomal recessive nonsyndromic
hearing loss (ARNSHL), accounting for 470% of the cases
[Morton, 1991]. In recent years, improved molecular genetic
techniques have led to the identification of more than 67 loci
for ARNSHL (DFNB) and to date 23 of the corresponding genes
have been identified (Hereditary Hearing loss Homepage; http://
webhost.ua.ac.be/hhh/). Analysis of the physiological and patho-
physiological functions of the disease-associated proteins have
provided intriguing insights into the complex structure of the inner
ear and mechanisms of hearing. Although the progress in the field
is remarkable, further identification of novel deafness genes
and analyses of the function of the encoded proteins will enlarge
our knowledge of the highly complex regulation of inner ear
development and function.
Our strategy to identify novel deafness genes is based on
a collection of large consanguineous families with ARNSHL; a
genomewide, homozygosity mapping approach was used to identify
novel DFNB loci and subsequently novel disease-causing genes.
In the course of this study, we mapped two Turkish families to
the DFNB67 locus on chromosome 6p21.3–p21.1 and identified
homozygous mutations in the gene named lipoma HMGIC fusion
partner-like 5 (LHFPL5) gene (MIM] 609427), alias tetraspan
membrane protein of hair cell stereocilia (TMHS), which was recently
shown to be mutated in the ‘‘hurry scurry’’ mouse [Longo-Guess
et al., 2005] and in two DFNB67-linked families from Pakistan
[Shabbir et al., 2006].
MATERIALSANDMETHODS
Subjects
Participating family members underwent otoscopy and pure-
tone audiometry. Hearing loss was quantified by pure-tone
audiometry with aerial and bone conduction at 250, 500, 1,000,
2.000, 4,000, 6,000, and 8,000 Hz in a sound-treated room. The
air conduction pure-tone average (ACPTA) threshold in the
conversational frequencies (0.5, 1, and 2 kHz) was calculated for
each ear, and hearing loss was classified as mild (20oACPTAo40
dB), moderate (40oACPTAo70 dB), severe (70oACPTAo90
dB), or profound (ACPTA490 dB). Vestibular areflexia was
evaluated by the Romberg test and a questionnaire including
questions of childhood motor development, insecure feeling during
walking in darkness and on an uneven surface, problems with
gymnastics and sports, motion sickness, and visual fixation
(reading during walking) (Gendeaf homepage; www.gendeaf.org).
Written informed consent was obtained from adults and the
parents of children. The local ethics committee approved this
study. DNA was extracted from peripheral blood lymphocytes
by standard extraction procedures. We used control DNAs from
170 unrelated individuals of Turkish origin and over 90 Caucasian
individuals from The Netherlands.
LinkageAnalysis
The GJB2 (MIM] 121011) gene was excluded as the causative
gene in all families by sequencing of the 50-untranslated region
and the protein coding exon of the gene. In addition, all other
22 known ARNSHL genes were excluded in Family TR77 by analysis
of flanking microsatellite markers. We performed genomewide
linkage analysis in Family DF44 and homozygosity mapping in
Family TR77 using the Affymetrix GeneChip Human Mapping
10K Array, version 2.0 (Affymetrix, Santa Clara, CA). This
version of the Mapping 10K array comprises a total of 10,204 SNPs
with a mean intermarker distance of 258 kb, equivalent to
0.36 cM. Genotypes were called by the GeneChip DNA Analysis
Software (GDAS v2.0; Affymetrix). We verified the gender of the
samples by counting heterozygous SNPs on the X chromosome.
Relationship errors were evaluated with the help of the program
Graphical Relationship Representation [Abecasis et al., 2001].
The program PedCheck was applied to detect Mendelian errors
[O’Connell and Weeks, 1998] and data for SNPs with such errors
were removed from the data set. Non-Mendelian errors were
identified by using the program MERLIN [Abecasis et al., 2002]
and unlikely genotypes for related samples were deleted.
Nonparametric linkage analysis using all genotypes of a chromo-
some simultaneously was carried out with MERLIN. Parametric
linkage analysis was performed by a modified version of the
program GENEHUNTER 2.1 [Kruglyak et al., 1996; Strauch
et al., 2000] through stepwise use of a sliding window with sets
of 110 or 200 SNPs. In addition, the ExcludeAR Excel sheet was
used for autozygosity mapping [Woods et al., 2004]. We analyzed
additional microsatellite markers for fine-mapping of the critical
regions and calculated multipoint logarithm of the odds (LOD)
scores using SimWalk2 [Sobel and Lange, 1996] and the following
markers: Family DF44: D6S273, D6S2443, D6S2444, D6S1583,
D6S1629, D6S291, D6S943, D6S389, D6S426, D6S1575,
D6S1549, D6S400, D6S1582; Family TR77: D6S1615,
D6S1666, D6S2414, D6S1701, D6S1583, D6S1568, D6S1618,
D6S1611, D6S291, D6S1602, D6S943, D6S1019, D6S1610,
D6S1575, D6S282. Markers were taken from the ENSEMBL
(www.ensembl.org) and UCSC (www.genome.ucsc.edu) human
genome databases.
Mutation Analysis
We identified candidate genes in the critical region using the
ENSEMBL and UCSC human genome databases. The three
protein-coding exons and adjacent intronic sequences of
the LHFPL5 gene were amplified by PCR (MJ Research DNA,
Bio-Rad, Munich, Germany; www.mjr.com) using standard conditions
(exon 1, forward primer 50-GTCATCTCGGTTCAGGAAGG-3
and reverse primer 50-TCTGGGCTCAGAACCTCATC-30 exon
2: forward primer 50-GTGAGGAGAATGGCTGAAGG-30 and
reverse primer 50-TGATTTCAGGGAGGACAAGG-30; exon 3:
forward primer 50-CCATCTGCCCAACCAATAAC-30 and re-
verse primer 50-AAAATTAGCCAGGCATGGTG-30). Subse-
quently, PCR fragments were purified with QiaQuick spin
columns (Qiagen, Hilden, Germany; www.qiagen.com) and
directly sequenced using the corresponding forward primers with
the ABI PRISM Big Dye Terminator cycle sequencing V2.0 ready
reaction kit and an ABI PRISM 3730 DNA analyzer (Applied
Biosystems, Darmstadt, Germany; www.appliedbiosystems.com).
Primer sequences for amplification of coding exons of LHFPL3 and
LHFPL4 genes are available on request. DNA mutation number-
ing of identified mutations was given based on cDNA sequence
of LHFPL5 GenBank entry NM_182548.2 with 11 corresponding
to the A of the ATG translation initiation codon.
We resequenced all identified mutations in independent
experiments, tested for cosegregation within the families, and
screened more than 170 Turkish control individuals for the
mutations c.649delG and c.494C4T by PCR and subsequent
restriction digestion (using BshTI or BccI, respectively; Fermentas,
St. Leon-Rot, Germany; www.fermentas.com) or direct sequen-
cing. The c.527G4T mutation was not found in 90 Dutch control
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Human Mutation DOI 10.1002/humu
individuals. The presence of this mutation was analyzed by an
Amplification-Refractory Mutation System (ARMS) assay with for
the wild-type allele the forward primer 50-aagtacacgctgggccactg
caccatcag-30 and for the mutant allele the forward primer
50-aagtacacgctgggccactgcaccatcat-30. As reverse primer was used
50-ccaagccttagaggactggctaagatgaac-30. The PCR was performed
with 1.5 mM MgCl2 and an annealing temperature of 581C.
Accession Numbers
LHFPL5 mRNA: GenBank NM_182548.2; LHFPL4 mRNA:
GenBank AY278320.1; LHFPL3 mRNA: GenBank NM_199000.1.
RESULTS
Patients and Clinical Evaluation
Participating members of Families DF44, TR44, and TR77
underwent general otological examinations, pure-tone audiometry,
and affected individuals were diagnosed with nonsyndromic,
bilateral, severe to profound, sensorineural hearing loss. In each
affected individual hearing impairment was noticed by the parents
in the first six months of life. Vestibular evaluation did not display
any symptoms of vestibular dysfunction. Childhood milestones
were normal and the Romberg test was negative in all patients.
Most of the affected individuals were born to consanguineous
parents and an autosomal recessive inheritance pattern was
suggested in all families analyzed.
Homozygosity Mapping
After exclusion of GJB2 as the causative gene by direct
sequencing in Families DF44 and TR77, and exclusion of 22
known ARNSHL genes by linkage analysis in Family TR77,
we initially genotyped DNA samples from six affected and nine
nonaffected members in Family DF44, and five affected individuals
in Family TR77 using the Affymetrix GeneChip Human Mapping
10K Array. The combined maximum parametric LOD score of
3.56 was obtained in Family DF44 for a region located between
SNPs rs718254 and rs571770 on chromosome 6p21.3–p21.1
(Fig. 1A and D) defining a critical interval of about 14 Mb. By
fine-mapping with microsatellite markers and inclusion of addi-
tional family members, we reduced the critical region to an 8.4-Mb
interval between markers D6S1629 and D6S400 with a maximum
multipoint LOD score of 4.44 for markers between D6S291 and
D6S389, calculated by using SimWalk2 [Sobel and Lange, 1996]
(Fig. 1B and D; Fig. 2A). Analyses of genotype data of the TR77
family revealed two significant homozygous regions for the four
affected individuals in loop II (Fig. 2B). These regions were
interrupted by several heterozygous SNPs in individual V:1 in loop
I (Fig. 2B). One significant homozygous region was detected on
chromosome 6p22.3-p21.2 between the SNPs rs1022558 and
rs976482 and another region was found on chromosome 20q13.12
between the SNPs rs3908612 and rs869136. Analysis of micro-
satellite markers of these regions in additional family members
excluded the putative locus on chromosome 20 (data not shown).
FIGURE 1. Mapping of the 6p21.3^p21.1 locus. A:Graphical view of additive LODscore calculations of genomewide SNPmapping in
familyDF44 indicating a single locus on 6p21.3^p21.1 (markedby the arrow). B andC. Multipoint analysis ofmicrosatellitemarkers
used for ¢ne-mappingof thecritical region inFamiliesDF44 (B) andTR77 (C). Along thex-axis, cMaregiven fromthe telomereof the
p-arm to the telomere of the q-arm of chromosome 6. Additional family members, who were not available for the genome scan, were
included in the ¢ne-mapping study in both families. D: Ideogram of chromosome 6 and detailed presentation of the critical region
identi¢ed in the families DF44 andTR77 in comparisonwith the publishedDFNB66 andDFNB67 locus.The locations of COL11A2
and LHFPL5 are indicated and the combined critical region is marked with the yellow bar. [Color ¢gure can be viewed in the online
issue,which is available at www.interscience.wiley.com]
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A critical homozygous region of approximately 7.5 Mb was defined
on chromosome 6p21.3-p21.1 between the markers D6S1583
and D6S1575 (Figs. 1D and 2B). A maximum two-point LOD
score of 4.1 was calculated for marker D6S1602 and a maximum
multipoint LOD score of 6.12 for markers between D6S1568 and
D6S1610 (Fig. 1C).
The critical region in both Family DF44 and Family TR77
partially overlapped with the recently described DFNB66 locus,
for which the gene has not yet been identified [Tlili et al., 2005], but
it excluded COL11A2 (MIM] 120290; see DFNB53, MIM]
609706) [Chen et al., 2005] by recombination events in Patients
DF44-III:5 and IV:8 and TR77-V:1 and V:2 (Fig. 1D; Fig. 2A and B).
Mutation Analysis of the LHFPL5 Gene
We considered the LHFPL5 gene (alias TMHS), as a highly
relevant positional candidate gene because a homozygous missense
mutation in Lhfpl5 was known to cause deafness and vestibular
dysfunction in the ‘‘hurry-scurry’’ (hscy) mouse [Longo-Guess
et al., 2005]. In human, the LHFPL5 gene is comprised of four
exons, of which the first three contain the protein coding
sequences for a predicted four-transmembrane-spanning protein
of 219 amino acids (Fig. 3D). We sequenced the three LHFPL5
coding exons in two affected individuals from each family and
identified homozygous mutations in both families. All affected
members of Family DF44 carried the homozygous one base-pair
deletion c.649delG in exon 2 (Fig. 3A). The nucleotide c.G649 is
the last nucleotide of exon 2 followed by the invariant GT-motif
of the intron 2 splice donor site. Computational analysis using the
splice-site prediction program SpliceView (http://l25.itba.mi.cnr.it/
webgene/www.spliceview.html) predicted that the splice donor
site of intron 2 in the mutant allele is still recognized without a
decreased splice-score compared to the wild-type sequence.
Therefore, the c.649delG mutation can be predicted to cause a
frameshift at amino acid position 216 that introduces an extended
C-terminal part of LHFPL5 with a termination codon after
additional 25 erroneous amino acids (p.Glu216ArgfsX26)
(Fig. 3D). None of the unaffected individuals in Family DF44
carried the c.649delG in a homozygous state and it was not
detected in 170 matched control individuals. In Family TR77, the
homozygous LHFPL5 c.494C4T mutation in exon 2 was detected
in all affected members (Fig. 3B). This nucleotide substitution
was not observed in 170 ethnically matched control individuals.
The c.494C4T mutation predicts the amino acid substitution
p.Thr165Met in the second extracellular region between
the transmembrane domains three and four (Fig. 3D). Residue
p.Thr165 is conserved among most species and homologs with
a conservation score of 7 as calculated by CONSEQ (http://
conseq.bioinfo.tau.ac.il) and is located in close vicinity to the
p.Cys161Phe mutation present in the hscy mouse (Fig. 3E)
[Longo-Guess et al., 2005].
LHFPL5 Analysis in Additional Families and Patients
Sequencing of the three coding exons of LHFPL5 was
performed in 96 index patients from large Turkish ARNSHL
FIGURE 2. Haplotypes in ARNSHL families linked to 6p21.3^p21.1. Markers are listed on the left of the haplotypes of Families DF44
(A),TR77 (B), andTR44 (C).The location of theLHFPL5 gene is indicated by an arrow.Themutation-carrying haplotype is identical
in Families DF44 and TR44, suggesting a founder mutation. [Color ¢gure can be viewed in the online issue, which is available
at www.interscience.wiley.com]
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families and in 90 Dutch ARNSHL patients without a mutation
in GJB2. In the index patient of Family TR44, we again identified
the c.649delG mutation and subsequent family analysis showed
cosegregation of the mutation with hearing loss in the family
(Fig. 2C). Both Families DF44 and TR44 originated from different
cities at the East Black Sea region in Turkey and although a
connection between the two families could not be established,
haplotype analysis showed that the c.649delG mutation was
located on the same haplotype in both families, suggesting
c.649delG to be a founder mutation. In addition, the transversion
c.527G4Twas identified in a Dutch patient with ARNSHL in a
heterozygous state predicting a substitution of leucine for the
highly conserved arginine at position 176 (p.Arg176Leu) with the
maximal conservation score of 9 (calculated by CONSEQ).
Arg176 is predicted to be the last amino acid of the second
extracellular loop between transmembrane domains three and four
(Fig. 3C–E). This putative mutation was not detected in 90 Dutch
control individuals. A second mutation in the known LHFPL5
exons and adjacent intronic sequences was not detected in this
patient. Since the LHFPL5 homologs LHFPL3 and LHFPL4 are
mainly expressed in neuronal tissue, we continued the molecular
analysis and sequenced these genes in 78 index patients from
Turkish ARNSHL families, but no disease-associated mutations
were identified.
DISCUSSION
We provide evidence that mutations in the LHFPL5 gene cause
ARNSHL in humans and identified two different missense
mutations and a one base-pair deletion in three consanguineous
Turkish families and a sporadic Dutch patient. LHFPL5 is the
second gene in the 6p21.3-p21.1 region causing ARNSHL.
A homozygous mutation in COL11A2 was recently described
in families linked to the DFNB53 locus [Chen et al., 2005].
An additional, yet unknown ARNSHL gene might be present
in this region since both genes, COL11A2 and LHFPL5, were
excluded by direct sequencing in the DFNB66-linked family
[Tlili et al., 2005].
The homozygous p.Cys161Phe mutation in Lhfpl5 was described
to cause deafness and vestibular dysfunction in the ‘‘hurry-scurry’’
(hscy) mouse [Longo-Guess et al., 2005] and very recently,
Shabbir et al. [2006] reported mapping of the DFNB67 locus and
identification of a homozygous deletion, c.246delC, leading to an
unchanged Pro83 followed by a stop codon (p.Pro83ProfsX1), and
missense mutation (p.Tyr127Cys) in LHFPL5 (referred as TMHS)
in two families from Pakistan. In both families, affected individuals
presented with bilateral profound hearing loss without vestibular
dysfunction. Therefore, no obvious phenotypic difference to our
families exists.
FIGURE 3. Mutations identi¢ed in LHFPL5. A^C: Sequence chromatograms showing themutations (upper sections) identi¢ed in the
ARNSHL families, and the wild-type sequences (lower sections). The c.649delG (Families DF44 and TR44) and p.T165M (Family
TR77)mutations arepresent in a homozygous state,whilep.R176Lwas foundheterozygously. DNAmutationnumberingof identi¢ed
mutationswasgivenbasedon thecDNAsequenceof theLHFPL5GenBankentryNM_182548.2,with11corresponding to theAof the
ATG translation initiationcodon.D:Predicted topologymodel of LHFPL5with four transmembranespanningdomains (TM1toTM4)
and localization of identi¢ed mutations in the current study (red), by Shabbir et al. [2006] (green), and in the hscy mouse (blue).
E: Alignment of part of the LHFPL5 protein sequences of several vertebrate and invertebrate species, and the human homologs
LHFPL1-4. Locationof predicted transmembranedomains 3 and 4 is givenby thebold line above the sequences. Identical residues in
all sequences are white on a black background, whereas amino acid residues that are present in six or more sequences are black on
a gray background. Identi¢ed missense mutations in our families and the mouse mutation (p.C161F) are indicated with an arrow.
[Color ¢gure can be viewed in the online issue,which is available at www.interscience.wiley.com]
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LHFPL5 belongs to the family of tetraspan proteins with four
transmembrane domains and two connecting extracellular loops
(Fig. 3D). Although the specific function of LHFPL5 is not yet
understood, it is intriguing to mention that mutations in various
other genes encoding tetraspan proteins have been described in
syndromic and nonsyndromic forms of hearing loss (e.g., GJB2;
GJB3, MIM] 600101; CLDN14, MIM] 605608; USH3A, MIM]
276901) [Kelsell et al., 1997; Xia et al., 1998; Joensuu et al., 2001;
Wilcox et al., 2001; Adato et al., 2002]. Immunohistochemical
studies suggested that LHFPL5 is specifically expressed in
stereocilia of inner and outer hair cells of the mouse during
stereocilia formation, suggesting an important role in hair bundle
morphogenesis [Longo-Guess et al., 2005; Shabbir et al., 2006].
As a consequence of p.Cys161Phe, homozygous hscy mice did not
express LHFPL5 protein in the inner ear, although mRNA was still
detected. Impairment of translation or rapid degradation of the
mutated protein due to modifications or mislocalization was
discussed as the underlying mechanism.
We identified the c.649delG (p.Glu216ArgfsX26) mutation on
the same haplotype in two Turkish families from the East Black Sea
region. Although both families originated from different cities, a
shared founder carrying this mutation is likely. It will be interesting
to test the frequency of c.649delG in an extended cohort of
ARNSHL patients from this region in Turkey. It is unlikely that
c.649delG changes the efficiency of the nearby located splice
donor site of intron 2 leading to an aberrant splice product. In a
preliminary experiment, we amplified and sequenced LHFPL5
mRNA isolated from lymphocytes of a heterozygous carrier of the
mutation and interestingly, could not detect the mutant allele
(data not shown). This result gives a first hint that the deletion
might cause mRNA decay, which would lead to complete loss
of LHFPL5 transcript and protein in a homozygous patient. In
addition. the c.246delC mutation reported by Shabbir et al. [2006]
predicts a truncation of the LHFPL5 protein at position 84. Even if
the mRNA is not decayed, the truncated protein would lack three
of its four transmembrane domains (Fig. 3D) and this would most
likely cause loss-of-function.
The p.Thr165Met and p.Arg176Leu mutations are both located
in the second extracellular loop of LHFPL5 in close vicinity to the
mutation found in the hscy mouse (Fig. 3D). Whether the human
LHFPL5 mutations cause an analogy to the suggested effect of
p.Cys161Phe in hscy mice [Longo-Guess et al., 2005], complete
loss of LHFPL5 protein due to, for example, consequences
for the solubility or structural properties of LHFPL5, remains to
be elucidated.
Interestingly, we did not observe vestibular dysfunction in the
patients of the presented families as could be expected from the
phenotype present in hscy mice. A different expression pattern of
LHFPL5 in humans or additional compensating mechanisms in
the vestibular system might explain the phenotypic difference.
Such a difference in vestibular phenotype has been described for
several other genes causing hearing loss in both human and mouse
(e.g., DFNB31/Whrn [Holme et al., 2002; Mburu et al., 2003]).
We did not detect a second LHFPL5 mutation in the Dutch
ARNSHL patient carrying the heterozygous p.Cys161Phe muta-
tion that she inherited from the normal hearing father. Clinically,
the patient presented with a profound congenital sensorineural
hearing loss. We cannot exclude a second mutation in a regulatory
domain or intronic sequence of LHFPL5. Also, digenic inheritance
might be present in this patient as it has been described in other
ARNSHL patients. A mutation in GJB2 was excluded.
Since the LHFPL5 homologs LHFPL3 and LHFPL4 are mainly
expressed in neuronal tissues, these genes were tested for
involvement in the pathogenesis of ARNSHL. No disease-causing
mutations were detected in 78 index patients from Turkish
ARNSHL families, excluding mutations in these genes as a
common cause for ARNSHL in the Turkish population.
In conclusion, we provide further evidence that mutations in
LHFPL5 (alias TMHS) cause ARNSHL without vestibular
dysfunction. Although further experimental support is needed,
loss of LHFPL5 function seems to be a plausible underlying
mechanism.
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disorders and ischaemic heart disease, the ITT
is a safe test when performed in experienced
centres.3 Indeed, a review of .6500 ITTs
reported that only seven patients (0.1%)
experienced an adverse event, all of which
reversed following intravenous glucose.6 To our
knowledge, only two studies have used the ITT
to investigate the HPA axis in asthmatic
children treated with inhaled fluticasone. The
first reported an inadequate response to
insulin-induced hypoglycaemia in three chil-
dren taking 1000–2250 mg/day.7 In the second
study, nine of 18 subjects treated with 250–
750 mg/day for up to 16 weeks exhibited
evidence of adrenal suppression which recov-
ered following cessation of treatment.1
Finally, as hypopituitarism of probable
autoimmune aetiology has been reported in
patients with celiac disease,8 the possibility
that autoimmune hypophysitis contributed to
the patients’ symptoms and pituitary defi-
ciency cannot be definitively excluded.
In summary, this report suggests that
inhaled (together with intranasal) flutica-
sone may suppress the HPA axis in adults
and that symptomatic adrenal insufficiency
may develop, particularly if dosing is variable
and intermittent. These cases illustrate that
clinical symptoms may alert the physician to
the possibility of adrenal suppression which
can then be confirmed using basal and/or
stimulated tests of HPA function in selected
patients. Further investigation to determine
the prevalence of these effects in adult
patients is warranted.
J R Greenfield, K Samaras
Department of Endocrinology, St Vincent’s Hospital,
and Garvan Institute of Medical Research, Sydney,
Australia
Correspondence to: A/Prof K Samaras, Diabetes and
Obesity Research Program, Garvan Institute of
Medical Research, 384 Victoria Street, Darlinghurst
2010, Australia; K.samaras@garvan.org.au
doi: 10.1136/thx.2005.049643
References
1 Mahachoklertwattana P, Sudkronrayudh K,
Direkwattanachai C, et al. Decreased cortisol
response to insulin induced hypoglycaemia in
asthmatics treated with inhaled fluticasone
propionate. Arch Dis Child 2004;89:1055–8.
2 Todd GRG, Acerini CL, Ross-Russell R, et al.
Survey of adrenal crisis associated with inhaled
corticosteroids in the United Kingdom. Arch Dis
Child 2002;87:457–61.
3 Greenfield JR, Samaras K. Evaluation of pituitary
function in the fatigued patient: a review of 59
cases. Eur J Endocrinol 2006;154:147–57.
4 Lipworth BJ. Systemic adverse effects of inhaled
corticosteroid therapy: A systematic review and
meta-analysis. Arch Intern Med
1999;159:941–55.
5 Casale TB, Nelson HS, Stricker WE, et al.
Suppression of hypothalamic-pituitary-adrenal
axis activity with inhaled flunisolide and
fluticasone propionate in adult asthma patients.
Ann Allergy Asthma Immunol 2001;87:379–85.
6 Fish HR, Chernow B, O’Brian JT. Endocrine and
neurophysiologic responses of the pituitary to
insulin-induced hypoglycemia: a review.
Metabolism 1986;35:763–80.
7 Todd G, Dunlop K, McNaboe J, et al. Growth and
adrenal suppression in asthmatic children treated
with high-dose fluticasone propionate. Lancet
1996;348:27–9.
8 Collin P, Kaukinen K, Valimaki M, et al.
Endocrinological disorders and celiac disease.
Endocrinol Rev 2002;23:464–83.
BTNL2 gene variant and
sarcoidosis
Sarcoidosis is an inflammatory granuloma-
tous disorder that primarily affects the lungs
and lymph nodes. Other organs such as the
brain, eyes, heart, and skin can also be
affected. The disease is characterised by
non-caseating granulomas and an exagger-
ated cellular immune response caused by
increased inflammatory activity.1 The course
of the disease is acute and mild in approxi-
mately 20% of all patients. In most patients a
chronic stage develops which can lead to lung
fibrosis. Although the exact pathogenesis of
sarcoidosis remains unclear, familial cluster-
ing of the disease and the increased risk of
relatives to develop sarcoidosis suggest that
there might be a genetic predisposition to
develop the disease.2
A significant association was recently
reported in Germany between sarcoidosis
and a frequent single nucleotide polymorph-
ism (SNP) in the BTNL2 gene, rs2076530.3
BTNL2 is a member of the immunoglobulin
gene family and is related to CD80 and CD86
co-stimulatory receptors, although its exact
function is unknown.4 BTNL2 is located on
chromosome 6p21.3 in close proximity to the
HLA gene cluster. rs2076530 is located at
position 1 of the donor splice site in intron 5
and the associated A allele causes the usage
of an alternative donor site leading to a 4 bp
deletion at the mRNA level, frameshift, and
premature truncation at the protein level.3
The rs2076530 SNP alone was also associated
with sarcoidosis in a case-control study of
white American subjects.4 No replication of
the BTNL2 rs2076530 susceptibility to sarcoi-
dosis has yet been studied in an independent
German case-control study. We therefore
performed a case-control association study
in 210 patients with sarcoidosis and 202
controls. Written informed consent was given
by each participant and the study was
approved by the ethics committee of Bonn
University School of Medicine.
The diagnosis of sarcoidosis was based on
evidence of non-caseating epitheloid cell
granuloma in biopsy specimens and chest
radiographic abnormalities. Different stages
were defined as previously described.5 A
chronic course was defined as disease over
at least 2 years or at least two episodes in a
lifetime. Acute sarcoidosis was defined as one
episode of acute sarcoidosis which had totally
resolved at the date of the examination. None
of the individuals in the control group
(healthy white German subjects of mean
age 38.32 (15.53) years) had a history of
lung disease or showed any symptoms of
lung or other disease by chest radiography or
laboratory blood tests. Genotyping of
rs207653 was performed using the Taqman
technique with a commercially available
assay (Applied Biosystems, Germany). SPSS
Version 12 was used for statistical analysis.
The genotype distributions in the cohort were
in accordance with the Hardy-Weinberg
equilibrium.
The A allele frequency of rs2076530 was
significantly increased in sarcoidosis patients
compared with controls (A = 0.6929,
G = 0.3071 in cases; A = 0.6188, G = 0.3812
in controls). It was significantly associated
with an increased risk of sarcoidosis in co-
dominant and dominant models (OR 2.31
(95% CI 1.27 to 4.23); p,0.006, table 1), but
not in a recessive model (p = 0.276). The
calculated population attributable risk (PAR)
for AA homozygotes and AG heterozygotes
was 34.6%. Our results were in accordance
with the reported association between BTNL2
and sarcoidosis and replicated the finding
that A allele carriers of rs2076530 have a
more than twofold increased risk of develop-
ing sarcoidosis compared with GG homo-
zygotes in the German population.
We also examined whether this increased
risk is present in both chronic and acute forms
of sarcoidosis. Interestingly, we found that the
chronic form—but not the acute form—was
significantly associated with the A allele in co-
dominant and dominant models (OR 2.87
Table 1 Baseline biochemistry and peak cortisol levels following insulin induced
hypoglycaemia in two female adult patients taking inhaled/intranasal
corticosteroids
Patient 1 Patient 2
08.00 cortisol (200–600 nmol/l) 169/198 113/198
08.00 ACTH (,12 pmol/l) 4.5 2.8/2.9
Insulin-like growth factor-1 (0.4–1.6 U/ml) 0.54 0.89/0.79
Free thyroxine (10–21 pmol/l) 11 15.9/15.6*
Thyroid stimulating hormone (0.3–4 mIU/l) 0.77 1.77/1.95*
Prolactin (50–370 mIU/l) 224 111/87
Luteinising hormone (IU/l) 11.3 26.4/18.4
Follicular stimulating hormone (IU/l)` 6.5 50.1/42.7
a-subunit (IU/l)1 0.41 Not done
Anti-microsomal antibodies Negative Positive
Dehydrepiandrosterone (mmol/l) ,1.0 ,1.0
Results of insulin tolerance test
Baseline cortisol (200–600 nmol/l) 160 159
Minimum blood glucose (,2.2 mmol/l) 1.9 1.6
30 minute cortisol (nmol/l) 327 343
60 minute cortisol (nmol/l) 450 492
90 minute cortisol (nmol/l) 313 388
120 minute cortisol (nmol/l) 227 282
Peak growth hormone (.13 mU/l) 40.3 4.9
Normal ranges and units are in brackets. ‘‘Normal’’ peak cortisol level following hypoglycaemia
.550 nmol/l. When more than one value is quoted, the tests were performed on different days.
*On thyroxine.
Reference range (RR): females – premenopausal 2.5–130 IU/l, postmenopausal .15 IU/l, males
1.5–14 IU/l.
`RR: females – premenopausal 1.6–33 IU/l, postmenopausal .16 IU/l, males 0.9–8.1 IU/l.
1RR: males and females – premenopausal 0.05–0.4 IU/l, postmenopausal 0.37–1.15 IU/l.
RR: females – premenopausal 2.2–9.1 mmol/l, postmenopausal 0.3–1.7 mmol/l, males 5.3–9 mmol/l.
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(95% CI 1.29 to 6.42), p,0.0069; table 1) with
a PAR for AA homozygotes and AG hetero-
zygotes of 50%.
This study underlines the importance of
the association of BTNL2 rs2076530 variant
with the susceptibility to develop sarcoidosis
in a German population. Furthermore, our
data suggest that susceptibility is pre-
ferentially towards the chronic form of the
disease.
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Asthma and allergies in Germany
We read the study by Zo¨llner and colleagues
published recently in Thorax about the level-
ling off of asthma and allergies among
children in Germany between 1992 and
2001.1 We have published a study looking at
the same issue and using a similar protocol
(ISAAC)2 to assess the symptoms, diagnosis,
and severity of asthma and allergies in more
than 15 000 children aged 6–7 and 13–
14 years between 1995 and 2000 in
Mu¨nster, Germany.3 We found a tendency
towards an increase in current symptoms of
asthma and allergies in both age groups, but
more so among girls.3
Indices of diagnosis either remained the
same or increased in parallel with the
increase in symptoms, arguing against a
change in diagnostic behaviour as an expla-
nation for our results. Indices of severity also
showed a homogenous increase in the 5 year
study period, pointing towards an increase in
the overall burden of asthma and allergies
within the society.3
Regrettably, these results, coming from
Germany, were not considered in either the
discussion of Zo¨llner’s report or in the
affirmative title that no increase in asthma
and allergies occurred in Germany in the
1990s. Even more regrettable is the fact that
when our study was alluded to in the
discussion and conclusion of the paper by
Zo¨llner et al, it was cited—contrary to our
results—as one of the studies showing a
decrease or levelling off of asthma and
allergies among children.1
W Maziak, U Keil
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maziak@net.sy
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Authors’ reply
Unfortunately, the paper by Maziak et al1
published in Allergy was listed as reference
number 18 instead of number 21 in the
reference list of our paper.2 We apologise for
any misunderstanding which may have
arisen from this error. A correction is
published below.
In the paper by Maziak et al1 the prevalences
in 1994/5 and 1999/2000 are compared. As we
know from our own studies, trend analyses
based on (only) two time points may be difficult
and should be interpreted with caution. Indeed,
in their investigation Maziak et al did not find a
significant increase in the lifetime prevalence of
asthma and hay fever, except in one subgroup.
The effect found in 13–14 year old girls could
also be due to a former underdiagnosis of
asthma in girls, as discussed in their paper.
Since our results are based on six cross
sectional surveys, we consider the title and
the conclusion—that we did not see an
increase in asthma and allergies from 1992
to 2001—to be appropriate.
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In the paper entitled ‘‘No increase in the
prevalence of asthma, allergies, and atopic
sensitisation among children in Germany:
1992–2001’’ by I K Zo¨llner et al which appeared
in the July 2005 issue of Thorax (2005;60:545–
8), the authors apologise for a mistake which
occurred in the reference list. Reference
number 18 should be number 21 and refer-
ences 19–21 should be listed as 18–20.
doi: 10.1136/thx.2005.040444corr1
The paper entitled ‘‘Anticholinergics in the
treatment of children and adults with acute
asthma: a systematic review with meta-analy-
sis’’ by G J Rodrigo and J A Castro-Rodriguez
(10.1136/thx.2005.040444) has been published
previously on 17 June 2005 as a Thorax Online
First article but under the incorrect DOI
(10.1136/thx.2005.047803). The publishers
apologise for this error. The definitive version
of the article can be found at the following
citation: Thorax 2005;60:740–6.
doi: 10.1136/thx.2005.040881corr1
In the paper entitled ‘‘Hormone replacement
therapy, body mass index and asthma in
perimenopausal women: a cross sectional
survey’’ by F Go´mez Real et al published in
the January 2006 issue of Thorax
(2006;61:34–40), the fourth author should
be K A Franklin, not K Franklin.
CORRECTIONS
Table 1 Statistical analysis of the case-control study
Co-dominant Dominant (AA/AG v GG) Recessive (AA v AG/GG)
AA AG GG
p
value AA/AG GG OR (95% CI)
p
value AA GG/AG OR (95% CI)
p
value
Controls 84 (41%) 82 (41%) 36 (18%) 166 36 84 116
Cases 99 (47%) 93 (44%) 18 (9%) 0.021 192 18 2.31 (1.27 to 4.23) 0.006 99 111 1.25 (0.85 to 1.85) 0.276
Acute 30 (42%) 32 (45%) 9 (13%) 0.576 62 9 1.49 (0.68 to 3.28) 0.358 30 41 0.99 (0.57 to 1.71) 0.97
Chronic 59 (52%) 47 (41%) 8 (7%) 0.021 106 8 2.87 (1.29 to 6.42) 0.007 59 55 0.67 (0.43 to 1.07) 0.095
Significant associations are shown in bold.
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